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Immediately after single-stranded break (SSB) and double-stranded break (DSB) 
formation, the synthesis of poly(ADP-ribose) (PAR) reconfigures the local chromatin environment 
and initiates recruitment of DNA repair proteins. The degradation of PAR chains by poly(ADP-
ribose) glycohydrolase (PARG) is essential for DNA repair progression.  Here, we show that 
pharmacological interference of PAR metabolism disrupts the homology-directed repair (HDR) 
mechanisms that mediate alternative lengthening of telomeres (ALT). Using a proteomics strategy, 
we uncovered PAR-regulated telomere-associated proteins that coordinate the early stages of the 
ALT mechanism. These distinct factors exhibit PAR dependency for localization to ALT telomeres 
in order to orchestrate diverse functions, such as RNA stabilization, actin nucleation, and 
chromatin remodeling. Most significantly, we identified a key function for PARylation in 
recruiting the HIRA histone chaperone complex to ALT telomeres, where it is required for 
deposition of histone H3.3 specifically during G2 Break-Induced Replication (G2-BIR). We 
propose that HIRA acts to compensate for the loss of a functional ATRX-DAXX complex in ALT 
cancers and therefore adopts elevated importance in sustaining ALT+ cell viability.  
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Telomeres are specialized nucleoprotein structures that protect the ends of chromosomes 
from degradation and fusion. Telomeric DNA sequences are tandem arrays of the 5’-TTAGGG-
3’ hexanucleotide (1). Telomeres consist of a 3’ G-rich overhang that folds back and anneals to 
the double-stranded hexameric repeats, forming a lariat-like structure termed the t-loop (2–4). The 
six-member protein complex, Shelterin (TRF1, TRF2, POT1, RAP1, TPP1, and TIN2), associates 
at telomeres and stabilizes the t-loop (5). TRF1 (Telomere Repeat Binding Factor 1) and TRF2 
(Telomere Repeat Binding Factor 2) bind to the double-stranded TTAGGG region. RAP1 
(Repressor/Activator Protein 1) associates with and stabilizes TRF2. POT1 (Protection of 
Telomere 1) binds to the single-stranded telomeric overhang. TPP1 (Adrenocortical Dysplasia 
Homolog (ACD)) is a binding partner of POT1. TIN2 (TRF1-and TRF2-Interacting Nuclear 
Protein 2) tethers the TPP1/POT1 complex to TRF1 and TRF2, which bridges the single-stranded 
and double-stranded regions of the telomere (5). These properties are integral to chromosome end-
protection and act as a safeguard to shield exposed chromosome ends from being recognized as 
double-stranded breaks (DSBs) by the DNA repair machinery (6).  
 In normal somatic human cells, telomeres shorten overtime after each cell division due to 
the end replication problem, which arises from incomplete replication of the lagging strand (7). 
Progressive and irreversible loss of telomeres eventually reaches a critical point when cellular 
senescence is triggered to prevent genomic instability (8). To bypass this barrier, cells containing 
inactivating mutations in p53 and Rb pathways gain proliferative activity (9–11). However, 
eventually chromosome ends can become too short and unprotected, which generates end-to-end 
fusions and dicentric chromosomes (12). Telomere crisis results in an array of genomic 
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aberrations, including chromosome deletions, amplifications, translocations, chromothripsis, 
kataegis, and polyploidization (12,13). As a consequence, these cells are eliminated by autophagic 
cell death and apoptosis (13).  
Cancer cells circumvent telomere dysfunction by adopting telomere maintenance 
mechanisms to achieve replicative immortality (14). Approximately 85% of cancers reactivate the 
specialized reverse transcriptase telomerase to synthesize de novo telomeric DNA (15). Two 
components of telomerase, the non-coding telomerase template RNA (hTR) and dyskerin, are 
constitutively expressed. The TERT promoter region is enriched with binding motifs for a range 
of transcription factors, including the MYC oncogene, but lacks TATA and CAAT boxes (16). 
Notably, the TERT promoter is unmethylated in normal somatic cells, which is thought to favor 
repressor-binding (17). Together, the silencing of the promoter and low basal transcription rate 
limit the number of molecules of the key catalytic subunit TERT (18). To counteract this, 
acquisition of TERT promoter mutations and upstream genomic rearrangements elevate TERT 
mRNA expression and telomerase activity. Genomic rearrangements in regions proximal to the 
TERT gene locus (5p15.33) can introduce enhancers that increase TERT expression (17). Hotspot 
mutations in the promoter of TERT, the catalytic subunit of telomerase, leads to telomerase 
activation (19–21). In familial and sporadic melanomas, two common non-coding mutations are 
located at -124 and -146 nucleotides upstream from ATG within the TERT promoter region (22). 
The prevalence of TERT promoter mutations varies according to cancer type and histology (23). 
However, TERT expression is permanently repressed in 10-15% of cancers, which are 
largely derived from the mesenchymal-adrenergic lineage (24). These cancers engage in the 
recombination-mediated pathway termed Alternative Lengthening of Telomeres (ALT) (25). ALT 
telomeres display a permissive chromatin state, stochastic DNA damage, replication stress, as well 
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as inactivation of type I interferon response – all of which contribute to a favorable environment 
for homology-directed repair (HDR) pathways that mediate telomere maintenance and aberrant 
tumor growth (26–30). Understanding how ALT cancers hijack HDR mechanisms is the primary 
focus of this dissertation, as discussed in detail below.  
1.1 The Physiological Basis of ALT 
 Clinical Relevance of ALT 
10%-15% of all cancers activate the ALT pathway for telomere maintenance (25,31–33). 
While ALT is not commonly detected in tumors of epithelial origin (carcinomas), it is prevalent 
in tumors of mesenchymal (osteosarcomas and soft tissue sarcomas) and neuroepithelial 
(astrocytomas) origins (24,34,35). In addition, it is detected in highly aggressive tumor types such 
as pancreatic neuroendocrine (PanNETs), glioblastoma multiforme, and neuroblastoma. It still 
remains elusive as to why these cancers rely on the ALT pathway. However, it has been proposed 
that tumors of mesenchymal origin may have greater barriers to upregulation of telomerase 
activity, which force cells to favor the emergence of ALT (36,37). It is speculated that these cell 
types have altered control of senescence and crisis, which lead to stochastic telomeric damage and 
replication stress. Another possibility is that varying tissue types may have differential regulation 
of recombination and chromatin remodeling pathways (33,37,38). Interestingly, hybrids of ALT 
and telomerase-positive (TEL+) cells continue to exhibit immortalization, but with suppressed 
ALT phenotypes (37,39,40). This suggests that there is the existence of an ALT repressor in 
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telomerase-positive cells. Nevertheless, it is unknown whether loss of such repressor occurs in 
cancer cells of mesenchymal lineage.  
 Phenotypic Characteristics of ALT cancers 
 Loss of function mutations and deletions in ATRX/DAXX: One of the signature 
markers associated with ALT is the loss of expression of alpha-thalassemia/mental retardation 
syndrome, X-linked (ATRX) and death domain associated protein (DAXX) (41). Missense 
mutations and exon deletions that produce a non-functional or truncated ATRX protein, 
respectively, are identified in whole genome sequencing (WGS) of a wide range of tumor types 
that invariably become classified as ALT positive (42). Additionally, 70%-80% ALT cell lines 
have ATRX/DAXX mutations. Similarly, inactivating mutations in DAXX are also detected, 
particularly in vivo, with some ALT+ cell lines harboring a chimeric fusion protein formed 
between DAXX and kinesin motor protein KIFC3 (43). Clinical observations of PanNETs have 
identified loss of ATRX/DAXX protein expression and the manifestation of ALT as late events in 
tumor evolution, linked with metastatic disease (44). This late origin of ALT is consistent with 
numerous in vitro studies when the transient depletion or disruption of ATRX or DAXX is not 
sufficient to initiate ALT (42,45). The supposition is that additional genetic and/or epigenetic 
alterations in p53 or the acquisition of other passenger mutations may be mitigating factors for 
ALT initiation (46). Indeed, recurrent mutations in Isocitrate Dehydrogenase (IDH1) are more 
prevalent in gliomas and can promote ALT initiation in cells lacking ATRX in vitro (47,48). IDH1 
is a metabolic factor that catalyzes decarboxylation of isocitrate to -ketoglutarate (-KG). IDH1 
regulates the demethylation of histones and DNA. 
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ALT-associated PML bodies (APBs):  APBs are structural complexes enriched in 
promyelocytic leukemia (PML) bodies, telomeric DNA, telomere associated proteins, and DNA 
repair proteins (49). PML bodies are matrix-associated domains in the nucleus that recruit proteins 
with diverse cellular functions. Specifically, APBs are only observed within a small subset, 
approximately 5-10%, of asynchronously dividing ALT-positive cell populations (50). 
Immunofluorescence-Fluorescence in situ Hybridization (IF-FISH), based on colocalization of 
PML and telomeres, is used to detect APBs in ALT+ immortal cell lines and archived formalin-
fixed paraffin-embedded tumors (34,51). It has been reported that APBs are enriched in the G2/M 
phase and are decreased in frequency in cells exiting mitosis and re-entering the G1 phase. This 
suggests that the formation of APBs is a dynamic process and is coordinated with the cell cycle 
(52).  
APBs structurally comprise of PML/SP-100 that form a 0.01-1m diameter shell enclosing 
telomeric DNA, telomere specific proteins (Shelterin components TRF1 and TRF2), as well as 
DNA damage response and repair factors (such as gamma-H2A Histone Family Member X 
(H2AX), ATP-binding Cassette-ATPase (Rad50)/Meiotic Recombination 11 Homolog 1 
(Mre11)/Nijmegen Breakage Syndrome Protein 1 (NBS1), and Structural Maintenance of 
Chromosomes Protein 5/6 (SMC5/6)) (53–55). Several lines of evidence indicate that APB 
formation is driven by SUMOylation events mediated by SUMO E3 Ligase MMS21, a component 
of the SMC5/6 complex (55,56). SUMOylation is a post-translational modification that covalently 
conjugates small ubiquitin-like modifiers (SUMO) to an array of cellular proteins in a similar 
manner to ubiquitylation (57). To initiate APB formation, MMS21 SUMOylates telomere binding-
proteins, TRF1 and TRF2, to assemble PML/SP100 at telomeres through interactions between 
SUMO and SUMO-interacting motifs (SIM) (58). These SUMOylation events facilitate the 
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formation of liquid-liquid demixing condensates that can dynamically alter the scaffold-protein 
interaction (59). A positive SUMOylation feedback loop is established, leading to the recruitment 
of repair and recombination factors that promote telomere elongation (55,58). Additionally, NBS1, 
which is a vital component of the Mre11-Rad50-Nbs1 (MRN) repair and recombination complex, 
is essential for assembly of functional APBs (60,61) 
Although the function of APBs is not well-defined, there is strong evidence arguing that 
the presence of APBs promotes ALT activity. The presence of APBs have been used to identify 
most ALT+ tumors while the repression of ALT is accompanied by a decrease in APBs (34,62). It 
has been shown that PML bodies in ALT cells directly associate with chromosome ends, allowing 
for telomere clustering and recombination (63). In addition, a recent study proposed that ALT 
telomere DNA synthesis is exclusively detected in APBs during G2 (64). However, DNA synthesis 
could not be differentiated between a single telomere, multiple telomeres, or extrachromosomal 
circles. APBs likely serve as a recombinogenic platform to enrich proteins that enhance replication 
and homologous recombination. By sequestering these proteins to telomeres, APBs provide the 
prime environment for telomere recombination and extension in ALT. Understanding the exact 
mechanisms of APB formation will lead to improved assessment of ALT tumors. 
Extrachromosomal Telomeric Repeats (ECTRs): Although ECTRs are present in ALT 
cells, their function is not well-characterized (65–68). There are two common types of ECTRs that 
are linked with ALT. Firstly, partially single-stranded C-rich circles (c-circles) are abundant in 
ALT+ cancers, but not in TEL+ cancers (69–71). An established PCR-based method is used to 
measure c-circle levels in cancer cell lines and human blood samples (72). The abundance of c-
circles can be quantified using a modified rolling circle amplification (RCA) assay that relies on 
29 DNA polymerase. Thus, c-circles are widely used as a specific and quantitative biomarker for 
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ALT activation (69,72). Secondly, heterogenous double-stranded telomeric circles (t-circles) are 
also commonly found in ALT (65,70,73). However, t-circles are neither ALT nor cancer specific; 
they can be the result of telomere trimming in normal germline cells and in cells with 
overexpression of telomerase components, both of which have extensively long telomeres (74,75). 
Although ALT+ and TEL+ cells are able to produce t-circles, only ALT+ cells contain c-circles, 
which suggests that c-circles may arise from an undetermined mechanism of altered telomerase 
activity (71).  
 Telomere Sister Chromatid Exchanges (T-SCEs): ALT cancers display hyper-
recombination, which manifests as elevated frequency of telomere-sister chromatid exchanges (T-
SCEs) (76–80). These events can be detected using telomere specific chromosome-orientation 
fluorescent in situ hybridization (CO-FISH), which utilizes specific telomere probes for the G-rich 
lagging and C-rich leading strands  (50). The exchange between two sister chromatids is visualized 
as a double signal at one telomere. Although T-SCEs are a marker of ALT, it is not indicative of 
telomere extension (81). Additionally, it is speculated that crossover events can also arise from 




Figure 1. Schematic of ALT-associated HDR mechanisms occuring in APBs. SUMOylation of Shelterin 
components, TRF1 and TRF2, recruits PML/SP100 via SUMO-SIM interactions. SUMOylation-induced APB 
condensates lead to clustering of telomeres and DNA repair factors within the PML/SP-100 shell. A positive 
SUMOylation feedback loop enhances APB formation.  APBs act as a platform to concentrate repair and 
recombination factors to facilitate telomeric DNA synthesis, particularly of extra-chromosomal C-circles. APBs are 




 Telomerase-Independent Lengthening of Yeast Telomeres 
Budding yeast cells lacking a functional est1 gene, which encodes yeast telomerase, exhibit 
progressive shortening of the terminal G1-3T telomeric repeats  (82). While the majority of cultured 
yeast cells in an est1- culture die, a minor subpopulation of survivors regains the ability to divide 
and maintain telomere length. Thus, when the primary pathway for telomere maintenance is 
defective, an alternative pathway emerges to bypass senescence and cell death. These survivors 
consist of two types: Type I utilizes Rad51-dependent recombination while Type II engages in a 
Rad51-indpendent mechanism that is mediated by break-induced replication (BIR) (60,83). While 
POLD32, homolog of POLD3, is dispensable for replication and gene conversion, it is required 
for BIR to establish a full replication fork by recombination in the absence of an origin of 
replication (84). Type I survivors have tandem duplication of the Y’ element, a highly polymorphic 
repetitive sequence present in the subtelomeric regions of many yeast telomeres (83,85,86). These 
show amplification of the Y’ elements, but have very short G1-3T telomeric repeats. Meanwhile, 
Type II survivors exhibit rearrangement and/or tandem duplication of the distal portion of the Y’ 
element. Type II survivors demonstrate highly heterogeneous long tracts of G1-3T, resembling 
telomeres present in ALT cancers. These studies suggest that Type II survivors in budding yeast 
and the mammalian ALT pathway may share mechanistic similarities.  
1.2 Homology-directed Repair Mechanisms in ALT 
Through imaging of individual proteins and unbiased proteomics profiling of ALT 
telomere composition, an undoubted constitutive and selective association of HR factors with ALT 
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telomeres has been determined (87–90). They include the central recombinase RAD51, single-
stranded DNA binding Replication Protein A (RPA), the DNA resection MRN complex, Bloom 
helicase (BLM) and several HR accessory factors Breast Cancer Gene 1 (BRCA1), Breast Cancer 
Gene 2 (BRCA2), RAD51-associated Protein 1 (RAD51AP1) and RAD52 (27,28,64,91–94). 
These are frequently sequestered together with clusters of telomeres and Shelterin subunits in 
APBs, which are characteristic markers of recombination-mediated repair and extension of 
telomeres in ALT cancer cells (49). Recombination and extension are two independent, potentially 
competing HDR mechanisms that underpin ALT, both of which utilizes exposed DNA ends at 
stochastic telomere or stalled replication forks as primers (Figure 2). RAD51-dependent 
homologous recombination facilitates error-free repair of telomeres (95,96). Later in G2/M phase, 
a pathway that is dependent on RAD52, Proliferating Cellular Nuclear Antigen (PCNA), 
Replication Factor C 1-5 complex (RFC), and DNA polymerase  (PolD3) mediates conservative 
DNA synthesis and extends telomere length (93,97,98). Recent studies have shed light on the 
complex regulation of these HDR mechanisms. 
The intrinsic difficulty of replicating long tracts of GC rich telomeric sequences has been 
implicated as the basis for constitutive HDR activity at ALT telomeres (Figure 2). Stalling of 
replication forks pose a threat to genome stability. This can arise due to polymerase collision with 
DNA nicks, DNA gaps or polymerase barriers like G-quadruplexes that can readily form within 
ALT telomeres (99,100). These replisome collisions are detected by the DNA damage sensor 
kinase, Ataxia-Telangiectasia and Rad-3 related (ATR) (98). The ATR signaling cascade initiates 
the processing of stalled forks and downstream signaling to attenuate telomere replication (101–
103). Subsequently, repair and restart of these stalled forks involves dedicated remodeling 
enzymes like SWI/SNF-related, matrix associated, actin-dependent regulator of chromatin, 
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subfamily A-like 1 (SMARCAL1), an ATP-dependent strand annealing helicase, and/or Fanconi 
anemia complementation group M (FANCM), a DNA-dependent ATPase/Translocase subunit of 
the Fanconi Anemia (FA) core complex (29,30,104). FANCM also works with RNaseH1 to 
dissolve aberrant R-Loops that form between the TERRA lncRNA and telomeric DNA sequences, 
which can accumulate and destabilize replication forks and HR intermediates within ALT 
telomeres (105). The activity of these proteins is essential for mediating replication fork reversal 
and repair. Preventing fork remodeling, by depletion of SMARCAL1 or disruption of FANCM, 
unleashes staggering increases in APB frequency and size (27,29,30). These cells exhibit elevated 
RAD51-dependent clustering of telomeres, chromosomal abnormalities, and DNA damage 
signaling that is consistent with rampant, uncontrolled recombination. ALT cell lines that are 
deficient in these proteins, particularly FANCM, display acute cell death. Thus, this initial 
response by SMARCAL1 and FANCM represents a critical mechanism to salvage stalled forks at 
ALT telomeres (12,13,69). It also acts as a front-line tolerance mechanism that limits excessive 
telomere recombination and damage to preserve ALT cancer cell survival and proliferation.  
Once stabilized and repaired, an active fork can be restored by RAD51-dependent HR 
(Figure 2). RAD51 presynaptic filaments explore nuclear space, probing for identical telomeric 
sequences that provide the template for error-free repair (96). At genomic DSBs, RAD51-
dependent homology search involves the consumption of ATP and polymerization of nuclear F-
actin filaments that propel homologous DNA sequences into proximity of each other (106). 
Though yet to be determined, the same processes are likely to stimulate telomere clustering in 
ALT. As with HR at genomic DSBs, homology search during ALT is co-regulated and stimulated 
by HR accessory factors such as BRCA1, BRCA2, RAD51AP1 and the SMC5/6 heterodimer 
(28,55,91). However, ALT is distinct from conventional HR due to the involvement of the 
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Homologous Pairing Protein 2-Meiotic Nuclear Division Protein 1 (HOP2-MND1) heterodimer 
that is normally associated with meiotic HR (98). The involvement of HOP2-MND1 at telomeres 
could assist in overcoming reduced homology search and capture kinetics at G-C rich regions, 
such as those at telomeres. It was also proposed that HOP2-MND1’s role in gametogenesis is a 
remnant of a primordial meiotic origin of ALT that is reactivated in telomerase deficient cancer 
cells (96). However, the basis of meiotic factors like HOP2 involvement in ALT remains unclear.  
Once homologous telomeric sequences have been captured, the presynaptic filament 
invades, aligns and combines with the double-stranded partner DNA, forming the synaptic 
complex (Figure 2). This action displaces a strand of DNA, forming the Displacement Loop (D-
Loop). At the terminal 3’hydroxyl group, PCNA is loaded by RFC to prime and initiate semi-
conservative DNA synthesis. Given the high GC-rich content at telomeres, the translesion DNA 
polymerase, Pol , might be employed to initiate DNA synthesis before Pol  takes over (87). 
During DNA synthesis that emanates from stalled forks, the translocase activity of FANCM works 
in unison with the DNA unwinding and decatenation activities of the BLM-TOP3A-RMI1-2 
(BTR) complex to promote branch migration and eventual dissolution of D-loops and Holliday 
Junctions (HJs) (81,107,108). The dissolution activity of the BTR complex is crucial as it 
facilitates Pol  -dependent telomere extension and suppresses telomere sister chromatid exchange 
(t-SCE) events, thereby preserving the original orientation of telomeric DNA strands (81).  
In addition to HJ resolution, BLM has also been shown to alleviate persistent telomere 
replicative stress at forks that escape reversal (Figure 2). Here, BLM’s helicase activity can 
facilitate EXO1-DNA2 dependent resection that potentially sets the stage for repair by an alternate 
RAD51-independent HDR pathway (93). RAD52 could be recruited and initially stabilize these 
HR intermediates, perhaps to limit resection. Then, utilizing its single-strand annealing (SSA) 
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activities, RAD52 subsequently facilitates intra-chromosomal pairing of telomeric DNA 
sequences located on proximal sister chromatids and D-loop formation (64,94). This process 
primes break induced replication (BIR)-related DNA synthesis at ALT telomeres. In fact, recent 
evidence has implicated several BIR-like pathways that are essential aspects of ALT telomere 
maintenance (98). These conservative DNA synthesis pathways take place beyond the confines of 
S-phase, function in G2 and M-phases, share independence from RAD51-dependent HDR, and 
universally adopt the specialized PCNA-RFC-Pol replisome. The predominant pathway, called 
G2-BIR, relies on RAD52-mediated restoration of stalled replication during G2 mentioned above 
since cells lacking any of RAD52 or the POLD3-POLD4 subunits of Pol  display attenuated DNA 
synthesis and extensive telomere shortening (64,94,98). RAD52 is also crucial for a spontaneous 
form of DNA synthesis during the early stages of mitosis, termed Mitotic DNA synthesis, or 
spontaneous mitotic DNA synthesis (MiDAS), which can occur at chromosome arms and at 
telomeres (109–111). The predominance of the RAD52-dependent pathway over its RAD51-
mediated counterpart has been attributed to each protein’s distinct binding kinetics (94,98). Also, 
the individual substrate requirements of RAD51 and RAD52, as well as the mechanisms of HR 
intermediate processing, will likely dictate commitment to either pathway. 
Stalled forks that escape or are incompatible with repair using the mechanisms outlined 
above must be salvaged before mitosis (Figure 2). These can be subjected to endonucleolytic 
resolution by a complex comprised of SLX1-SLX4, MUS81-EME1, XPF-ERCC1 (SMX). The 
SMX complex cleaves or resolves each junction of the intermediate structure (112). The SMX 
complex associates with telomeres, irrespective of whether telomerase or ALT is active (113,114). 
It acts as an all-purpose responder to detrimental telomere damage, where it dismantles complex 
HR entanglements. This generates large deletions of telomeric DNA at these intermediates. 
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RAD52 also stimulates MiDAS at intermediates that are resolved by SMX (110). However, unlike 
RAD52-dependent DNA synthesis during G2, MiDAS that is stimulated by SLX4 appears to be 
abortive or non-productive. This is corroborated by SLX4-deficient cells that display a net loss in 
overall telomere length in ALT cells. 
In ALT cells, the SMX complex appears to fulfill a greater role in antagonizing the HJ 
dissolution of the BTR complex, which seems to be essential for telomere length homeostasis (81) 
(Figure 2). In the absence of functional BTR, the promiscuous resolvase activity of SMX becomes 
uncontrolled and promotes unwarranted recombination, yielding excessive t-SCEs and diminished 
DNA synthesis. In contrast, disrupting SMX-mediated resolution promotes unrestrained BLM- 
mediated dissolution and DNA synthesis at telomeres. Interestingly, an auxiliary constituent of the 
SMX complex, SLX4IP, was shown to directly bind and potentially antagonize BLM’s dissolution 
activity (112). ALT cells lacking both SLX4 and SLX4IP exhibit staggering increases in 
recombination, mitotic anomalies and a severe synthetic lethal phenotype that was fully rescued 
by depletion of BLM. Thus, the BTR dissolution and SMX resolvase activities are subject to 





Figure 2. HDR mechanisms of ALT. Telomeres pose a challenge for the replication machinery, leading to 
replication fork stalling. There are various pathways to resolve this impediment in ALT, which are RAD51-
dependent HR, RAD52-dependent HDR, and RAD52/SLX4-dependent MiDAS. 
1.3 Chromatin Remodeling in ALT 
It is speculated that remodeling of telomere architecture plays a key role in the emergence 
and maintenance of ALT. Through a sequencing approach, it was recently discovered that variant 
repeats (TCAGGG, TGAGGG, and TTGGGG) are interspersed throughout the telomeres of ALT 
cells (115). The C-type (TCAGGG) variant repeat is predominantly enriched within the canonical 
repeat arrays and provides a high affinity binding site for the nuclear receptors COUP-TRF2 and 
TRF4 (116). The binding of nuclear receptors to telomeres leads to the engagement with ZNF827, 
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a zinc-finger protein that recruits the nucleosome modeling and histone deacetylation (NuRD) 
complex. The result is decreased shelterin binding, destabilization of the telomere architecture, 
and an elevated recombinogenic telomeric state.  This disequilibrium primes a positive feedback 
loop for further spreading of variant repeats from the proximal region of telomeres, which has 
profound implications for ALT telomere structure and function (115,117).    
Intriguingly, ATRX/DAXX-associated mutations functionally converge through their 
effects in reconfiguring chromatin structure. DAXX and ATRX form a multifunctional chromatin-
remodeling histone chaperone complex that is responsible for the replication independent 
deposition of histone H3.3 (118). In the absence of functional ATRX-DAXX, failure to assemble 
chromatin with histone H3.3 can have pleiotropic effects on transcription and single-stranded DNA 
(ssDNA) repair mechanisms such as nucleotide excision repair (NER), while also negatively 
impacting chromatin compaction and integrity (119). ATRX deficiency has also been implicated 
in alterations in sub-telomeric DNA methylation on the basis that it interacts with DNA 
methyltransferase 1 (DNMT1) (120). Remarkably, heterozygous mutations in histones H3.1 and 
H3.3 at or adjacent to key lysine residues, K27M and G34R/G34R, which are targeted by lysine 
methyltransferases complexes Enhancer of Zeste 2 (EZH2) and SET domain containing 2 
(SETD2), respectively, have also been identified in ALT-positive glioma (121,122). Thus, it 
appears that at singular or multiple distinct points during ALT cancer cell evolution, telomeric 
chromatin undergoes considerable modification and expansion, losing its DNA repair refractory 
state and becoming more accessible and permissive for HDR mechanisms that sustain telomere 




Figure 3. Distinct chromatin landscape of ALT facilitates HR. While TEL+ telomeres have a more closed 
chromatin structure, ALT+ telomeres are more accessible to facilitate a favorable environment for HDR. ALT 
telomeres exhibit stochastic DNA damage and replication stress, all of which contribute to a permissive telomeric 
state for ALT mechanisms. 
1.4 Poly(ADP-ribosyl)ation 
 Poly(ADP-ribose) Polymerase (PARP) Family  
ADP(ribosyl)ation is a reversible post-translational modification that covalently attaches 
ADP-ribose (ADPr) onto Glu, Lys, or Asp residues of acceptor proteins by using nicotinamide 
adenine dinucleotide (NAD+) as a substrate (123). While mono(ADP-ribosyl)ation (MARylation) 
adds a single ADPr unit, poly(ADP-ribosyl)ation (PARylation) can add up to 200 ADPr units via 
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linear and branched glycosidic linkages (124). This modification is catalyzed by diverse members 
of the poly(ADP-ribose) polymerase (PARP)/ADP(ribosyl)transferase (ADPRT) family (123). In 
humans, there are 17 members in the PARP family, which belong to five subfamilies based on 
functional domains in regions outside of the PARP domain. These include: 1) DNA-dependent 
PARPs, 2) tankyrases, 3) CCCH zinc finger PARPs, 4) macro PARPs, and 5) unclassified PARPs 
(123,125–127). The DNA-dependent PARPs (PARP1, PARP2, and PARP3) are the only members 
of the PARP family that are expressed in the nucleus (128–130). These PARPs, along with PARP4-
6, share a conserved His-Try-Glu (H-Y-E) triad in their catalytic domains (131). PARP1 
recognizes different lesions, including SSBs, DNA crosslinks, stalled replication forks, and DSBs 
(132). On the other hand, PARP2 binds less efficiently to SSBs and has been proposed to recognize 
gaps and flap structures that correspond to advanced repair intermediates (133,134). PARP3 has 
been shown to play a role in the cellular response to DSBs during classical non-homologous end-
joining (c-NHEJ) and mitotic progression (135,136). Tankyrase 1 (TNKS1) and Tankyrase 2 
(TNKS2) have redundant functions to regulate telomere maintenance via PARylation of TRF1, 
oncogenic pathways, as well as spindle pole formation in mitosis (137,138). The CCCH-type 
PARPs (PARP7, PARP12, and PARP13) and the macroPARPs (PARP9, PARP14, and PARP15) 
have been documented to regulate transcription and the viral response (123,139–143).  
 Poly(ADP-ribose) Polymerase 1 (PARP1) 
The focus of this dissertation is on PARP1, the most abundant and ubiquitous member of 
the PARP family (144). PARP1 is a 116-kDa protein that comprises of an N-terminal DNA-
binding domain, central automodification domain, and C-terminal catalytic domain (127). Amino 
acid acceptors of PARylation include Lys, Arg, Glu, Asp, Cys, Ser, and Thr (131). There are 
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several paradigms that propose the stoichiometry of PARP1 peptides involved in auto-PARylation 
(131). There is compelling evidence for the bimolecular model that argues asymmetric PARP1 
dimerization (145–147). Here, one DNA-bound PARP1 molecule functions as the catalyst while 
the second PARP1 molecule is inactive, but serves as the PAR acceptor.  In addition, it is proposed 
that both PARP1 molecules can act as catalysts and acceptors simultaneously if the PARP1 binding 
sites on DNA are closely adjacent to each other (145–147) Despite the convincing argument for 
the bimolecular model, it has been speculated that PARP1 functions as a monomer to modify itself 
intramolecularly in cis. The structural model of PARP1 bound to DNA nicks and 
hydrogen/deuterium exchange-mass spectrometry data suggest that the BRCT-WGR linker is 
flexible enough to reach the active site of PARP1 when the monomer is bound to DNA nicks. 
Thus, one PARP1 molecule is sufficient to serve as both the catalyst and acceptor of PAR 
(148,149). Using atomic force microscopy (AFM), PARP1 has been shown to bind nicks, ends, 
and abasic sites in DNA as a monomer. PARP1 changes from three-dimensional DNA damage 
searching to one-dimensional diffusion after auto-PARylation or in the presence of APE1 (150).  
PARP1 plays a prominent role in DNA repair, chromatin remodeling and transcription, 
which will be discussed in detail in the below sections (132,151,152). There are hundreds of 
proteins that directly or indirectly interact with PAR (153). This leads to a diverse array of 
biological outcomes that are involved in genotoxic, oxidative, oncogenic, and inflammatory stress 
responses (144). These proteins bind PAR through distinct PAR-binding modules, such as: basic 
PAR-binding motif (PBM), PAR-binding zinc finger (PBZ), Macrodomains, WWE domains, FHA 
and BRCT domains, RNA and DNA binding motifs, RNA recognition motif (RRM), SR repeats 
and KR-rich motifs, OB-fold, PIN domains, and RGG motifs (154). Due to the many facets of 
PAR in the DSB response, deficiencies in PARP1 and PARP2 have profound consequences for 
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genome stability (155). Studies have shown that there is a functional interaction between PARP1 
and PARP2 in regulating chromosomal stability and embryonic development in mice (155–157). 
Both can homo- and heterodimerize, and are involved in the base excision repair (BER) pathway. 
While Parp1-/- mice exhibit higher sensitivity to high-dose ionizing radiation and alkylating 
agents, Parp2-/- mice demonstrate hyper-radiosensitivity to low-dose radiation. Parp1
-/- Parp2-/- 
double mutant mice are not viable and die at the onset of gastrulation. These studies indicate that 
PARP1 and PARP2 have distinct roles in the DNA damage response, but play a redundant role 
with regard to cell survival.  
 Poly(ADP-Ribose) Glycohydrolase (PARG) 
Although extensive and rapid PARylation is necessary to elicit recruitment of the DNA 
damage machinery to DNA lesions, hyper-PARylation is detrimental to cells and is resolved by 
poly(ADP-ribose) glycohydrolase (PARG) (158). Excessive PARylation may trap DNA damage 
repair factors at the damaged site, blocking access to downstream processes. In addition, this leads 
to PARthanatos, a process in which PAR acts as a cell death effector (159). Excessive PAR 
migrates from the nuclei to cytosol, which leads to apoptosis inducing factor (AIF) translocation 
from the mitochondria to the nucleus (159–161). In addition, PARP1 overactivation may deplete 
cellular energy through NAD+ consumption, triggering the release of AIF and ultimately, cell 
death (159,162,163). Thus, the timely and orderly degradation of PAR is important to maintain 
efficient repair and cellular processes. 
 To date, PARG is the only enzyme that can hydrolyze the O-glycosidic linkages of PAR 
polymers, thereby generating free ADPr (164). PARG catalyzes PAR chain degradation through 
endo- and exoglycolytic activities, but still leaves a terminal ADPr moiety attached to the acceptor 
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amino acid residue from its substrate (165). There are five other dePARylation enzymes that have 
been identified, including ARH3 (ADP(ribosyl)hydrolase 3), TARG1 (Terminal ADP-ribose 
protein glycohydrolase), NUDT9 (Nudix Hydrolase 9), NUDT16 (Nudix Hydrolase 16) , and 
ENPP (Ectonucleotide pyrophosphatase/phosphodiesterase) (166). Although ARH3 contains exo-
glycohydrolysis activity to release free ADPr, its activity is much lower than that of PARG (167). 
TARG1 does not hydrolyze PAR to ADPr and can only remove whole PAR chains from glutamate 
residues of acceptor proteins (168). NUDT9 and NUDT16 only cleaves pyrophosphate bonds to 
release iso-ADP-ribose and AMP from PAR chains or MARylated proteins (169,170). 
There are five isoforms of PARG that have been described – the nuclear, full-length PARG 
protein (110 kDa), two splice variants that lack exon 1 (102 kDa) or exons 1 and 2 (99 kDa), and 
two mitochondrial isoforms (60 kDa and 55 kDa) (125,171–173).  Nuclear, full-length PARG 
comprises of an N-terminal regulatory region, PCNA binding motif, nuclear export signal, 
mitochondrial export sequence, a highly structured B-domain, and essential catalytic macrodomain 
(164). The crystal structure of PARG was resolved from the bacterium Thermomonospora curvata 
by Slade et al. (174). This revealed that the catalytic domain of PARG belongs to a distant member 
of the ubiquitous ADPr-binding macrodomain family (175,176). They proposed a model for PAR 
binding and catalysis by modelling the PARG complex with ADP-ribose and the PARG inhibitor 
ADP-HPD as well as complementing with biochemical studies.  The diphosphate-binding loop 
that flanks one side of the ADPr binding cavity is highly conserved between PARG and other 
macrodomain structures. However, the other side of the cavity is lined with the PARG-specific 
signature sequence (GGG-X6-8-QEE), which is inserted into the macrodomain fold to allow for the 
Glu115 side chain to protrude into the PARG active site. This PARG-specific loop differentiates 
PARG from the other macrodomain proteins and enables the ability for PAR hydrolysis (174). 
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 Nuclear PARG exhibits a dual recruitment mode to damaged lesions, which involves its 
dependency on PARP1, PAR, and PCNA binding. PARP1 and PAR provide access to the damaged 
lesions by relaxing the chromatin structure and serving as a docking site for PARG recruitment. 
PARG then interacts with PCNA through a non-canonical PIP box-domain located within the 
disordered regulatory region (177). Specifically, the acetylation site K409 permits stabilization of 
the PCNA-PARG interface via hydrophobic and electrostatic interactions. This interaction 
enhances PARG residency at damaged lesions. Since PCNA displays slow and constant 
accumulation at damaged lesions, PARG’s interaction with PCNA could potentially keep PAR 
levels at a lower, steady-state for later steps of repair (178). In fact, PARG is recruited to replication 
forks through PCNA where it hydrolyzes PAR that accumulates at unligated Okazaki fragments 
(179). 
As PARG is the primary enzyme to degrade PAR, it plays a fundamental role in embryonic 
development and maintenance of genome stability (180). Loss of the PARG gene results in early 
embryonic lethality at the gastrulation stage (embryonic day 6.5), which phenocopies Parp1-/- 
Parp2-/- double mutant mice (156). This deleterious consequence affirms that the regulation of 
PAR levels is essential for cell survival and that there is a lack of a compensatory mechanism for 
PARG. In addition, proper PAR catabolism is essential for the completion of efficient repair in 
response to genotoxic stress. Depletion of the nuclear isoform of PARG, PARG110, leads to 
compromised repair of DNA damage caused by various genotoxic agents (171,181). PARG110
-/- 
cells display elevated genome instability, as seen by high frequency of sister chromatid exchanges, 
micronuclei formation, and chromosomal aberrations. PARG activity is dispensable for DNA 
replication in unperturbed conditions and recovery from transiently stalled replication forks  
(171,181). However, PARG is crucial during prolonged replication stress to prevent massive PAR 
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production, which leads to replication fork collapse and DSBs. Another study showed that PARG 
depletion leads to perturbed fork progression and accumulation of abnormal DNA replication 
(182). PARG-defective cells also exhibit ataxia-telangiectasia-mutated (ATM) and ataxia-Rad3-
related (ATR) activation, as well as downstream DSB repair factors, such as p53-binding Protein 
1 (53BP1) and RAD51. Thus, PARG is essential to sustain cellular energy supplies and ensure the 
faithful stepwise transitions during DNA repair and replication. This collectively affirms that tight 





Figure 4. PARylation is an apical signal of DNA damage. A damaged DNA lesion, such as a DSB, recruits 
PARP1 to the site of damage to propagate the DNA damage signal for various cellular events. The completion of 
repair is marked by PARG-mediated PAR hydrolysis. 
 Role of PARylation in DSB Repair  
DSBs are repaired through HR or NHEJ depending on the cell cycle and chromatin state. 
PARP1 is required for a robust DSB response, as it is an apical sensor that is recruited to the 
damaged lesion within seconds of DSB formation (183). Initial DSB responders, such as ATM 
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and Mre11 contain PAR-binding domains and have been shown to interact with PAR in vitro. 
PARP1-stimulated recruitment of the MRN complex could favor pathway choice for repair of 
DSBs towards HR (184–186). PARP1 also regulates the early recruitment of other HR factors, 
including BRCA1. PARP1 may indirectly enhance BRCA1 localization through its interaction 
with BRCA1-associated RING domain protein 1 (BARD1), which facilitates BRCA1’s role in end 
resection and loading of RAD51 onto DNA (187). However, BRCA1 is only partially dependent 
on PARP1 since it can still be recruited to DSBs by ubiquitylation (188). This indicates that there 
are compensatory mechanisms for the initial DSB response because PARP1 depletion does not 
completely abolish the recruitment of these HR factors and only delays their recruitment. However, 
it is well-established that loss or inhibition of PARP1 leads to a hyper-recombinogenic phenotype 
(189,190). An explanation for this phenotype involves PARP1-mediated stabilization of BRCA1 
and receptor-associated protein 80 (RAP80), which restricts HR by blocking strand invasion. 
Another possibility is that PARP1 deficiency leads to processing of SSBs into DSBs, which would 
enhance reliance on HR. This is supported by the synthetic lethality that results from loss of 
BRCA1 and BRCA2 in combination with PARP inhibitors (191,192).  
PARP1 competes with Ku70/80 for pathway choice in G1 and S/G2-phase. PARP1 and the 
Ku70/80 complex are recruited to DSBs at similar kinetics (183). While the Ku70/80 complex 
occupies DSBs specifically in the G2-phase, PARP1 can PARylate the Ku70/80 complex and 
displace it during S/G2-phase. This prevents Ku70/80 complex-mediated c-NHEJ during S/G2-
phase, leading to PARP1 regulation of alt-NHEJ during this phase. Alt-NHEJ involves minimally 
resected ends that are joined through microhomology. The gap is then filled by Pol  and ligated 
by LIG3 (193). Alt-NHEJ is considered a backup pathway for c-NHEJ (194). Intriguingly, 
telomere-internal DSBs are also repaired by both HR and PARP1/LIG3-dependent end-joining 
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(195). The inability of the Shelterin complex to repress alt-NHEJ and HR at telomere internal 
DSBs poses a confounding question regarding the unique telomeric environment that is permissive 
to these repair mechanisms.  
 Role of PARylation in Replication  
 PARP1 plays a pivotal role in regulating replication fork progression during replication 
stress. Impediments to replication can generate unrepaired single-strand breaks at DNA replication 
forks, which cause fork stalling until the lesion is fully repaired. Persistent fork stalling leads to 
fork collapse, resulting in one-ended DSBs that become substrates for HR (196). It has been 
established that RecQ1 helicase interacts with PARylated PARP1, which restrains its fork 
restoration activity to prevent premature restart of regressed forks after camptothecin (CPT) 
treatment (197). Inhibition of PARP1 allows for untimely restart of reversed forks, which 
ultimately primes replication run-off and increased DSB formation. This affirms the importance 
of PARP1 as a mediator of the stabilization of replication forks through regulation of fork reversal.  
Interestingly, Maya-Mendoza et al. showed that inhibition of PARP1 accelerates fork 
progression, but does not increase fork stalling, which is in contrast with the previously described 
accepted model by Berti et al (197,198). DNA fiber analysis revealed aberrant acceleration of fork 
progression by 60% above the normal speed without affecting fork symmetry (198). The authors 
proposed that PARylation acts as a sensor for replication stress and can signal fork arrest. PARP1 
also induces p53-mediated accumulation of p21, which further prevents defective forks from 
progression. PARP1 inhibition exceeds the threshold for fork speed and triggers DDR in cells. 
Increased fork speed may lead to bypass of DNA lesions as well as reduced fidelity of DNA 
polymerases, which further contribute to genomic instability (198).  Overall, both viewpoints agree 
 
 27 
that controlled regulation of fork progression via PARP1 is crucial for preservation of genome 
integrity.  
 Role of PARylation in Chromatin Remodeling 
Cells rely on reorganization of chromatin structure to increase the accessibility of the DNA 
repair machinery to damaged lesions. PARP1 modulates chromatin architecture through direct 
PARylation of histones and chromatin remodelers (128,199). Early studies showed that 
PARylation of nucleosomes leads to chromatin decondensation in vitro (200).  Later evidence 
proposed a more intricate interplay between PARylation and the histone core of nucleosomes 
(H2A, H2B, H3, and H4) as well as the linker histone H1 (201). Biochemical tools and mass 
spectrometry revealed that PARP1 covalently modifies the lysine residues of the core histone tails 
(K13 of H2A, K30 of H2B, K27 and K37 of H3, and K16 of H4). It is speculated that the 
accumulation of negatively charged PAR polymers neutralizes the positive charge from the amino 
acid side chain of the histone core and can act as a repellant to DNA. PARylation of the histone 
tails may also interfere with other post-translational modifications that rely on the same residue. 
Therefore, PARylation likely has a global impact on histone dynamics, histone degradation, and 
histone incorporation (201).  
Chromatin relaxation and nucleosome eviction from the DNA facilitates recruitment of 
chromatin remodelers for the unfolding and spatial expansion of chromatin regions. One of the 
well-characterized chromatin remodeling enzymes is Amplified in Liver Cancer 1 (ALC1), which 
becomes active upon release by PARP1’s product, PAR (202,203). The ALC1 macrodomain 
regulates auto-inhibition to ensure that chromatin relaxation is dependent on DNA damage. When 
DDR is activated, PAR serves as an allosteric activator and triggers ALC1-mediated chromatin 
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expansion. Furthermore, the chromatin remodeler chromodomain helicase DNA-binding protein 
2 (CHD2) is recruited to DSBs in a PARP1-dependent manner (204). PARP1 recruitment of CHD2 
permits chromatin expansion and deposition of histone variant H3.3 at sites of DNA damage, 
which function to promote NHEJ. In addition, the SWI/SNF-related matrix-associated actin-
dependent regulator of chromatin subfamily A member 5 (SMARCA5) likely binds to PAR chains 
on the E3 ubiquitin ligase RNF168 upon DNA damage (205). This PARP-mediated signaling 
cascade that links SMARCA5 to RNF168 also drives DSB repair by NHEJ.  
 PARP Inhibitors 
PARP inhibition exploits the vulnerabilities in cancers that have a deficiency in 
homologous recombination (HR). There has been dramatic advancement towards the development 
of PARP inhibitors for treatment of tumors with BRCA1/2 mutations. Germline BRCA1/2 
mutations are linked to inherited breast and ovarian cancers (206).  These tumors are selectively 
targeted due to synthetic lethality. PARP inhibitors lead to persistent SSBs that convert to DSBs 
upon fork collapse. Thus, tumors that harbor HR defects are particularly vulnerable to PARP 
inhibitors because they cannot repair these DSBs and eventually undergo cell death.  
PARP inhibitors drive cytotoxicity through differential inhibition of PARP catalytic 
activity and PARP trapping, in which trapped PARP1-DNA complexes interfere with DNA 
replication and repair (207). Four PARP inhibitors have FDA-approval for treatment in women 
with an inherited BRCA1/2 mutation who have ovarian cancer – Talazoparib (Talzenna), Olaparib 
(Lynparza), Rucaparib (Rubraca), and Niraparib (Zejula). The relative trapping capacity of these 
inhibitors is: Talazoparib > Niraparib > Olaparib > Rucaparib (208–210). This dissertation 
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specifically uses Olaparib (Kd~1 M), which was first approved in 2014 and is currently the first-
line maintenance therapy in BRCA-mutated advanced ovarian cancer.  
 PARG Inhibitors 
There is currently no PARG inhibitor that is approved by the FDA, which highlights the 
fact that PARG inhibitors are much more underdeveloped than PARP inhibitors. PARG inhibition 
is a promising approach to exploit vulnerabilities in cancers with an altered DDR pathway. There 
is no known close homolog of PARG, which limits the possibility of redundant pathways to arise 
upon PARG inhibition. PARG inhibitors have been grouped into three major categories: DNA 
intercalators, tannins, and ADPr analogues. DNA intercalators and tannins were not ideal 
candidates because they lack specificity and elicit severe toxicity (211). Adenosine diphosphate 
(hydroxymethyl)pyrrolidinediol (ADP-HPD), an analogue of ADPr, became a more promising 
PARG inhibitor due to its higher potency and selectivity (IC50 = 120 nM) (212,213).  In addition, 
rhodamine-based small molecules were developed and showed selectivity since they did not inhibit 
ARH3 or PARP1 (214). However, none of these inhibitors were cell-permeable and only 
biochemical assays were performed with them (214). Although Mono-galloyl glucose derivatives 
and modified salicylanilides were discovered as an attempt to overcome lack of cell permeability, 
they also inhibited PARP1 and had lower potency (215,216). Thus, the lack of selective, cell-
permeable PARG inhibitors have hampered the study of PARG inhibition in the biological context.  
James et al. discovered the first selective, potent PARG inhibitor from a high throughput 
screen (HTS) of 1.4M compounds in 2016 (217).  They were able to detect PAR accumulation in 
murine cells and a variety of human cancer cells in response to DNA damage and treatment with 
the PARG inhibitor. Only in the presence of DNA damage did the PARG inhibitor lead to dose-
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dependent increase in nuclear PAR chain signal.  Upon optimization of the lead compound, they 
managed to improve the EC50 to 0.040 M. Thus, their compound (PDD00017273) became 
commercially available on Tocris. PDD00017273, termed PARGi in this dissertation, is used for 
all experiments (218).  
Pharmacological inhibitors of PARP and PARG are used in this thesis dissertation to 
elucidate the role of PAR metabolism in ALT telomere maintenance. Olaparib is an FDA-approved 
inhibitor of PARP1. Its mechanism of action is two-fold (219). First, its structure is a nicotinamide 
moiety that competes with NAD+, which is the substrate to generate ADP-ribose. Second, Olaparib 
traps PARP onto the DNA and interferes with DNA repair. Many studies reveal that PARP1 
trapping drives the cytotoxicity of Olaparib in HR-deficient cancers (207,220,221). PARP1 
trapping leads to elevated collisions at the replication fork, which eventually generates DSBs that 
cannot be repaired. Thus, there is an important distinction between PARP1 inhibition and PARP1 
depletion. On the other hand, there are no PARG inhibitors in the clinic. However, the lab acquired 
a cell-permeable competitive PARG, as an well as an inactive analog (218). These inhibitors 




Figure 5. Mechanism of PARP and PARG inhibitors. Olaparib inhibits PARP1 activity by competing with 
NAD+ as well as traps PARP1 onto the DNA, which interferes with DNA repair. PDD-00017273 (PARGi) 
 is the first cell-permeable competitive inhibitor of PARG. Adapted from Shen et al., ASPET, 2015 (219) 
(http://jpet.aspetjournals.org/content/353/3/446) and Tucker et al., Plos One, 2012 (222) 
(https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0050889). 
1.5 Major Hypotheses 
There are several outstanding questions in the field regarding the exact stimulus that 
activates ALT, as well how multiple DNA repair pathways are coordinated in ALT telomere 
maintenance. There are three hypotheses in this thesis dissertation.  1) If the tight regulation of 
PAR turnover is necessary to control the dynamic state of telomeres in ALT, then pharmacological 
inhibition of PARP1 and PARG will have consequences on ALT activity. 2) If we identify 
PARylated telomeric proteins in ALT, then this will give us a snapshot into the apical events that 
promote ALT activity. 3) If we determine the importance of PAR-regulation in the function of 
 
 32 
early ALT regulators, then we can target these vulnerabilities to kill ALT cancers. Specifically, in 
ALT cancers that predominantly have loss of function mutations in ATRX/DAXX, PAR-mediated 
regulation of HIRA-mediated chromatin assembly is potentially a compensatory pathway at ALT 
telomeres. Each hypothesis is discussed in detail below with a summary of the pertinent 
background information that supports the hypothesis.  
 PAR metabolism is an important regulator of the recombinogenic potential of 
telomeres in ALT cancer cells 
To date, the implications of deregulated PAR turnover at ALT telomeres have not been 
described. PARylation likely holds an elevated importance in ALT cancers since they rely on 
maintaining the balance between DNA damage signaling and genomic stability. One evidently 
critical outcome of the reconfiguration of chromatin is that telomere integrity is challenged and 
subject to recurrent replicative stress and stochastic DNA double strand breaks (27,29). It is 
generally accepted that recurrent cycles of DNA damage provide the trigger and DNA substrates 
for ALT-associated HDR. However, prolonged DNA damage signaling and genomic instability 
may lead to anti-proliferative signaling that induces apoptosis or cell cycle arrest. ALT cellular 
phenotypes, such as APB formation, presence of ECTR DNA, and increased T-SCEs, highlight 
the recombinogenic potential of ALT telomeres (34,58,63,65). The enrichment and activity of 
SMARCAL1 and FANCM at ALT telomeres affirms the prevalence of replication stress and how 
resolution of this replication stress is crucial for ALT telomere maintenance (29,30,104). It was 
also recently proposed that FANCM unwinds telomeric R-loops formed by TERRA, which 
normally enhances replicative stress at ALT telomeres (30). Depletion of SMARCAL1 and 
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FANCM suppresses ALT activity, indicating the importance of reversing and remodeling stalled 
replication forks to overcome replication impediments (29,30,104).  
These lines of evidence suggest that ALT cells have adopted a dynamic interplay between 
telomeric damage and genomic stability. The role of PARylation is of particular interest in ALT 
because of its expansive function in regulation of DDR. As PARylation is an apical event in DDR, 
it can potentially be a driver for fine-tune control of telomeric damage to maintain a specific 
threshold for telomere elongation and cell viability. PARP inhibition leads to bypass of damaged 
lesions and fork acceleration, which triggers replication stress (198). Additionally, PARylated 
PARP1 directly limits the restart capacity of RecQ1 in order to stabilize forks in the regressed state 
until the damage is repaired (197). This leads to the hypothesis that perturbing PAR metabolism 
would alter replication stress levels at ALT telomeres and ultimately disrupt ALT telomere 
maintenance. PARP inhibition likely causes saturation of the DDR machinery, leading to 
unresolved intermediates that convert to DSBs. These DSBs would prime fragile telomeric regions 
for recombination. On the other hand, PARG inhibition likely results in unscheduled recruitment, 
retention and repulsion of DDR factors, which culminate in impaired HDR and ALT activity. The 
data supporting this hypothesis is presented in chapter 2.  
 PAR-regulated telomere-associated proteins coordinate the early steps of ALT 
telomere maintenance 
PARylation is a critical sensor that detects damaged lesions generated by endogenous and 
exogenous toxic stresses. PARylation is involved in an array of DDR pathways, yet only recently 
were the molecular targets of PARylation characterized. Jungmichel et al. identified a differential 
impact of various types of genotoxic stress on protein PARylation by using a sensitive proteomics 
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approach based on high-accuracy quantitative mass spectrometry (223). Analysis of the genotoxic-
stress PARylome revealed proteins enriched in DNA repair, DNA replication, chromosome 
organization, transcription, RNA processing, and RNA splicing. Interestingly, more than 60% of 
their diverse protein network contained nucleic-acid binding activity. This proteomics approach 
was adapted in this dissertation to characterize the PARylome at ALT telomeres. The identification 
of a PAR-regulated protein network at ALT telomeres would be beneficial to pinpoint the key 
factors that are essential in ALT initiation and maintenance.  
The first wave of proteins that respond to telomeric DNA damage may rely on PARylation 
to aggregate at ALT telomeres. Jungmichel et al. identified that the enrichment of RNA-binding 
proteins, such as the FET proteins (FUS, EWS1, TAF15), was 2-fold greater than the total number 
of RNA binding proteins in the entire genome (223). RNA-binding proteins typically harbor low-
complexity domains (LCDs) and have been shown to undergo PAR-seeded liquid demixing to 
orchestrate the earliest cellular response to DNA damage (224). In addition, it is thought that APB 
assembly is mediated by liquid phase separation, via SUMO-SIM interactions, to coalesce DNA 
repair factors for ALT telomere synthesis (225). The proteomics approach employed in this 
dissertation allows for the capture of these early ALT mediators, which would otherwise be 
transient as they undergo PAR hydrolysis. Chapter 3 of this dissertation provides support for the 
hypothesis that sustained PAR at telomeres, through PARG inhibition, would dramatically 
reconfigure the telomeric proteome and abrogate ALT activity. 
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 HIRA adopts elevated importance in ALT due to loss of a functional ATRX-DAXX 
complex 
Chapter 3 of the dissertation identifies the HIRA chaperone complex and all of its 
components, Histone Regulator A (HIRA), Calcineurin Binding Protein 1 (CABIN1) and 
Ubinuclein 1 (UBN1), to be PAR-regulated and associate at ALT telomeres. The HIRA complex 
plays a key role in the repair of UV-C lesions (226,227). HIRA depletion was reported to disrupt 
transcription recovery after DNA repair. HIRA also collaborates with histone binding protein 
ASF1a to deposit histone H3.3 onto chromatin in a DNA replication-independent manner 
(226,227). This is an important feature, since loss of function mutations in ATRX/DAXX, which 
deposits H3.3 during replication, are pervasive in ALT cancers. In fact, re-expressing ATRX in an 
ALT-cell line reverses the ALT phenotype (228). ATRX mitigates aberrant secondary structures, 
such as G-quadruplexes, that arise during telomeric replication. ATRX can also sequester MRN, 
which prevents HR from being initiated at telomeres. Thus, the lack of ATRX activity in ALT 
cancers leads to unresolved replicative impediments and enhanced HR.  
It is plausible that due to lack of ATRX activity, HIRA is potentially the sole functional 
H3.3 histone chaperone in many ALT+ cancers. HIRA’s elevated importance in ALT is supported 
by data from Project Achilles, which identified ALT cell lines, such as U2OS, SAOS2, and 
CAL72, to have greater gene dependency on HIRA. With this line of reasoning, it is hypothesized 
that HIRA does not fully compensate for ATRX’s ability to alleviate replication stress at ALT 
telomeres. These secondary structures become unresolved or directly cleaved by MRN, which 
results in fork collapse that generates DSBs. This ultimately triggers HDR and potentiates the ALT 
phenotype. PARylation of HIRA is the early signal that recruits it to sites of telomeric damage to 
deposit H3.3 for chromatin remodeling during DNA synthesis in G2-BIR. Thus, HIRA enables the 
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basal level of stochastic DNA damage and replication stress that promotes ALT.  Upon PARG 
inhibition, HIRA is retained at telomeres, which abrogates ALT telomere maintenance by 
impairing chromatin remodeling and uncoupling it from efficient repair by G2-BIR. This is the 
focus of chapter 4 in this dissertation.  
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2.0 Disrupted PAR metabolism alters recombinogenic activity at ALT telomeres  
2.1 Introduction 
There are several lines of evidence that strongly supports ALT as an HR-mediated DNA 
synthesis mechanism that arises from inherent replication stress and stochastic DNA damage at 
ALT telomeres. Double-stranded breaks (DSBs) at internal telomeric regions and telomeric 
replication forks act as substrates for homology-directed repair (HDR) in ALT (195). In S-phase, 
telomeres pose a challenge for the replication machinery, leading to replication fork stalling. The 
stalled replication fork can undergo fork reversal and restart by the FANCM-BTR complex (104). 
Replication stress is relieved at telomeres and ALT activity is restrained. However, unresolved 
replication stress leads to fork collapse, which provides direct DSB substrates for ALT-mediated 
telomere synthesis and recombination by RAD51-dependent mechanisms (96,98). The SMX 
complex (SLX1-SLX4, MUS81-EME1, and XPF-ERCC1) and BTR complex (BLM-TOP3A-
RMI) maintains the balance between telomeric recombination and extension (81). The SMX 
complex promotes resolution of telomeric recombination intermediates in the absence of telomere 
extension. This is counteracted by the BTR complex, which initiates telomere dissolution for long-
tract ALT-mediated telomere synthesis. Intra-telomeric strand invasion and persistence of 
collapsed forks in G2 activates PCNA-RFC-POLD3-mediated DNA synthesis. However, SLX4IP 
can antagonize the BTR complex to favor SMX-dependent resolution (112).  
Although the molecular events involved in ALT are well-studied, the stimulus of HDR 
pathway choice and the regulation of such events to maintain the equilibrium between DNA 
damage and cell viability still remains elusive. PARylation is a promising candidate because it is 
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an apical molecular response to DNA breaks and replicative stress. Published data in the 
O’Sullivan lab characterized the telomeric proteome in the ALT+ U2OS cell line using proximity-
dependent biotinylation (BioID) (87). This work revealed a greater enrichment of PARP1 at ALT+ 
telomeres compared to TEL+ telomeres. The exposed termini of chromosomes represent natural 
triggers of PARP activity (229). Indeed, PARPs including PARP1, PARP2 and Tankyrase, reside 
at telomeres in human cell lines (230). TRF1 and TRF2 are core constituents of the Shelterin 
complex that shield telomeres from DNA damage sensors, including any unwarranted PARP 
activity (231). However, upon telomere dysfunction through loss or genetic disruption of Shelterin 
and the canonical Ligase IV dependent non-homologous end joining mechanism (cNHEJ), 
PARP1-XRCC1-Ligase III can promote telomere fusions by alternative non-homologous end 
joining (alt-NHEJ) (232). In contrast, internal telomeric DSBs appear to be preferentially repaired 
by similar PARP1-dependent alt-NHEJ, which resembles HDR (195). Recent findings have 
identified a role for PARylation in response to replication fork destabilization when the Regulator 
of Telomere Elongation (RTEL) helicase is non-functional (233). Thus, PARylation or the 
synthesis of PAR by PARPs is a crucial factor in the management of damaged telomeres. 
The breakdown of PAR chains occurs via enzymatic hydrolysis by the essential enzyme 
PARG (174). PARG-mediated hydrolysis of PAR salvages NAD+ that is recycled and transferred 
to mitochondria to eventually generate essential metabolites, including adenosine triphosphate 
(ATP). Unhydrolyzed PAR sequesters cellular NAD+ that cannot be replenished without PARG, 
leading to catastrophic energy failure (180). Another consequence of PARG depletion is that 
failure to hydrolyze PAR chains compromises DNA repair, leading to the accumulation of 
unrepaired DNA lesions and DSBs (182,234). In fact, PARG is recruited to replication forks 
through PCNA where it hydrolyzes PAR that accumulates at unligated Okazaki fragments (179). 
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Therefore, PARG is essential to sustain cellular energy supplies and ensure the faithful stepwise 
transitions during DNA repair and replication.   
Here, we show that pharmacological interference of PAR metabolism disrupts the HDR 
mechanisms that mediate ALT. PARP and PARG inhibition have opposing effects on ALT 
activity. While PARP inhibition (PARPi) exacerbates ALT features, such as APBs, T-SCEs, and 
C-Circles, PARG inhibition (PARGi) diminishes these ALT phenotypes. Intriguingly, prolonged 
PARG treatment leads to dramatic telomere shortening in ALT+ cells. To further understand how 
alterations in PAR turnover affects ALT activity, we used an established system where an 
inducible U2OS cell line expresses the FokI endonuclease fused to TRF1. This introduces DSBs 
specifically at telomeres, which serve as substrates for HDR mechanisms in ALT. PARG inhibition 
leads to decrease in telomere clustering, mobility, and replication, which indicates that both HR 
and G2-BIR are impaired as a consequence of PAR accumulation. Together, our work establishes 
the importance of PAR catabolism for mediating efficient HDR in ALT. 
2.2 Results 
 Effectiveness of the PARP inhibitor (Olaparib) and PARG inhibitor (PDD00017273) 
The availability of highly specific and effective compounds (e.g. Olaparib) enabled the 
phenotypic assessment of PARP inhibition in a wide range of cellular contexts, including the 
synthetic lethal elimination of BRCA1/2 deficient breast and ovarian cancer cells (191,192). 
Following the resolution of the crystal structure of PARG, specific small molecules that block the 
active site of PARG have been developed (214). We verified the effectiveness of one of these, 
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PDD00017273 (PARGi), by monitoring the accumulation of PAR in hydroxyurea treated U2OS 
cells by western blot using a specific anti-PAR (10H) antibody (Figure 6A). PARylation is a 
reversible, transient modification, which means that the suppression of PARG is necessary to 
prevent PAR degradation. In addition, other studies have also used exposure to DNA-damaging 
agents to enhance DNA damage-dependent PARylation (166). Thus, PAR accumulation is only 
observed in cells treated with the combination of HU and PARGi, which confirms the effectiveness 
of the inhibitor. We also examined PARGi’s specificity by treating cells with an inactive analog 
(PARGiMe), which contains an additional methyl group that blocks the inhibitor’s catalytic activity. 
Indeed, damaged cells treated with PARGiMe did not retain PAR. In addition, the same pattern was 
seen in cells where PARP1 and PARG were depleted using shRNA knockdown (Figure 6B). The 
effectiveness of PARPi was confirmed through the abolishment of PAR accumulation in cells with 
PARG shrRNA knockdown. After proven effectiveness and specificity, we decided to utilize these 





Figure 6. Western blot analysis of PAR induction. A) Western blot analysis of PARP1, PARG, and PAR 
expression in U2OS cells treated with DMSO, PARPi, PARGi or inactive PARGiMe (all 5M). Cells were untreated 
or treated with 2mM hydroxyurea (HU) for 4hrs to control for PARylation induction. B) Western blot validation of 
PARP1 and PARG knockdown and PAR accumulation in U2OS cells expressing non-targeting scrambled 
shControl, shPARP1 or shPARG. Cells were untreated or treated with hydroxyurea (HU) to control for PAR 
induction. 
 PARP and PARG inhibition have opposing effects on ALT activity 
We next assessed the effect of PARP and PARG inhibition on telomeres that are 
maintained by the ALT pathway. ALT-positive (ALT+) cancer cell lines are typified by the 
presence of a low but consistent percentage of cells containing telomeres that localize to PML 
bodies forming unique sub-nuclear structures known as ALT-associated PML bodies (APBs). 
These are thought to represent centers of telomeric HR. Quantification of their numbers by 
immunofluorescence combined with fluorescence in situ hybridization (IF-FISH) is routinely used 
as a first line measurement of ALT activity. We found that a 72hr treatment using standard 5M 
doses of Olaparib (PARPi) or PARGi elicited the opposite effect on APB levels in several 
independent ALT cell lines including U2OS and Saos2 (Figure 7A and 7B). Whereas PARPi 
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increased their frequency, PARGi significantly decreased the percentage of APB positive (APB+) 
U2OS and Saos2 cells.  Interestingly, we found that PARP inhibition led to de novo formation of 
APBs in a HeLa LT cell line that maintains its hyper-extended telomere length through telomerase 
mediated TTAGGG repeat addition (Figure 7B). This is consistent with previous findings that 
PARP inhibition can provoke ALT-like features at telomeres. To control for possible off-target 
effects, we treated cells with an inactive PARGi analog, PDD00031704, (PARGi-Me) which cannot 
engage PARGs active site (Figure 7B). Treatment with this small molecule had no effect on APB 
levels. Experiments using lower doses of 100nM-1M of PARGi for prolonged periods (Figure 
7C), as well as shRNA depletion of PARP1 and PARG in U2OS, Saos2 and HeLa LT (Figure 7D 
and Figure 42), produced results similar to inhibitor treatments. Notably, the reduction of APBs 
was reversed to normal levels when PARPi was added to PARG depleted U2OS cells. These data 




Figure 7. PARP and PARG inhibition have opposing effects on APBs. A) Representative images of APBs 
(PML-TTAGGG colocalization) in U2OS cells treated with indicated inhibitors. B) Quantification of APBs (%) in 
U2OS, Saos2, and Hela LT after the indicated treatments. C) APBs (%) in U2OS cells treated with lower doses of 
PARPi or PARGi (100nM and 1mM) over 3, 6, 9 and 12 days. D) Quantification of APBs (% positive cells) in 
U2OS, Saos2 and HeLa LT cells expressing shControl, shPARP1 or shPARG. All graphed data in the figure are 
mean ± SEM, n=1200 cells. Statistical significance was determined using one-way ANOVA. *P≤ 0.05, **P≤ 0.001, 
***P≤ 0.001, ****P< 0.001. 
 
We next assessed whether PARP and PARG inhibition impacted the frequency of telomere 
sister chromatid exchanges (T-SCEs), that are commonly studied as a surrogate of telomere 
recombination, using the chromosome orientation FISH (COFISH) assay. Metaphase spread 
chromosomes were prepared from DMSO, PARPi and PARGi-treated U2OS, Saos2 and HeLa LT 
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cells (Figure 8A). This revealed that PARPi significantly increased T-SCEs in the ALT+ U2OS 
and Saos2 cells, but also in HeLa LT cells where this recombination associated activity is normally 
restrained. As seen previously with the inhibitor data, the same trend was evident in cells where 
PARP1 or PARG were depleted by shRNA knockdown (Figure 8B). 
 
Figure 8. PARP and PARG impact frequency of T-SCEs. A) Telomere sister chromatid exchanges (T-SCEs) in 
U2OS,  12 days after PARPi (1M) or PARGi (1M) treatment. B) Quantification of T-SCEs (% per metaphase) in 
U2OS, Saos2 and HeLa LT cells expressing shControl, shPARP1 or shPARG. All graphed data in the figure are 
mean ± SEM, n=45 metaphases. Statistical significance was determined using one-way ANOVA. *P≤ 0.05, **P≤ 
0.001, ***P≤ 0.001, ****P< 0.001. 
 
The robust opposing effects observed in inhibitor-treated cells raised the question of 
whether telomere length might be altered in ALT+ cells that are chronically deprived of PARP or 
PARG activity. We subjected ALT+ U2OS and TEL+ HeLa LT cells to prolonged treatments with 
lower doses of PARPi (1 M) and PARGi (1 M) for ~30PDs and assessed telomere length by 
pulsed field gel electrophoresis (PFGE) (Figure 9). This showed that PARPi in U2OS cells greatly 
reduced the overall signal of telomeric DNA while not overtly affecting the mean telomere length. 
In contrast, PARG inhibition profoundly reduced telomere length in U2OS cells and another 
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independent ALT+ cell line, VA13, with lengths now ranging from 2kb-25kb and a mean length 
of ~10kb (Figure 9 and Figure 43). Parallel treatment of HeLa LT with PARPi and PARGi did not 
change telomere length (Figure 9). We also found that PARPi inhibition significantly enhanced 
the levels of extra-chromosomal C-circles in U2OS cells and provoked their de novo formation in 
HeLa LT cells. In contrast, PARG inhibition had no effect on C-circle levels in ALT cells. These 
results suggest that the changes in telomere length were due to telomere shortening and not the 
accumulation of extra-chromosomal telomeric DNA species. Overall, this comprehensive analysis 
demonstrates that the equilibrium between the anabolism and catabolism of PAR is a determinant 
of the recombinogenic potential of telomeres that sustains telomere length in ALT cancer cells. 
 
Figure 9. PARGi leads to telomere shortening in ALT+ cells. PFGE of DMSO, PARPi (1M) or PARGi (1M) 
treated U2OS cells. The mean telomere length (kb) was calculated using TeloTool and is indicated by the red dot. 
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 ALT cancer cells exhibit modest sensitivity to PARG inhibition 
To assess whether ALT cells display greater susceptibility to PARP and PARG inhibition, 
we conducted clonogenic survival assays of ALT+ (U2OS, Saos2, LM216J) and TEL+ (HOS, 
SJSA1, LM216T) cells that were exposed to the same doses (1 M) that elicited alterations in ALT 
recombination and telomere length maintenance (Figure 10). It should be noted that LM216J and 
LM216T cells are isogenic cell lines Whereas the ALT+ and TEL+ cell lines were all sensitive to 
d PARP inhibition, ALT+ cell lines were indeed more sensitive to PARGi. However, the 





Figure 10. ALT+ cells display modest sensitivity to PARGi. Representative images and quantification from 
clonogenic survival assays with ALT+ and TEL+ cells treated with DMSO, PARPi (1M) or PARGi (1M) for 7 
days. All graphed data in the figure are mean ± SEM, n=3. Statistical significance was determined using student t-
test. *P≤ 0.05, **P≤ 0.001, ***P≤ 0.001, ****P< 0.001. 
 
  PAR metabolism is required to sustain the key steps of the ALT mechanism 
To understand how disrupting PAR metabolism affects ALT telomere maintenance, we 
took advantage of U2OS cells that express the Doxycycline/4-OHT/Shield inducible (WT) or 
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catalytically inactive (DA) c-terminal of FokI endonuclease fused to TRF1. FokI is a type IIS 
restriction endonuclease that recognizes the non-palindromic recognition site (5’GGATG) and 
cleaves 9 to 13 nucleotides downstream of it (235). In solution, FokI exists as a monomer with two 
domains: N-terminal DNA-binding domain that associates with the entire recognition site and C-
terminal catalytic domain with one active site (236). FokI must dimerize to cleave both strands of 
DNA or it can nick DNA and block replication fork progression (237). Our TRF1-FokI system 
induces the DSB cleavage of telomeric DNA to trigger HR and G2-BIR (Figure 11). This results 
in larger telomeric foci that can be visualized and quantified by immunofluorescence (IF). This 
accentuates the presence of these ALT-associated processes that are otherwise relatively difficult 





Figure 11. TRF1-FokI schematic. Targeted introduction of DNA nicks and DSBs at telomeres through FokI 
endonuclease fused to TRF1 activate HDR responses. Long-range homology search is performed through a RAD51-
dependent mechanism that involves the RAD51-HOP2-MND1 complex. DNA synthesis in ALT cancer cells is 
RAD51-independent and largely restricted to G2 and M-phases. In G2-BIR, RAD52-PCNA-RFC-mediated loading 
of Pol is essential for conservative synthesis of both leading and lagging DNA strand.  
 
 We first asked whether TRF1-FokI-induced DSBs provoked the accumulation of PAR 
directly at telomeres (Figure 12). Immediately following induction of wildtype (WT) or inactive 
(DA) TRF1-FokI, DMSO, PARPi, PARGi, or the inactive PARGi-Me analog, was added to induced 
U2OS cell cultures. PAR accumulation was only detected by western blot using the 10H anti-PAR 
antibody in extracts from WT TRF1-FokI cells that were treated with PARGi (Figure 12). As 
previously shown, U2OS cells expressing WT TRF1-FokI exhibited elevated levels of Histone 
H2AX Serine 139 (H2AX) and CHK2-Threonine 68 (CHK2-T68) phosphorylation. Acute 
treatment with PARPi enhanced these markers of DNA damage in WT TRF1-FokI cells and was 
sufficient to generate DNA damage response signaling in DA TRF1-FokI. In contrast, acute 
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PARGi treatment did not alter the initial or downstream TRF1-FokI-induced DNA damage 
response signaling.  
 
Figure 12. WT TRF1-FokI induces telomeric DNA damage. Comparison of PAR levels and DSB responses in 
WT TRF1-FokI and DA TRF1-FokI cells with DMSO, PARPi (5M) or PARGi (5M) TRF1-FokI expression is 
similar across all samples, as indicated by FLAG western. 
 
IF revealed a focal enrichment of PAR specifically at telomeres only in WT TRF1-FokI 
cells treated with PARGi, and not DA TRF1-FokI cells, indicative of the DNA damage 
dependency of this response (Figure 13A-B). TRF1-FokI-induced DSBs are mostly processed by 
HDR-based mechanisms, though perhaps not entirely, with alt-NHEJ also fulfilling a role at repair 
of internal telomeric DSBs (195). During HDR, loading of the HR presynaptic filaments with 
RAD51 stimulates the search for homologous DNA sequences with which to pair and recombine. 
In the context of TRF1-FokI, this can be optically visualized as the clustering of telomeres into 
large foci (96,98). This has the effect of increasing the size and reducing the overall number of 
telomeric or TRF1-FokI foci as detectable by IF (Figure 13C). This dynamic was readily observed 
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following quantification of telomere size and number in DMSO treated WT TRF1-FokI-induced 
cells Although PARPi did not enhance clustering events in WT TRF1-FokI cells, such events were 
observed in DA TRF1-FokI cells. This is consistent with earlier observations that PARPi is 
sufficient to induce ALT like phenotypes in non-ALT cells. Strikingly, when PARGi was added 
to WT TRF1-FokI cells, the number and size of individual telomeres remained close to levels 
observed in DA TRF1-FokI cells. The same outcome was observed in PARGi-treated VA13 ALT+ 
cells, but not in TEL+ HeLa LT cells, reflecting a specific perturbation of ALT-associated telomere 




Figure 13. PARGi abolishes TRF1-FokI -telomere clustering. A) Representative IF-FISH images showing PAR 
localization at telomeric foci in WT TRF1-FokI cells. B) Quantification of PAR foci colocalization with TRF1-FokI 
telomeric foci. C) TRF1-FokI telomeric foci number and size in WT and DA cells for each experimental condition. 
All graphed data in the figure are mean ± SEM, n=75 cells. All graphed data in the figure are mean ± SEM, n=45 
metaphases. Statistical significance was determined using one-way ANOVA. *P≤ 0.05, **P≤ 0.001, ***P≤ 0.001, 




This PAR accumulation was abolished upon co-treatment with both PARGi and PARPi, 
but not with XAV939, an inhibitor of the specialized PARP, Tankyrase (Figure 14A). We also 
determined that PARG localizes directly to WT TRF1-FokI DSBs. This was dependent on its 
PCNA interaction peptides (PIPs) and PARP1 activity (Figure 14B). Therefore, PARP1-mediated 
PARylation, and its hydrolysis by PARG, represent direct mediators of the response to DSB 





Figure 14. PARylation is an early and direct mediator of TRF1-FokI DSB formation. A) Representative IF 
images and graph displaying PAR localization to TRF1-FokI telomeres in response to PARPi (5M) and TANKi 
(XAV939) (10M). B) Representative IF images and graph showing PARG localization in WT TRF1-FokI cells 
transfected with GFP-PARG-FL and GFP-PARG Q76A-K409A. All graphed data in the figure are mean ± SEM, 
n=25 cells. All graphed data in the figure are mean ± SEM, n= 50 cells. Statistical significance was determined 
using one-way ANOVA. *P≤ 0.05, **P≤ 0.001, ***P≤ 0.001, ****P< 0.001. 
 
We also tested whether PARylation affects telomere mobility independently of TRF1-
FokI-induced DSBs, in typical ALT+ cells. Optical visualization and tracking of telomeres can be 
achieved using fluorescently tagged TRF1 fusion protein. The mobility of individual or groups of 
eGFP-TRF1 molecules, representing telomeres, is empirically calculated as a function of mean 
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squared displacement (MSD). Undamaged telomeres in normal and TEL+ cancer cells exhibit 
patterns of nuclear mobility that are consistent with random diffusion. In contrast, ALT+ telomeres 
display trajectories that are consistent with directed motion as part of homology search and pairing 
of telomeres during HR (96). Using U2OS cells that stably express eGFP-tagged TRF1 (eGFP-
TRF1), we captured the three-dimensional telomere motion in x, y and z planes at 2-minute 
intervals for 2hrs following acute treatment with DMSO, PARPi and PARGi (Figure 15). 
Uninterrupted telomere motion was tracked, analyzed and quantified as a function of MSD. While 
PARP inhibition significantly increased the cumulative MSD from ~8m/hr to ~12.45 m/hr, 
PARG inhibited U2OS cells were clearly constrained, having an MSD of ~6.9 m/hr. 
Cumulatively, these data independently show that PARylation influences the long-range, 
directional motion of telomere. Ultimately, this impacts telomere contacts that are an intrinsic and 




Figure 15. PARylation perturbs long-range telomere movement in ALT cells. Representative movie stills of 
tracked telomere (eGFP-TRF1) movement in U2OS cells treated with DMSO, PARPi (5M) or PARGi (5M). 
Graph displays the cumulative Mean Squared Displacement (MSD) of telomeres imaged and analyzed, n=100 
telomeres. Statistical significance was determined using student t-test. *P≤ 0.05, **P≤ 0.001, ***P≤ 0.001, ****P< 
0.001. 
 PARG inhibition impairs G2-Break Induced Replication (G2-BIR) 
During G2-BIR, nascent DNA synthesized at the break can be labeled with BrdU, 
immunoprecipitated with anti-BrdU antibodies, and then quantified by telomere southern blot. The 
addition of PARPi to WT TRF1-FokI-induced cells did not enhance overall nascent telomere 
synthesis (Figure 16A). Notably, cells treated with PARGi showed a 50% decrease in BrdU 
incorporation, indicating a perturbation in break-induced telomere DNA synthesis. One possibility 
is that the localization of key mediators of DNA synthesis to telomeres is altered. In agreement 
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with this hypothesis, the accumulation of essential G2-BIR replisome constituents, PCNA and 
POLD3, following TRF1-FokI induction was diminished when PARGi was present (Figure 16B). 
 
Figure 16. PARGi impairs G2-BIR. A) TRF1-FokI-mediated break-induced synthesis assay to measure nascent 
DNA synthesis during G2-phase. B) Representative images and graph displaying PCNA or POLD3 localization at 
WT TRF1-FokI and DA TRF1-FokI telomeres. All graphed data in the figure are mean ± SEM. A) n=3 and B) n=75 
cells. Statistical significance was determined using one-way ANOVA. *P≤ 0.05, **P≤ 0.001, ***P≤ 0.001, ****P< 
0.001. 
 
We next employed a modified DNA combing technique in combination with telomere 
FISH to investigate individual telomeric replication events following deregulation of PAR 
metabolism. After 3hrs of induction, WT TRF1-FokI U2OS cells were sequentially pulsed for 20 
minutes with nucleotide analogs, Chlorodeoxyuridine (CldU) and Iododeoxyuridine (IdU). PARP 
and PARG inhibitors were added at induction.  DNA fibers that contained CldU, IdU and telomeric 
FISH signals were then imaged and analyzed (Figure 17A). In agreement with previous studies, in 
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control DMSO-treated cells, we observed nascent telomere DNA fibers averaging 9.224 m in 
length, from which we calculated a mean DNA synthesis rate of 0.9kb per minute (Figure 17B). 
Fibers from PARPi and PARGi-treated cells averaged 11.13m and 7.228m, respectively. We 
then calculated the average rates of DNA synthesis of 1.1kb/min and 0.7kb/min, respectively. The 
former is consistent with evidence that PARP inhibition accelerates replisome velocity (198). We 
then plotted the individual IdU and CldU tract lengths to determine progression of DNA synthesis 
between pulses. Whereas IdU-CldU tracts from DMSO treated cells were approximately equal, 
having a high degree of linearity (Pearson coefficient r2=0.9524), those from both PARPi and 
PARGi-treated cells differed significantly – irrespective of the large differences in track length 
(Figure 17C). This reflects the perturbation of replication fork restart and elongation upon 





Figure 17. Disrupted PAR metabolism interferes with telomeric replication. A) Schematic of DNA combing in 
WT TRF1-FokI cells treated with DMSO, PARPi or PARGi, as above. Representative images of telomeres (green) 
with CldU (red) and IdU (blue) for indicated conditions. B) Quantification of telomeric fiber length of combined 
pulses. Left: Length of telomere fibers was measured by NIS-element software. Right: Violin plot analysis of fork 
velocity calculated based on the conversion of 0.26 micron to 1kb DNA over the combined 40 min CldU/IdU pulse. 
C) Graph of telomeric tract length distribution in each experimental condition by plotting CldU telomeric tract 
length with IdU telomeric tract length for 100 telomeric fibers. Statistical significance was determined using one-
way ANOVA. *P≤ 0.05, **P≤ 0.001, ***P≤ 0.001, ****P< 0.001. 
 
Overall, these results demonstrate that PARG inhibition prevents the localization of 
constituents of the G2-BIR replisome to ALT telomeres, providing a rationale for the observed 
deficiency in telomeric DNA synthesis. Overall, the data suggest that the fine-tuned control of 
PAR catabolism by PARG maintains efficient HDR at ALT telomeres. This implicates PAR-
dependent processes in regulating telomere recombination and G2-BIR. This also indicates a 
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biphasic activation of PARP and PARG at early stages of these processes in S and G2 cell cycle 
phases, with the inhibition of PARG presumably having major ramifications on the progression of 
HDR. 
2.3 Discussion 
In this chapter, we report that the equilibrium of PAR synthesis by PARP and hydrolysis 
by PARG are critical aspects of telomere maintenance by the ALT pathway. Whereas inhibition 
of PARP1 stimulates telomere recombination, we found that inhibition of PARG and subsequent 
retention of PAR perturbs HDR mechanisms that mediate ALT. PARP inhibitors are the first 
cancer therapy designed to exploit synthetic lethality (238). PARP inhibitors trap PARP on the 
DNA, which can impede replication fork progression (207). In ovarian and breast cancers with 
BRCA1/2 mutations, persistence of SSBs from fork collapse leads to DSBs that cannot be repaired 
due a defect in HR (192). In addition, PARP inhibition allows untimely RECQ1-catalyzed fork 
restart upon DNA damage, which leads to replication run-off and increased DSBs (197). However, 
in ALT cancers whose telomeres are predisposed to initiate HDR, PARPi-generated DSBs become 
substrates to further prime HDR mechanisms. This model explains how PARPi promotes ALT 
hallmarks, such as increased T-SCEs, c-circles, and APBs. Notably, PARPi is sufficient to induce 
ALT-like phenotypes in the TEL+ Hela LT cell line. A possible explanation for this is that Hela 
LT cells have long telomeres with disrupted telomere homeostasis that predispose them for ALT 
upon a DDR stimulus. This is corroborated by previous studies showing that telomere extension 




Our data shows that PARPi enhances HR and G2-BIR in U2OS DA TRF1-FokI cells. This 
is seen by the increase in T-SCEs and APBs, as well as telomere clustering in DA TRF1-FokI 
cells. A reasonable interpretation for the telomere clustering results is that the number of DSBs 
generated by the TRF1-FokI system already saturates the HR machinery. In this case, PARPi 
would not further potentiate the maximum threshold for ALT reliance on HDR mechanisms. 
However, PARPi still perturbs replication at these telomeres and enhances the progression past 
damaged lesions, which is consistent with a previous study (198). Thus, PARPi still contributes to 
the chronic replication stress and spontaneous DNA damage that is already observed at ALT 
telomeres. It is already known that the G-rich, repetitive regions of telomeres impinge on 
replication efficiency and are considered common fragile sites (240,241). This can be heightened 
in ALT due to non-canonical variant sequences that can disrupt binding of TRF1 and TRF2 (115). 
Nucleosome assembly defects and decondensation of chromatin at ALT telomeres also contribute 
to a permissive landscape for HDR-mediated DNA synthesis (41,242). In addition, loss of ASF1, 
which mediates H3.3 histone eviction and deposition, leads to the induction of ALT (243). In this 
context, PARPi simply tips the balance in favor of an environment that is conducive to 
recombination.  
PARGi has opposing consequence on ALT telomere maintenance and cell viability. At a 
fundamental level, negatively charged PAR imposes a biophysical reconfiguration of chromatin 
known as PAR-seeded liquid phase separation that sets the stage for DNA repair (224). This is 
consistent with evidence that PAR-regulated phase separators have key functions in sensing DSBs, 
including those at telomeres (224). Liquid phase transitions can promote RAD52 assembly and 
BITS during G2-phase (244). This involves BLM-dependent DNA resection and synergistic 
interactions between SUMOylated peptides and SUMO-interaction motifs (SIMs). However, 
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emerging evidence indicates PARP activity can stimulate SUMOylation of HDR factors (245). 
Thus, a parsimonious model to explain the observed effects of PARG inhibition on ALT-
associated HDR could be that while PAR is initially synthesized at the DSBs or ssDNA gaps by 
PARP, PARG inhibition prevents the hydrolysis of PAR, recycling of NAD+ cofactor and 
downstream target modification. This would block PAR-regulated phase separation – in essence 
paralyzing the repair process at its early or intermediate stages, providing a means to tune repair 
with the cellular metabolism. 
2.4 Methods 
 Statistics 
GraphPad Prism was used to calculate statistical significance for one-way ANOVA or 
student t-test. Statistical tests, number of cells scored, and biological replicates are indicated in the 
figure legends. *P≤ 0.05, **P≤ 0.001, ***P≤ 0.001, ****P< 0.001. 
 Cell Culture 
U2OS, Saos2, Hela LT, HOS, SJSA1 cell lines were obtained from ATCC. VA13, 
LM216T/J and WT/DA TRF1-FokI U2OS cell lines were obtained from Roger Greenberg 
(University of Pennsylvania). Each cell line was cultured in DMEM +Glutamax (Life 
Technologies) supplemented with 10% bovine growth serum or 10% fetal bovine serum. Cells 
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were cultured at 20% O2 and 7.5% CO2. U2OS, HeLa LT and 293FT cell lines were validated by 
STR profiling and confirmed mycoplasma free by ATCC cell line authentication services. 
 PARP and PARG Inhibitors 
The active (PDD00017272) PARG inhibitor and its inactive analogue (PDD00031704) 
used in this study were developed and generously provided by the Drug Discovery Unit at Cancer 
Research UK (Manchester). The pharmacokinetics and selectively of these molecules towards 
PARG have been described. Olaparib (KU-0059436, AZD2281) used to inhibit PARP1 and 
PARP2 was purchased from Selleck Chem. 5  of PARPi and PARGi were used in short term 
experiments (less than 3 days). 100 nM and 1 M of PARPi and PARGi were used in long term 
experiments, (greater than 4 days). 
 
 Western Blotting  
Cells were harvested with trypsin, quickly washed in PBS, counted with Cellometer Auto 
T4 (Nexcelom Bioscience) and directly lysed in 4X LDS sample buffer at 104 cells per l. Proteins 
were gently homogenized using universal nuclease (Pierce/ThermoFisher), denatured for 10mins 
at 68°C and resolved by SDS-Page electrophoresis, transferred to nitrocellulose membranes, 
blocked in 5% milk or BSA and 0.1 % Tween for 30mins and probed with primary antibodies. For 
secondary antibodies, HRP-linked anti-rabbit or mouse (Amersham) was used, and the HPR signal 
was visualized with SuperSignal ECL substrate (Pierce) as per the manufacturer's instructions. 
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 Direct Immunofluorescence (IF) 
Cells on glass coverslips were washed twice in PBS and fixed with 2% PFA for 10mins. 
Cells were permeabilized with 0.1% (w/v) sodium citrate and 0.1 % (v/v) Triton X-100 for 5mins 
and incubated with fresh blocking solution (1 mg/mL BSA, 10% normal goat serum, 0.1% Tween) 
for at least 30mins. Primary antibodies were diluted in blocking solution and added to cells for 1hr 
at RT or overnight at 4°C. Next, cells were washed in 3 times with PBS for 5mins and incubated 
with Alexa coupled secondary antibodies (488nm, 568nm, 647nm) (Life Technologies) for 1hr at 
RT. Then, cells were washed 3 times with PBS and mounted on slides with Prolong Gold Anti-
fade reagent with DAPI (Life Technologies). Once the Prolong Anti-fade has polymerized and 
cured for ~24hrs cells were visualized by conventional florescence with 40X and/or 63X Plan λ 
objective (1.4 oil) using a Nikon 90i or Nikon A1R Spectral confocal microscope.  
 IF-FISH 
After secondary antibody incubation, cells were washed as above but then the IF staining 
was fixed with 2% paraformaldehyde (PFA) for 10mins. PFA was washed off with PBS and 
coverslips dehydrated with successive washes in 70%, 95% and 100% EtOH for 3mins were 
allowed to air dry completely. Next, the coverslips were mounted on glass slides with 15l per 
coverslip of hybridization mix (70 % deionized Formamide, 1mg/ml of Blocking Reagent [Roche], 
10mM Tris-HCl pH 7.4) containing Alexa 488-(CCCTAA)4 PNA probe (PNA Bio). DNA was 
denatured by setting the slides on a heating block set to 72°C for 10mins and then incubating for 
at least 4hrs or overnight at RT in the dark. The coverslips were then washed twice for 15mins 
with Wash Solution A (70% deionized formamide and 10mM Tris-HCl pH7.2) and three times 
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with Solution B (0.1M Tris-HCl pH7.2, 0.15M NaCl and 0.08% Tween) for 5mins at RT. EtOH 
dehydration was repeated as above and finally the samples were mounted and analyzed as 
mentioned above. 
 ALT-Associated PML Bodies (APBs) Quantification 
Anti-PML antibody was used in conjunction with telomere-FISH to identify APBs. Cells 
were visualized by conventional florescence with 40X objective (1.4 oil) using a Nikon 90i 
microscope. Large image scans of 3x3 fields were taken. Colocalization of PML and telomeres 
were analyzed using a macro in the NIS Elements software. APB+ cells were scored if there was 
one colocalization event per cell.  
 Chromatin Orientation Fluorescent In Situ Hybridization (CO-FISH) 
CO-FISH was performed as described with the variation that cells were incubated with 
BrdU and BrdC simultaneously for ~12hrs, and hybridization was performed with Alexa 488-
(CCCTAA)4 and Alexa 568-(TTAGGG)4 PNA probes. In brief, cell cultures were incubated with 
7.5mM BrdU and 2.5mM BrdC for ~12hrs. After removal of nucleotide analogs, colcemid (Gibco) 
was added for ~2hrs, cells were harvested by trypsinization, swelled in 75mM KCl and fixed in 
70% Methanol: 30% Acetic Acid. Samples are stored at -20°C for days. Metaphase chromosomes 
were spread by dropping onto washed slides, then RNase A (0.5 mg/ml) and pepsin treated. Slides 
were incubated in 2×SSC containing 0.5 mg/ml Hoechst 33258 for 15mins in the dark and 
irradiated for 40mins (5.4 x 105 J/m2, energy 5400) at in a UV Stratalinker 2400 (Stratagene). The 
nicked BrdU/C substituted DNA strands are degraded by Exonuclease III digestion. The slides 
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were then washed in PBS, dehydrated by EtOH washes and allowed to air dry completely. The 
remaining strands were hybridized with fluorescence labeled DNA probes of different colors, 
specific either for the positive telomere strand (TTAGGG)4 (polymerized by lagging strand 
synthesis) (Alexa-488, green color), or the negative telomere strand (CCCTAA)4, (polymerized by 
leading strand synthesis) (Alexa-568, red color).  Prior to hybridization of the first PNA, DNA is 
denatured by heating at 72°C for 10mins, as in IF-FISH, and then incubated for 2hrs at RT. Slides 
were washed for 15mins with Wash Solution A (see IF-FISH), dried and then incubated with the 
second PNA for 2hrs at RT. The slides were then washed again twice for 15mins with Wash 
Solution A and 3 times with Wash Solution B (see IF-FISH) for 5mins at RT. The second wash 
contained DAPI (0.5g/mL). Finally, cells were dehydrated in EtOH as above and mounted 
(Vectashield). The resulting chromosomes show dual staining and allow distinction between 
leading and lagging strands. Metaphase chromosomes were visualized by conventional florescence 
microscope with a 63X Plan λ objective (1.4 oil) on a Nikon 90i microscope.  
 C-Circle Assay 
CC assay was performed as described previously. Genomic DNA was purified, digested 
with AluI and MboI and cleaned up by phenol-chloroform extraction and precipitation. DNA was 
diluted in ultraclean water and concentrations were exhaustively measured to the indicated 
quantity (30, 15, 7.5ng) using a Nanodrop (ThermoFisher). Samples (10μl) were combined with 
10μl BSA (NEB; 0.2 mg/ml), 0.1 % Tween, 0.2mM each dATP, dGTP, dTTP and 1× Φ29 Buffer 
(NEB) in the presence or absence of 7.5U ΦDNA polymerase (NEB). Samples were incubated at 
30°C for 8hrs and then at 65°C for 20mins. Reaction products were diluted to 100μl with 2×SSC 
and dot-blotted onto a 2×SSC-soaked nylon membrane. DNA was UV cross-linked onto the 
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membrane and hybridized with a P32 end-labeled (CCCTAA)4 oligo probe to detect C-circle 
amplification products. All blots were washed, exposed to PhosphoImager screens, scanned using 
a Typhoon 9400 PhosphoImager (GE Healthcare) and quantified with Image J. In all reactions, 
when Φ29 was omitted as a negative control, DNA was used.  
 
 Pulse Field Gel Electrophoresis 
Telomere gels were performed using telomere restriction fragment (TRF) analysis. 
Genomic DNA was digested using AluI and MboI (NEB). 4–10 μg of DNA was run on a 1% PFGE 
agarose gel (Bio-Rad) in 0.5×TBE buffer using the CHEF-DRII system (Bio-Rad) at 6V cm−1; 
initial switch time 1 second, final switch time 6 seconds, for 17hrs at 14°C. The gel was then dried 
for 2hrs at 60°C, denatured in a 0.5M NaOH/1.5M NaCl solution, and neutralized. Gel was 
hybridized with 32P-labelled (TTAGGG)4 oligonucleotides in Church buffer overnight at 55°C. 
The next day, the membrane was washed three times in 2×SSC buffer and once in 2x SSC 0.5% 
SDS, exposed onto a storage phosphor screen and scanned using Typhoon 9400 PhosphoImager 
(GE Healthcare). Telomere length was determined using TeloTool software 
 Clonogenic Assay 
1000 cells were seeded in 6 well plates in duplicate and cultured for 7 days before fixation 
and staining in a 1% crystal violet solution. Plates were scanned and analyzed with ImageJ, which 
was used to count positive stained colonies and calculate total cell coverage per well. 1 mM of 
PARPi and PARGi were diluted in media and replaced every 3 days.  
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 Live Cell Imaging 
As a surrogate for telomeres eGFP-TRF1 foci were tracked in a 3-dimensional volume 
after imaging with a Nikon A1RS point scanning confocal microscope.  Fields were imaged with 
a 60x 1.40 NA objective using 405nm and 488nm excitation laser lines at 500nm steps in Z. 
Nuclear volumes were corrected for gross displacement in X & Y due to cell migration using NIS 
Elements software.  Images were deconvolved again using NIS Elements to account warping due 
to spherical aberration.  The nuclear volumes and relative foci positions were then corrected for 
nuclear rotation by defining the medial axis of a z-projected nucleus, and determining its angular 
displacement relative to the field.  The volumetric data was rotated to correct for angular 
displacement relative to the previous time point.  Telomere (eGFP-TRF1) foci positioning and 
tracks were defined with Imaris analysis software.  Fine X, Y, and Z-axial displacement were 
corrected by defining a centroid point for each nuclear volume and correcting individual foci 
positions.  Each telomere focus position was corrected relative to the centroid displacement from 
the previous time point in the X, Y and Z-axis.  This fine correction accounts for slight nuclear 
drift concentrated in the Z-axis, as slight upward and downward motion of the nucleus can 
drastically skew the displacement of individual telomere foci.  Telomere movement from a 
minimum of 30 cells per condition was captured. The complete motion of >100 telomeres over 60 
mins analyzed using the methods previously described, with the adjustments for motion in z. 
Telomeres whose motion could not be tracked for a complete hour were omitted from analysis.  
A Euclidian model was used to calculate the vector displacement for the nuclear centroid 
and telomere foci over time. 
𝒅𝒕𝒏 = √(𝒙𝒕𝒏 − 𝒙𝒕𝒏−𝟏)
𝟐 +  (𝒚𝒕𝒏 − 𝒚𝒕𝒏−𝟏)
𝟐 + (𝒛𝒕𝒏 − 𝒛𝒕𝒏−𝟏)
𝟐 .   
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The same vector displacement model was used in determining the mean squared 
displacement for foci over time 
 TRF1-FokI Telomere Clustering 
mCherry-DD-ER-WT/DA TRF1-FokI cells were induced by adding 40ng/mL 
Doxycycline for ~24hrs followed by 4-OHT (1M) and Shield1 ligand (1M). Inhibitors were 
added at the start of induction. Cells were processed for immunofluorescence and telomere number 
and size were quantified using NIS-Elements Advanced Research software (Nikon). 
 BrdU Pulldown Dot Blot 
BrdU-IP was performed as described with minor modifications. Briefly, TRF1-FokI-
inducible cells were induced by adding 40ng/mL Doxycycline for ~24hrs followed by 4-OHT 
(1 M) and Shield1 ligand (1M). Cells were pulsed with 100μM BrdU (Sigma) for 2hrs before 
collection. Extracted genomic DNA was sheared by sonication into 100–300 bp fragments. 
Sheared gDNA was denatured for 10mins at 95°C and cooled in an ice-water bath. Denatured 
gDNA was incubated with 2μg anti-IgG (Sigma) or anti-BrdU antibody (BD) diluted in 
immunoprecipitation buffer (0.0625 % (v/v) Triton X-100 in PBS) rotating overnight at 4°C. The 
next day, samples were incubated with 30μl Protein A/G agarose beads (Santa Cruz) pre-bound to 
a bridging antibody (Active Motif) for 1h rotating at 4°C. Beads were then washed three times 
with immunoprecipitation buffer and once with TE buffer. Beads were then incubated twice in 
elution buffer (1% (w/v) SDS in TE) for 15mins at 65°C. Pooled eluates were purified with ChIP 
DNA Clean & Concentrator kit (Zymo). Samples were diluted into 2×SSC buffer, treated at 95°C 
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for 5mins, and dot-blotted onto an Amersham Hybond-N+ nylon membrane (GE). The membrane 
was then denatured in a 0.5N NaOH/1.5M NaCl solution, neutralized, and ultraviolet crosslinked. 
The membrane was hybridized with 32P-labelled (TTAGGG)4 oligonucleotides in Church Buffer 
overnight at 55°C. The next day, the membrane was washed four times in 2X SSC buffer and once 
in 2X SSC/0.5% SDS, exposed onto a storage phosphor screen (GE Healthcare), scanned and 
analyzed with ImageJ.  
 DNA Fiber Combing Combined with Telomere FISH 
350,000 WT TRF1-FokI cells were seeded in a 60mm dish and were induced by adding 
40ng/mL Doxycycline for ~24hrs followed by 4-OHT (1M) and Shield1 ligand (1M) for 3hrs. 
PARPi (5M) or PARGi (5M) were added to the media upon induction. Cells were subsequently 
labelled by incubating with 25M CldU for 20mins followed by 250M IdU for 20mins.  Cells 
were harvested with trypsin and resuspended in ice-cold PBS at 1.2 x 106 cells/ml. 2L of the cell 
suspension was pipetted onto a slide. 10L of lysis solution (1M Tris-Cl (pH 7.4), 500mM EDTA 
(pH 8), and 10% SDS) was gently added to the cell suspension and slides were incubated for 5mins. 
Slides were tilted at a 15º angle to allow the drop to travel the length of the slide. Slides were then 
dried for 7-8mins and fixed with MeOH and Acetic Acid (3:1) for 7-8mins. Slides were kept in 
70% EtOH until denaturation for a maximum of 7 days. For denaturation, slides were initially 
incubated in MeOH/0.1% ME for 5 min and then incubated in denaturation buffer (0.1M NaOH, 
70% EtOH, and 0.1% ME) for either 12mins. Subsequently, slides were incubated in fixation 
buffer (0.5% Glutaraldehyde in denaturation buffer) for 5mins. Slides were rinsed sequentially 
with 70%, 95%, and 100% EtOH and left to dry for 30mins-1hr. DNA fibers were hybridized 
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overnight with biotin-OO-(CCCTAA)4 locked nucleic acid (LNA) probe (Exiqon)  at 37ºC. The 
LNA probe was visualized using the Alexa Fluor 488-conjugated streptavidin antibody (Life 
Technologies) followed by incubation with the biotinylated anti-avidin antibody (Vector) and 
sequential addition of the Alexa Fluor 488-conjugated streptavidin antibody (Life Technologies). 
IdU and CldU were detected using mouse anti-IdU (BD) and rat anti-CldU (Abcam) monoclonal 
antibodies followed by Alexa Fluor 647-goat anti-mouse (Life Technologies) and Alexa Fluor 
555-goat anti-rat (Life Technologies) secondary antibodies. Images were acquired using the Nikon 
90i microscope equipped with a 63X Plan λ objective (1.4 oil). The line measurement tool on the 
NIS-element software (Nikon) was used to calculate the length of replication tracts and telomeres. 
For conversion of microns to kilobases, 0.26 micron corresponded to 1kb of DNA.   
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3.0 Proteomic interrogation of the ALT-associated PARylome 
3.1 Introduction 
ALT telomeres exist in a dynamic state to facilitate HR events that drives telomere 
elongation. This behavior was initially described in a study that artificially inserted a tag sequence 
near the telomeric repeats to probe for telomere length (95,246). ALT+ telomeres demonstrate 
rapid elongation and shortening during cell division, which is not seen in TEL+ telomeres. In fact, 
this tag sequence can be duplicated from one chromosome to other chromosome ends in ALT+ 
cells. Time-lapse imaging also reveals that a subfraction of telomeres associate with and 
disassociate from telomere clusters at relatively immobile PML bodies (247). These telomere 
clusters are not stable structures, but are transient in nature to promote spatial movement for 
recombination. In addition, the telomeric DSB response at ALT telomeres triggers inter-telomere 
associations that are mediated by the RAD51-HOP2-MND1 machinery (96). This implicates a 
specialized homology search mechanism that requires surveillance of nuclear space to enable 
telomere synapsis and recombination.  
Although it is established that the molecular events in ALT are intimately connected to 
telomere dynamics, the intricate interplay between these diverse factors are not fully characterized. 
The exact stimulus that drives these processes have yet to be determined. Our previous results link 
PARylation to ALT telomere maintenance. PARylation is considered a reversible, dynamic post-
translational modification that is an early sensor of diverse processes, including HR (223). It is 
possible that PARylation modulates early processes in ALT, which can be a determinant for cell 
fate.  Therefore, characterization of the PAR-regulated ALT proteome would be useful to fully 
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explore the exquisite control of PARylation during HR and G2-BIR. To date, there has been studies 
that identify the ALT-associated proteome as well as the PARylated proteome in response to 
genotoxic agents (87,223). However, the PARylome in ALT has not been characterized and will 
be discussed in further detail in this chapter. 
The ALT proteome has already been established by published work from the O’Sullivan 
lab. Garcia-Exposito et al. isolated and compared the telomeric protein composition of ALT+ and 
TEL+ cells using BioID (87). Mutant BirA is fused to TRF1, which binds exclusively and 
constitutively at telomeres. Upon addition of biotin, BirA promiscuously biotinylates proximal 
proteins to the telomeres, which can either be through direct or indirect interactions. They 
identified a total of 454 proteins, of which 139 are exclusively associated at ALT telomeres. As a 
proof of concept, all six components of the Shelterin complex are recovered in the pulldown for 
ALT+ and TEL+ telomeres. Several Shelterin accessory factors, such as MRE11a, APOLLO, 
FEN1, PARP1, BLM, and Tankyrase 1, are also retrieved in both cell lines. Known factors that 
are unique to ALT are only captured at ALT+ telomeres. These factors include: PML, SLX4, 
ERCC1, NR2C1, NR2C2, and ZNF827. Proteins that only associate at ALT+ telomeres are 
involved in DDR, including those responsible for chromatin remodeling, DNA replication, HR, 
mismatch repair, single-strand annealing, and translesion DNA synthesis. Although these factors 
have defined roles in DDR, their convergence at ALT telomeres still remains elusive. This study 
was able to use proteomics as a starting point to identify a non-canonical role of Pol to ameliorate 
replicative stress and sustain HDR mechanisms at ALT telomeres (87). Thus, this distinct 
telomeric landscape lends the opportunity to explore non-canonical, distinctive regulators of ALT-
associated proteins.  
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Mass spectrometry-based studies have established that the PAR-regulated proteome is 
extensive and that diverse protein groups are modified depending on the particular lesion or 
genotoxic stress. These strategies have involved immunoprecipitation of PARylated proteins using 
a PAR specific antibody (10H) and/or a PAR-binding module, often in combination with metabolic 
or chemical labeling (248). A well characterized ADP-Ribose binding module used for proteomic 
studies is the Archeoglobus fulgidus macrodomain, Af152. Af1521 is a wide-spread and conserved 
190-residue domain that is found in approximately 300 proteins (249). A high degree of sequence 
conservation is seen at the Af1521 ligand binding pocket (176). Specifically, hydrophobic residues 
that line the adenine and ribose binding pockets are generally conserved to retain the correct fold. 
spectrometry (BioID) using BirA fused to TRF1 (BirA-TRF1) (87). This provided a broad 
annotation of proteins that constitutively Thus, Af1521 selectivity towards ADPr relies on its 
recognition of this distal ribose. Af1521 recognizes both mono ADP-Ribose and the terminal ADP-
Ribose of PAR chains with high affinity (Kd=0.13M) as well as selectivity for covalently 
modified proteins. The latter property of Af1521 is important as it confers specificity for proteins 
that are PARylated over proteins that contain motifs such as PBZ (PAR binding Zinc finger) or 
WWE domains that bind PAR in cis (250). Additional specificity in determining true PARylated 
proteins is provided by the use of a mutant Af1521 (G42E) that is defective in PAR binding. These 
studies reveal a myriad of proteins involved in RNA and DNA metabolism that provides an 
additional layer of crosstalk between different machineries in DDR (176,223,251). Overall, it is 
plausible that there are also functional intersections between PAR and ALT-associated factors due 
to the basal levels of replication stress and stochastic DNA damage at ALT telomeres.  
This chapter highlights our employed proteomics strategy to isolate and assess the 
PARylated proteome at ALT telomeres. This technique allows for the capture of early regulators 
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of ALT that are transient and dynamic at steady-state conditions. Sustained PARylation 
dramatically reconfigures the ALT proteome. Specifically, PAR-regulated mediators of the ALT 
pathway belong to diverse functional groups, such as DNA repair, RNA-binding, chromatin 
remodeling, chromatin assembly, and F-Actin nucleation. These PAR-regulated factors only 
localize to ALT telomeres upon PARG inhibition, which validate their dependency on PAR. Our 
mass spectrometry hits also display a functional relevance in ALT cancers since their depletion 
leads to diminished ALT activity. Collectively, these results reveal the importance of PARylation 
in the fine-tune control of ALT telomere maintenance.  
3.2 Results 
 Identification of the telomeric protein targets of PARG inhibition 
We hypothesized that the phenotypes observed with PARGi are due to the inability of 
PARG to hydrolyze PAR on its target proteins, whose dynamics and functions are likely to be 
altered as a consequence. We chose to employ wildtype (wt) and mutant (mut) Af1521 
macrodomain PAR binding modules to determine the ALT telomere-associated PARylome that is 
induced by WT TRF1-FokI in U2OS cells. We also performed Af1521 pulldowns from DA TRF1-
FokI expressing cells to discriminate proteins that are PARylated due to endonucleolytic cleavage 
of telomeric DNA (Figure 18A). WT/DA TRF1-FokI were induced for 4hrs before cells were 
harvested. A mainstay in previous PARylation studies has been the requirement to deplete cells of 
PARG by RNAi to prevent PAR hydrolysis. In this case, PARGi was added to preserve cellular 
PAR following the induction of WT/DA TRF1-FokI. PARG and PARP1 activity that can be 
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stimulated by DNA shearing and oxidation were inhibited in solution by the addition of PARGi 
and PARPi in lysis and dilution buffers during sample processing.  
After initial processing, each sample was split into two for subsequent pulldown with wt 
and mut-Af1521 macrodomains and western blot for PAR detection using the validated 10H anti-
PAR antibody, as well as some known PARylated proteins (Figure 18B). The expected 
accumulation of PAR chains was observed in pulldowns using wt-Af1521 from WT TRF1-FokI-
induced cells that harbor telomere specific DSBs. Most of the accumulation of PAR represents 
auto-PARylation of PARP1 protein that was also enriched in wt-Af1521 pulldowns from WT 
TRF1-FokI-induced cells. We also probed for PARylation of known DNA damage-induced 
PARP-targeted proteins such as ALC1 (also known as CHD1L) and RECQ1 (202,223). Both were 
readily detected using specific antibodies. We also confirmed PARylation of TRF1 and TRF2, 
which has been previously reported (229). We did not detect PARylation of the p65 subunit of 
NFB, a negative control previously used in similar studies (223). Following this successful initial 
optimization, we were confident that the approach would allow for proteomic identification of the 




Figure 18. Proteomics approach to characterize the ALT PARylome. A) Schematic representation of TRF1-
FokI-Af1521 proteomic strategy to identify ALT PAR-modulated telomeric proteins. B) PAR-modulated proteins 
from WT TRF1-FokI and DA TRF1-FokI U2OS cells were pulled down with GST-Af1521_wt and GST-
Af1521_mut beads. Western blotting was performed with the indicated antibodies to detect PAR and enriched 
PARylated proteins. NF-B antibody was used as a negative control. 
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 Characterization of the ALT telomeric PARylome 
In total, six samples prepared from wt/mut-Af1521 experiments using WT TRF1-FokI 
U2OS cells were subjected to protein identification by LC/MS mass spectrometry. Two negative 
control wt/mut-Af1521 samples prepared from DA TRF1-FokI U2OS cells were also analyzed. 
The final dataset was parsed using SAINT and CRAPOME proteomic databases (see Methods) 
producing a list of 117 proteins reliably detected in Af1521 pulldowns (Figure 19). We previously 
conducted an assessment of telomere composition in ALT+ U2OS cells by proximity dependent 
protein biotinylation mass spectrometry (BioID) using BirA fused to TRF1 (BirA-TRF1) (87). 
This provided a broad annotation of proteins that constitutively reside at, and transiently associate 
with, ALT telomeres. . A possible explanation is that the distinct telomeric landscape allows for 
certain DSB repair pathways to be more preferable 
We re-analyzed this BirA-TRF1 dataset in tandem with the Af1521 data by using the same 
statistical and protein annotation software (19). This produced a list of 280 protein constituents of 
U2OS telomeres. Strikingly, when we assessed the overlap between the two datasets, a mere 13 
proteins were present in both datasets (Figure 19). This reflects how fundamentally reconfigured 
ALT telomeres become following PARG inhibition. Given the evidence that PARylation is among 
the earliest modifications at sites of DNA damage, yet must be rapidly hydrolyzed by PARG, 
PARG inhibition likely facilitates the detection of PAR-regulated DSB associated proteins that are 
difficult to detect under steady-state conditions (252). In other words, these proteins likely 
represent the first responders to DSBs and early initiators of repair by HDR – providing a window 




Figure 19. Distinct reconfiguration of ALT landscape upon PARGi. Comparison between telomere composition 
of ALT+ U2OS cells to factors identified by Af1521-PAR proteomics. 
 PAR-regulated mediators of the ALT phenotype 
Functional annotation revealed an equal number of nuclear (59/117) and cytoplasmic 
proteins (58/117) (Figure 20A). The cohort included protein binding (88/117), DNA binding 
(25/117), poly-A RNA binding (22/117) and an unexpected number of actin binding (13/117) 
proteins (Figure 20A). Parsing the data for gene ontology (GO) classification determined that the 
protein hits most associated with chromatin structure modification, lagging strand replication, 
DNA and RNA metabolism and DNA Repair. For the latter, PARP1’s obligate partners XRCC1 
and LIGIII were identified by wt-Af1521 mass spectrometry confirming a role for alternative end 
joining in repair of TRF1-FokI-induced DSBs (Figure 20B).  
Among the chromatin regulators ALC1, Scaffold Attachment Factor B1 (SAFB1) and 
Vasolin-containing Protein (VCP/p97) were found to localize to DSBs to mediate the relaxation 
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and remobilization of DSB vicinal chromatin (202,253–255) (Figure 20 and Figure 45A) Several 
RNA binding proteins present in this dataset included heterogeneous nuclear RNA binding 
proteins; heterogenous nuclear ribonucleoprotein A1 (hnRNPA1), heterogenous nuclear 
ribonucleoprotein U-like 1 (hnRNPUL1) and RNA-Binding Motif Protein X-Linked (RBMX) that 
have also been linked with maintaining telomere integrity and DNA repair by HDR (Figure 21B) 
(256–258). Other RNA binding proteins present included the FET (FUS; fused in 
liposarcoma/EWS; Ewing sarcoma/TAF15; TATA-box binding protein associated factor 15) 
proteins that have been implicated in initiating the PARP-mediated DNA damage response by 
promoting DNA repair complex assembly via liquid phase de-mixing (224) (Figure 20 and Figure 
45A). Interestingly, several factors involved in actin nucleation, such as Actin-related proteins 2 
and 3 (ARP2-3), ARP2/3 complex subunits 2 and 3 (ARPC2-3), were enriched in the wt-Af1521 
mass spectrometry (Figure 20 and Figure 45A). The ARP2/3 complex promotes nuclear actin-
dependent clustering of DSBs during homology directed repair (106). We confirmed that the 
ARP2/3 complex is responsible for telomere clustering since its inhibition impaired telomere 
clustering (Figure 47A-B). Inhibition of ARP2/3 also led to constrained telomere motion, similar 




Figure 20. Distinct functional groups of PAR-regulated ALT telomeric proteins. A) Left: Functional annotation 
of the cellular distribution and ribonucleoprotein associations of enriched proteins identified by Af1521-PAR 
proteomics. Right: GO term annotation and ranking of enriched proteins by biological processes and molecular 
functions. Ranking was determined by statistical significance using DAVID (https://david.ncifcrf.gov/). B) 




We examined whether any factors from these groups localize to TRF1-FokI-induced DSBs 
by transient expression in WT and DA cells (Figure 21A-B, Figure 45B, and Figure 46). None of 
the transiently expressed eGFP-tagged versions of SAFB1, RBMX, hnRNPUL1, FUS, VCP/p97 
or ARP3 localized to WT TRF1-FokI-induced U2OS cells. (Figure 21B). However, when induced 
cells were also treated with PARGi, the specific accumulation of these proteins within TRF1-FokI 
foci was readily observed and quantified. In each case, this localization pattern was abolished upon 
addition of PARPi, highlighting the PAR-dependent nature of their association with ALT telomere 
DSBs. We confirmed that RBMX, FUS and ARP3 are directly PARylated by in vivo PARylation 




Figure 21. PAR-regulated factors associate with ALT telomeres. A) Representative IF images showing the 
localization of one of the PAR-regulated hits, GFP-SAFB1, in WT TRF1-FokI U2OS cells following treatment with 
DMSO, PARPi (5M) and combined PARGi/PARPi (both 5M). B) Validation of telomere association of GFP-
fusion proteins from Figure 20. WT TRF1-FokI cells were transfected with the indicated GFP-tagged proteins. C) 
In vivo PARylation assay with GFP-tagged FUS, RBMX and ARP3. * indicates the band corresponding to the 
PARylated GFP-tagged target protein.  All graphed data in the figure are mean ± SEM, n=75 cells. Statistical 





We next asked if these factors (SAFB1, RBMX, hnRNPUL1, FUS, VCP/p97, and ARP3), 
are required to sustain ALT activity. Using siRNA knockdown, we depleted U2OS and VA13 
ALT+ cell lines of these factors and examined effects on APB levels after 72hrs (Figure 22A-B). 
In each case, the number of APB+ cells within the observed population was reduced by ≥50%. We 
also assessed the effects of depleting these factors on WT TRF1-FokI-induced telomere clustering, 
as before. As was the case with PARG inhibition, the depletion of SAFB1, RBMX, hnRNPUL1, 
VCP/p97, FUS and ARP2-3 strongly reduced telomere clustering when compared to cells 
transfected with control non-targeting siRNAs. Based on this analysis, we find that targeting PAR-
regulated factors for knockdown impairs telomere dynamics in multiple and diverse ways; possibly 
by limiting PAR-seeded liquid phase separation, repair-associated RNA remobilization, chromatin 
remodeling and even by perturbing actin nucleation. The net result is that critical aspects of the 
ALT mechanism and response to DSBs are systematically perturbed. In addition, these data 
provide strong validation of the proteomic approach taken here, in that we have several identified 
early regulators of ALT telomere maintenance whose activity relies on the timely and efficient 




Figure 22. siRNA knockdown of PAR-regulated factors impairs ALT actiivity. A) Western blotting performed 
with antibodies to validate siRNA knockdown of protein hits from Af1521-PAR proteomics in U2OS cells. All scale 
bars, 5m. B) Left: Quantification of APBs (%) and right: TRF1-FokI-mediated telomere clustering in U2OS cells 
transfected with indicated siRNA. All graphed data in the figure are mean ± SEM, n=75 cells. Statistical 
significance was determined using one-way ANOVA. *P≤ 0.05, **P≤ 0.001, ***P≤ 0.001, ****P< 0.001. 
3.3 Discussion 
By combining telomere specific proteomics and PARG inhibition, we uncovered factors 
that we propose to constitute the first wave of proteins that respond to telomeric DNA damage in 
ALT. The enrichment of chromatin remodelers, such as ACL1, SAFB1, and VCP/p9, corroborate 
that chromatin plasticity promotes ALT (202,253,254). PAR has been shown to recruit ALC1 to 
damaged lesions and enhance its enzymatic activity (202). Additionally, there is modular allostery 
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of ALC1 via its ATPase domain and macrodomain (203). PARP1 activation releases ALC1 from 
autoinhibition and ensures that it only promotes chromatin relaxation in response to DNA 
acetylation to promote efficient H2AX spreading. The AAA-ATPase VCP/p97 is recruited to 
DSBs in an RNF8- and ubiquitin-dependent manner (253). VCP/p97 displaces L3MBTL1, a 
Polycomb-group protein that binds the same H4K20Me2 modification as 53BP1. Therefore, 
exposed H4K20Me2 enhances spreading of 53BP1 at DSBs. This example reveals how 
ubiquitylation orchestrates the recognition of methylated histones to promote chromatin 
accessibility; it particularly emphasizes the importance of the exquisite crosstalk between various 
post-translational modifications to maintain genome integrity. 
Chromatin reorganization in response to DNA damage must be robust and tightly 
coordinated to maintain efficient DNA repair. There is an intricate molecular network of chromatin 
modifications with significant crosstalk and redundancies (259). Signal propagation across large, 
specialized chromatin domains provides accessibility for DDR factors. Signal amplification not 
only exists within one pathway, but can occur through the interplay between multiple pathways. 
Notably, there is a functional crosstalk between PARylation and SUMOylation. SUMOylation 
conjugates small ubiquitin-like modifiers (SUMO) onto target proteins. PARylation cooperates 
with SUMOylation to stabilize trapped topoisomerase I (TOP1) cleavage complexes at DNA 
damage sites (260). Together, they also recruit SLX4 nuclease scaffold complex to damaged 
lesions (245).  Other studies reinforce how PARylation positively feeds into the ubiquitylation 
pathway (261). SUMO E3 ligases PIAS1 and PIAS4 mediate chromatin ubiquitylation at DSBs, 
which leads to accrual of BRCA1, 53BP1, and E3 Ligase RNF4 (262–264). On the other hand, 
PARylation recruits the repressive Polycomb and NuRD complexes to sites of damage. This 
stimulates RNF8/RNF168-mediated histone ubiquitylation and the ubiquitin-dependent 
 
 87 
accumulation of RNF168 and BRCA1 (265,266). Ultimately, this promotes DSB repair and 
checkpoint activation in response to genotoxic stress.  
However, there are physiological barriers imposed by the chromatin architecture that 
safeguards against unwarranted and excessive DNA damage signaling. PTMS such as PARylation 
and SUMOylation are extremely transient to ensure faithful termination upon completion of repair 
(261). This is critical to prevent saturation of repair factors, which would be counterproductive 
and lead to uncoupling of downstream events. It was proposed that an abundance of rate-limiting 
chromatin modifiers could dictate pathway choice and chromatin spatial and temporal dynamics 
(259). For example, the absence of TRIP12 and UBR4, which are regulators of the RNF168 nuclear 
pool, leads to supraphysiological levels of RNF168 and excessive spreading of chromatin 
ubiquitylation. This is followed by deregulated accumulation of ubiquitin-regulated genome 
caretakers involved in NHEJ and HR, such as 53BP1 and BRCA1 (267).  
In the ALT context, the interplay between PTMs and regulators of chromatin assembly 
become more pertinent since chronic replication stress at telomeres generates high levels of DSBs. 
In ALT, disrupted regulation of chromatin modifications would permit continuous hyperactivation 
of chromatin remodeling at the precise threshold for HDR that does not trigger cell death. An 
outstanding question is whether there is an ALT-specific chromatin barcode that would 
differentiate the ALT telomeric landscape from other genomic regions. More specifically, is there 
differential regulation of PAR-dependent chromatin remodelers at ALT telomeres? If PARylation 
is the initial signal that sets chromatin modeling in motion, when are these events disengaged to 
prevent non-productive, sequestered cellular pools of genome caretakers? To resolve this 
conundrum, it is necessary to further understand the intricate role that PARylation plays in the 
hierarchy of signaling at ALT telomeres.  
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RNA-binding proteins are another group of PAR-mediated factors that associate at ALT 
telomeres. These include proteins such as FET proteins (FUS-EWS1-TAF15) and multiple 
hnRNPs, whose low-complexity domains (LCD) sense and compartmentalize damaged DNA 
within phase separated liquid condensates (224). The capacity to detect these factors likely reflects 
their prolonged retention, as the dissolution of these LCD aggregates is usually very rapid and 
requires that they undergo PAR hydrolysis (268).  The FET proteins are linked to pathological 
protein aggregation, exhibit frequent gene translocations in cancers, and are prototype intrinsically 
disordered proteins (IDPs) that contain prion-like SYQG-rich amino-terminal LCD and an 
extended RGG-rich carboxyl-terminal LCD-containing 18-22 RGG repeats (224,269). 
hnRNPUL1 is implicated in PARP1-dependent stimulation of DNA end resection in response to 
DSB repair (257,270). Steady-state PARG and the transient nature of DNA damage allows for the 
reversibility and dissolution of these compartments. Although liquid-liquid demixing events prime 
the initial recruitment of DNA repair factors to damaged sites, these proteins can independently 
form higher-order structures that become irreversible aggregates. The additional mechanisms to 
resolve such irreversible events are not known.  
Liquid phase separation is particularly relevant to the assembly of APBs, which are thought 
to be centers of recombination in ALT. Zhang et al. stimulated de novo formation of APBs in live 
cells and showed that APB assembly relies on liquid demixing that is driven by SUMO-SIM 
interactions (225). They confirmed that APB condensates contain PML as the scaffold component 
while DNA repair factors, such as 53BP1, PCNA, and POLD3, were recruited in a manner that is 
independent of condensation. Based on these studies and dissertation work, it is plausible that APB 
nucleation via phase separation events is mediated by a crosstalk between SUMOylation and 
PARylation. This PAR-SUMO switch would accommodate the rapid perturbations in ALT 
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telomere dynamics, in which rapid APB assembly and disassembly is critical for extensively short 
and long telomeres. However, the exact molecular details of this interplay and how it functions in 
the spatial and temporal regulation of APB nucleation still needs to be elucidated.   
Both HR (RAD50 and PCNA) and alt-NHEJ (LIG3 and XRCC1) factors were captured in 
the mass spectrometry results. It has already been established that RAD51 and the HR machinery 
mediates directional ALT telomere movement and clustering. It is not surprising that RAD50, 
which is part of the MRN complex (MRE11-RAD50-NBS1), is found at ALT telomeres to 
facilitate end-resection in HR (96).  In addition, PCNA is part of the G2-BIR replisome (RFC-
PCNA-POLD3), which underlies nascent telomeric synthesis during G2 in ALT (98). 
Interestingly, alt-NHEJ has been implicated in the repair of telomere-internal DSBs and is 
dependent on PARP1 and LIG3. Alt-NHEJ is considered a mutagenic DSB repair pathway that 
utilizes 1-16 nucleotides of homology flanking the DSB for end joining (271). It is often associated 
with deletions, insertions, and chromosome translocations. Generally, alt-NHEJ is a backup 
pathway for abrogated HR and c-NHEJ. However, alt-NHEJ may occur at telomeres because 
telomeric short tandem repeats are conducive for minimal resection and end joining. Overall, this 
represents how ALT telomeres elicit multifaceted repair pathways to preserve the balance between 
telomere dysfunction and telomere maintenance.  
The depletion of select PAR-regulated factors from our proteomics study leads to impaired 
APB formation and DSB-induced telomere clustering. This underscores the importance of 
PARylation in varying stages of ALT telomere maintenance. PARG inhibition allows for the 
retention and capture of factors that dynamically associate at ALT telomeres. Those involved in 
chromatin remodeling and liquid phase separation represent first-wave responders in the ALT 
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pathway. Thus, perturbing PAR regulation will have huge ramifications for the maintenance of 
repair mechanisms at tolerable levels in ALT cancers.   
3.4 Methods 
 Statistics 
GraphPad Prism was used to calculate statistical significance for one-way ANOVA or 
student t-test. Statistical tests, number of cells scored, and biological replicates are indicated in the 
figure legends. *P≤ 0.05, **P≤ 0.001, ***P≤ 0.001, ****P< 0.001. 
 Cell Culture 
U2OS cell line was obtained from ATCC. VA13 and WT/DA TRF1-FokI U2OS cell lines 
were obtained from Roger Greenberg (University of Pennsylvania). Each cell line was cultured in 
DMEM +Glutamax (Life Technologies) supplemented with 10% bovine growth serum. Cells were 
cultured at 20% O2 and 7.5% CO2. U2OS cell line was validated by STR profiling and confirmed 
mycoplasma free by ATCC cell line authentication services. 
 Af1521 Pulldown 
The Af1521 pulldown protocol was adapted from Jungmichel et al. Briefly, 4 x107 WT 
TRF1-FokI and DA TRF1-FokI cells were induced as usual. PARGi (5M) was added during the 
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4-hour induction period. Cells were lysed using ice-cold modified RIPA buffer (50mM Tris-HCl 
(pH 7.5), 400mM NaCl, 1mM EDTA, 1% NP-40, and 0.1% Na-deoxycholate). PARPi and PARGi 
were added to lysis buffers to block in vitro PARP and PARG activity. Equal protein amounts 
were incubated with wt or mut GST-Af1521 (Tulip Biolabs, PA) in modified RIPA buffer (without 
NaCl) for 2hrs at 4ºC. Beads were washed with modified RIPA buffer (150mM NaCl). Bound 
complexes were eluted in 4X LDS buffer. 
 Mass Spectrometry  
Mass spectrometry was conducted at MS Bioworks (Ann Arbor, MI.). Immuno-
precipitated samples stored in 4X LDS buffer were separated ~1.5cm on a 10% Bis-Tris Novex 
mini-gel (Invitrogen) using the MES buffer system. The gel was stained with coomassie and each 
lane was excised into ten equally sized segments. Gel pieces were processed using a robot 
(ProGest, DigiLab) as follow: First washes were with 25mM ammonium bicarbonate followed by 
acetonitrile. Then, reduced with 10mM dithiothreitol at 60°C followed by alkylation with 50mM 
iodoacetamide at RT. Samples were digested with trypsin (Promega) at 37°C for 4hrs, and then 
quenched with formic acid. Samples supernatants were analyzed directly without further 
processing using a nano LC/MS/MS with a Waters NanoAcquity HPLC system interfaced to a 
ThermoFisher Q Exactive. Peptides were loaded on a trapping column and eluted over a 75m 
analytical column at 350nL/min; both columns were packed with Jupiter Proteo resin 
(Phenomenex). The mass spectrometer was operated in data-dependent mode, with MS and 
MS/MS performed in the Orbitrap at 70,000 FWHM resolution and 17,500 FWHM resolution, 
respectively. The fifteen most abundant ions were selected for MS/MS.  
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 Proteomic Analysis 
Raw mass spectrometry files were converted into open mzML format using msconvert 
utility of Proteowizard software suite. MS/MS spectra were searched using the MSFragger 
database search tool (version 20180316) against a UniProt/SwissProt Homo sapiens protein 
sequence database downloaded in May 21, 2019, appended with TRF1_FokI and Y1521_ARCFU 
fusion proteins and its respective mutated versions. MS/MS spectra were searched using a 
precursor-ion mass tolerance of 20 p.p.m., fragment mass tolerance of 20 p.p.m., and allowing 
C12/C13 isotope errors (-1/0/1/2/3). Cysteine carbamylation (+57.0215) was specified as fixed 
modifications, and Methionine oxidation (+15.9949), N-terminal protein acetylation (+42.0106) 
were specified as variable modifications. The search was restricted to fully tryptic peptides, 
allowing up to two missed cleavage sites. The search results were further processed using the 
Philosopher toolkit (https://philosopher.nesvilab.org/) as follows. MSFragger output files (in 
pepXML format) were processed using PeptideProphet (with the high–mass accuracy binning and 
semi-parametric mixture modeling options) to compute the posterior probability of correct 
identification for each peptide to spectrum match (PSM). ProteinProphet was executed on all 
resulting pepXML files from PeptideProphet resulting in a list of proteins groups (in protXML 
format). This combined protXML file, as well as the pepXML for each individual experiment, 
were then processed using Philosopher’s filter and abacus functions to generate a combined 
spectral count matrix. The combined protXML file was filtered using the Philosopher filter 
function to 1% protein-level False Discovery Rate (FDR) using the target-decoy strategy. The 
PSM lists in each experiment were filtered using a sequential FDR strategy, keeping only PSMs 
passing 1% PSM-level FDR and mapped to proteins that also passed the global 1% protein-level 
FDR filter. Each peptide was assigned either as a unique peptide to a particular protein or (if 
 
 93 
shared) assigned as a razor peptide to a single protein that had the most peptide evidence. The 
combined filtered protein list, as well as the filtered PSM lists for each individual experiment, were 
then processed using Philosopher's abacus function to generate a combined spectral count 
matrix.  Each row in the resulting table represented a protein (with a single accession number 
selected among indistinguishable protein entries) and its abundance (unique plus razor PSM 
counts) across all experiments. The resulting quantification matrix was loaded into reprint-
apms.org online resource to calculate abundance Fold Change (FC) scores comparing WT vs MUT 
experiment. A final cut-off of FC≥2 was arbitrarily set. This produced a final listing of 117 proteins 
that was used for in silico functional annotation in DAVID (Database for Annotation, 
Visualization, and Integrated Discovery) (https://david.ncifcrf.gov/) and downstream functional 
validation by experimentation. 
 Transient Transfection 
U2OS and WT TRF1-FokI U2OS cell lines were seeded to obtain 70-80% cell density on 
day of transfection. Transfection mixture contained a 3:1 ratio of Lipofectamine 2000 to GFP 
construct. Specifically, for transfection of WT TRF1-FokI U2OS cells, 40 ng/mL of Doxycycline 
was added 2 hours prior to transfection for WT TRF1-FokI U2OS cells. Inhibitors and 
Doxycycline was added to media when media was changed 6 hours after the transfection. 4-OHT 
and Shield was added 24 hours later for 4hrs and cells were harvested for collection. 
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 In Vivo PARylation Assay 
GFP-immunoprecipitation was performed with GFP-TRAP®_A agarose beads 
(Chromotek). Briefly, 1 x 106 WT TRF1-FokI cells were seeded in a 10cm dish. ~24hrs later, cells 
were transfected with GFP-constructs using Lipofectamine 2000 (Invitrogen) as per 
manufacturer’s instructions and 40ng/mL Doxycycline was added to the media as before. Cells 
were later induced with 4-OHT (1M) and Shield1 ligand (1M) for 4hrs with the addition of 
PARGi (5M). Cells were harvested using ice-cold PBS, scraped from the dish and transferred to 
pre-cooled tubes. Cell pellets were resuspended in 200L ice-cold RIPA buffer (10mM Tris-HCl 
(pH 7.5), 150mM NaCl, 0.5mM EDTA, 0.5% NP-40, 0.09% Na-Azide) with 1mM PMSF, 2.5mM 
MgCl2, 1mg/ml DNase (Pierce) and protease inhibitor cocktail (Sigma). To extract HIRA proteins, 
modified RIPA buffer (500mM NaCl) was used as before. Tubes were placed on ice for 30mins 
with extensive pipetting every 10mins. Tubes were centrifuged at 20,000x g for 10 min at 4ºC and 
lysates were transferred to pre-cooled tubes. 300L ice-cold dilution/wash buffer (10mM Tris-
HCl (pH 7.5), 150mM NaCl, 0.5mM EDTA, 0.018% Na-Azide) with 1mM PMSF, 2.5mM MgCl2, 
and protease inhibitor cocktail (Sigma) was added to tubes. 50L of lysate was resuspended in 
50L 4X LDS buffer to save as 10% input samples. GFP-TRAP®_MA magnetic beads were 
equilibrated in dilution/wash buffer. 25L of the bead slurry was added to each tube and rotated 
for 1hr at 4ºC. Beads were magnetically separated and washed twice with wash/dilution buffer. 
Beads were resuspended in 100L 4X LDS buffer and boiled for 10mins at 95ºC. Beads were 
magnetically separated and SDS-PAGE was performed with the supernatant. PARylated proteins 
were detected using specific anti-PAR (10H) antibody.  
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 siRNA Knockdown 
 For siRNA knockdown the On-Target Plus (OTP) siRNA SMARTpools from Dharmacon 
(GE) were used. 400,000 cells were seeded per well of a 6-well plate containing growth medium 
without antibiotics. 4hrs later cells were transfected. siRNAs and Dharmafect were diluted in 
OptiMEM (Life Technologies). A working siRNA concentration of 20nM was used. We used 2.5 
L Dharmafect transfection reagent per well. The transfection reagent mixture was added 
dropwise to one well in 1.8 mL of media without antibiotics. The next day, cells were transferred 
to 10-cm plates with coverslips. Transfection medium was replaced with complete culture media. 
Cells were harvested at 72hrs post-transfection. Inhibitors were added 24 hours prior to collection.   
 APBs Quantification 
After 72 hours of siRNA knockdown, coverslips from 10-cm plates were collected for APB 
analysis. Anti-PML antibody was used in conjunction with telomere-FISH to identify APBs. Cells 
were visualized by conventional florescence with 40X objective (1.4 oil) using a Nikon 90i 
microscope. Large image scans of 3x3 fields were taken. Colocalization of PML and telomeres 
were analyzed using a macro in the NIS Elements software. APB+ cells were scored if there was 
one colocalization event per cell.  
 TRF1-FokI Telomere Clustering 
After 48 hours of siRNA knockdown, WT TRF1-FokI U2OS cells were induced by adding 
40ng/mL Doxycycline. After an additional 24 hours, 4-OHT (1M) and Shield1 ligand (1M) 
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were added to the media for 4 hours. Inhibitors were added at the start of induction. Cells were 
processed for immunofluorescence and telomere number and size were quantified using NIS-
Elements Advanced Research software (Nikon). 
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4.0 Regulation of HIRA-mediated chromatin assembly at ALT telomeres by PARylation 
4.1 Introduction 
A salient feature of ALT cancers are inactivating mutations in ATRX/DAXX/H3.3. ATRX 
belongs to the Snf2-family of ATP-dependent chromatin remodelers. Snf2 proteins are DNA 
translocases that remodel nucleosomes by placing an ATP-dependent torsional strain on DNA 
(272). Several studies have implicated mammalian ATRX in the deposition of histone variant 
H3.3, which differs from the core H3 (H3.1/H3.2) by 4-5 amino acids (273,274). While core H3 
is only incorporated during S-phase, variant H3.3 is expressed throughout the cell cycle and acts 
in a replication-independent manner. CHIP-Seq analyses reveal that H3.3 is enriched in 
transcriptionally active chromatin at transcription start sites, enhancers, and promoters (275–277). 
Interestingly, the ATRX/DAXX complex is critical for H3.3 incorporation at pericentric 
heterochromatin and at telomeres (278–280). ATRX/DAXX binds to G-rich tandem repeats that 
are prevalent in telomeres. Telomeric regions have predisposition to form G-quadruplex (G4) 
structures, which destabilize the genome. Thus, ATRX/DAXX resolves G4 structures at telomeres 
by remodeling and incorporation of H3.3 (120).   
This is particularly relevant for ALT tumors since loss of chromatinization may potentiate 
HDR processes. Re-introduction of ectopic ATRX in U2OS cells reverses the ALT phenotype 
(228).  ATRX expression reduces replication fork stalling by cooperating with DAXX to decrease 
the presence of telomeric G4. Thus, ATRX prevents fork collapse and subsequent restart by HDR 
in ALT. In addition, ATRX sequesters the MRN complex away from telomeric DNA and APBs, 
which halts end resection of DSBs and subsequent strand invasion. Notably, G4 structures are 
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favorable substrates for the MRN complex (281). It is likely that MRN cleaves G4 structures at 
ALT telomeres during DNA replication, which generates persistent DSBs followed by HDR-
mediated DNA synthesis. This model supports the mounting evidence that HR-mediated repair of 
collapsed forks is a key determinant of ALT telomere maintenance.  
Despite the importance of ATRX/DAXX at telomeres, transient depletion or disruption of 
ATRX is not sufficient to induce ALT (42). This implies that there are either additional alterations 
that trigger ALT or there are mitigating factors in TEL+ cancers that suppress the ALT pathway. 
It was recently reported that ATRX promotes HR at genomic regions in TEL+ cells. ATRX/DAXX 
incorporates H3.3 at sites of extended DNA synthesis to overcome any topological constraints at 
the moving D-loop (282). These findings are surprising since loss of ATRX/DAXX is frequently 
seen in ALT tumors that rely on HDR mechanisms. A possible explanation is that the distinct 
telomeric landscape allows for certain DSB repair pathways to be more preferable. In ALT, loss 
of ATRX/DAXX elevates the frequency of secondary structures at telomeric repeats, such as G4s 
and RNA/DNA hybrids, which may be driving events for the ALT pathway. ATRX has been 
shown to bind to G4 structures and ATRX deficiency leads to increased levels of G4s (120,283). 
ALT cells need to adapt a mechanism that allows for the tolerance of chronic replication 
stress and coordination of timely chromatin deposition to provide topological stability during 
HDR. The HIRA histone chaperone complex is a promising candidate that could potentially 
compensate for loss of ATRX/DAXX function in ALT tumors. The HIRA chaperone complex 
comprises of HIRA, UBN1, CABIN1, and it collaborates with Anti-Silencing Function 1A Histone 
Chaperone (ASF1a) to deposit H3.3 in a replication-independent manner (88,284). HIRA is the 
central scaffold for the assembly of the complex subunits. The stability of the complex is dependent 
on the presence of all three components, since knockdown or removal results in reduction of 
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protein expression. The N-terminal WD40 repeat domain in HIRA associates with a weakly 
conserved domain slightly N-terminal to the Hpc2-related domain (HRD) in UBN1 (285). UBN1 
is critical for H3.3 incorporation onto chromatin (88). HIRA interacts with CABIN1 through 
residues 736-963 of the C-terminal domain. While CABIN1 is dispensable for H3.3 incorporation, 
it contributes to maintaining the structural integrity of the complex (284).  The HIRA B-domain, 
which spans residues 439-475, makes contact with the ASF1a N-terminal core (286). ASF1a 
contacts HIRA to deliver H3.3 histones to the HIRA complex for deposition onto chromatin. It is 
proposed that UBN1 can reject the ASF1a/H3.1 complex because it has greater binding affinity to 
H3.3. This ensures that only H3.3 is deposited by the HIRA complex (287,288). 
Homotrimerization of HIRA is crucial for its 3:2 interaction with CABIN1 as well as enrichment 
and activity at UV damaged sites (227,287).  
HIRA-mediated H3.3 deposition underpins diverse biological functions. HIRA plays a role 
in DNA repair, cell senescence, sperm nucleus decondensation after fertilization, embryo 
development, and anti-viral immunity (226,275,289–298). It has been reported that HIRA 
promotes transcription restart after UVC irradiation (226). HIRA enhances de novo deposition of 
H3.3 at the damaged chromatin. This is critical for the bookmarking of damaged chromatin and 
subsequent priming for later transcription once the damage lesion is repaired. In addition, the 
HIRA complex can bind to regions of naked DNA without any sequence specificity to incorporate 
H3.3 by a nucleosome gap filling mechanism (291). This occurs at regions with transient naked 
DNA, such as sperm reprogramming or post-replication. RNA Pol II also associates with HIRA 
for additional targeting to promoters, coding regions, and a subset of cis-regulatory elements. This 
salvage pathway ensures that there are no nucleosome-free regions that would lead to chromatin 
defects. ChIP-seq and gene expression analyses demonstrate that most HIRA-binding sites 
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colocalize with UBN1, ASF1a, and H3.3 at the three main regulatory elements: promoters of active 
genes, active, and weak/poised enhancers (290). Overall, HIRA is involved in an intricate network 
of biological processes that could converge at ALT telomeres.  
In this chapter, we show that the HIRA histone chaperone complex associates at ALT 
telomeres. HIRA is likely the sole histone chaperone for H3.3 deposition during HDR. HIRA-
mediated chromatinization permits restrained replication stress that results in productive ALT 
telomere maintenance. PARylation targets HIRA to damaged ALT telomeres for rapid and faithful 
restoration of DSBs. However, PARG inhibition keeps HIRA at these lesions and perturbs 
incorporation of H3.3. Thus, HIRA retention at ALT telomeres has deleterious consequences on 
downstream HDR-mediated DNA synthesis and ultimately, cell survival.  
4.2 Results 
 Enrichment of HIRA-UBN1-CABIN1 complex at ALT telomeres 
Of the many potentially PAR-regulated factors identified by wt-Af1521 mass 
spectrometry, it was striking that peptides corresponding to constituents of the HIRA histone H3.3 
chaperone complex (HIRA-UBN1-CABIN1) were highly enriched. This was in contrast with the 
histone H3.1/H3.2 chaperone complex Chromatin Assembly Factor (CAF1) complex consisting 
of three subunits CAF1a (p150), CAF1b (p60) and Retinoblastoma binding protein 4 (RBBP4) 
(Figure 23). The CAF1 complex differs from the HIRA complex because it only deposits newly 
synthesized H3/H4 in a replication-dependent manner (299). Meanwhile, H3.3/H4 can be 
incorporated during and outside of S-phase. In fact, the ATRX/DAXX complex deposits H3.3/H4 
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at pericentric heterochromatin and telomeres (279). Missense mutations in ATRX and DAXX are 
pervasive in ALT+ cancers, with one or both proteins not expressed in most ALT+ tumors or 
cancer cell lines (41,42). Consequently, HIRA may be the sole functional H3.3 histone chaperone 
complex for nucleosome assembly during G2/M in many ALT+ cancer cells. Therefore, it seemed 
plausible that HIRA, and its PARylation, could contribute to HDR repair associated activities at 
ALT telomeres, neither of which has previously been determined. 
 
Figure 23. The HIRA complex is enriched at ALT telomeres. Spectral counts of the HIRA (HIRA-UBN1-
CABIN1) and CAF1 (CAF1A-CAF1B-RBBP4) complexes Af1521-PAR proteomics. The CAF1 complex (green) is 
not enriched at ALT telomeres.  
 Depletion of HIRA complex abrogates HDR in ALT  
HIRA is the molecular scaffold in the HIRA-CABIN-UBN1 chromatin assembly complex, 
in which knockdown of HIRA also co-depletes CABIN1 and UBN1, as was previously shown 
(291) (Figure 24A) Depletion of each protein abrogated APB levels and TRF1-FokI-induced 
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telomere clustering in U2OS and VA13 cells. HIRA depletion elicited the strongest effects (Figure 
24B). By BrdU-IP we found that HIRA depletion strongly impaired G2-BIR (Figure 24C).  
 
Figure 24. Depletion of HIRA impairs ALT telomere maintenance. A) Western blot validation of HIRA, 
CABIN1 and UBN1 knockdown. B) Left: Quantification of APBs and right: TRF1-FokI-induced clustering in 
U2OS cells following transfection with the indicated siRNAs. C) TRF1-FokI-mediated break-induced synthesis 
assay following transfection with non-targeting (NT) and HIRA siRNAs. B) left: n=1200 cells, right:150 cells and 




 HIRA is responsible for H3.3 deposition at ALT telomeres 
We reasoned that the phenotype observed with HIRA depletion is linked with deficiencies 
in histone H3.3 deposition at sites of G2-BIR. We confirmed this by combining transient ectopic 
expression of GFP-tagged histone H3.3 and HIRA depletion in G2-synchronized U2OS cells and 
WT TRF1-FokI cells, both of which allow for G2-BIR to occur. Here, we observed punctate foci 
corresponding to GFP-H3.3 that co-localized with telomeres in U2OS cells that were arrested in 
G2 with the cyclin-dependent kinase (CDK) inhibitor, RO-3306, and WT TRF1-FokI-induced 
U2OS cells (Figure 25A-B). However, these GFP-H3.3 foci were completely abolished upon 
depletion of HIRA.  
 
Figure 25. HIRA mediates H3.3 localization at ALT telomeres. A) Representative IF images of GFP-Histone 
H3.3 localization to telomeres in G2-synchronized and WT TRF1-FokI-induced U2OS cells. B) Quantification of 
colocalization between GFP-Histone H3.3 and telomeres in the conditions shown in A. All graphed data in the 
figure are mean ± SEM, n=75 cells. Statistical significance was determined using one-way ANOVA. *P≤ 0.05, **P≤ 
0.001, ***P≤ 0.001, ****P< 0.001. All scale bars, 5m. 
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The localization of transiently expressed YFP-HIRA to telomeres was not readily apparent 
in asynchronous U2OS cells, even though some vicinal associations were observed (Figure 26A). 
However, the telomeric accumulation of YFP-HIRA was readily evident and was accentuated by 
PARGi (Figure 26A-B). A small number of YFP-HIRA telomere associations were observed in 
cells expressing WT TRF1-FokI. PARGi markedly changed this with YFP-HIRA forming clear 
foci at telomeres harboring WT TRF1-FokI-induced DSBs. Telomeric YFP-HIRA foci were 
reduced in the presence of PARPi, indicative of a PARP1 dependency. In agreement with previous 
findings, we found that YFP-HIRA readily formed foci shortly after irradiation of U2OS cells with 
UV-C (Figure 48A-B). Although YFP-HIRA foci were also observed after exposure to ionizing 
radiation (IR), their frequency was substantially lower. In these instances of DNA damage, the 
dependency on PARG inhibition was not as clear as what was observed in the context of YFP-
HIRA accumulation at ALT telomeres. These set of experiments indicate that PAR-mediated 
HIRA assembly at ALT telomeres is responsible for H3.3 deposition during and outside of S-phase 





Figure 26. PAR-dependent localization of HIRA to ALT telomeres. A) Representative IF images of YFP-HIRA 
localization to telomeres in asynchronous, G2-synchronized and WT TRF1-FokI-induced U2OS cells treated with 
DMSO, PARGi or co-treated with PARGi and PARPi (all 5M). B) Quantification of colocalization between YFP-
HIRA and telomeres in the conditions shown in a. All graphed data in the figure are mean ± SEM, n=75 cells. 
Statistical significance was determined using one-way ANOVA. *P≤ 0.05, **P≤ 0.001, ***P≤ 0.001, ****P< 0.001. 
All scale bars, 5m. 
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 Identification of a PAR-modulated HIRA region 
The requirement for PAR in recruitment of HIRA to ALT telomeres prompted us to 
determine whether HIRA was itself directly modified by in vivo PARylation assay. Indeed, the 
signature PAR smear corresponding to YFP-HIRA protein was detected only in WT TRF1-FokI 
cells, confirming that HIRA is PAR-modulated following telomeric DSB formation (Figure 27A). 
To determine the requirements for PAR modulation of HIRA, we used a series of mutants that 
disrupt HIRA complex formation via homotrimerization (W799A-D800A), HIRA binding to 
ASF1a (I461D), as well as Δ427-472 (also termed ΔB-domain) (227,286). By in vivo PARylation 
assay, we found that loss of the B-domain, and preventing homotrimerization, abolished YFP-




Figure 27. HIRA exhibits direct PAR-modulation. A) In vivo PARylation assay. YFP alone (Vec) or YFP tagged 
HIRA were transfected into WT/DA TRF1-FokI U2OS cells containing PARGi, or a combination of PARGi and 
PARPi to test for PARP1 dependency. Captured GFP proteins were subjected to western analysis and blotted with 
anti-GFP and anti-PAR (10H) antibodies. (B) Top: Schematic of HIRA domain structure. Mutated regions are 
shown in red and blue stars. Below: In vivo PARylation assay of WT, homo-trimerization (W799A-D800A) I461D 
mutants and ∆B domain truncated YFP-HIRA in WT TRF1-FokI U2OS cells. 
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 PAR modulation of HIRA is critical for its role in ALT 
We next determined whether loss of PARylation at these mutants is critical for the 
localization of HIRA to ALT telomeres (Figure 28A-B). The homotrimerization and B-domain 
mutants abrogated YFP-HIRA localization to TRF1-FokI DSBs (Figure 28B). Interestingly, the 
ASF1a interaction point mutant I461D could be PAR-modulated and retained the ability to localize 
to telomeric DSBs. However, deletion of the complete B-domain, which also encompasses the 





Figure 28. PAR-modulation of HIRA B-domain recruits HIRA to ALT telomeres. A) Representative IF images. 
B) Quantification of WT, W799A-D800A, I461D, and ∆B domain truncated mutants YFP-HIRA localization to WT 
TRF1-FokI telomeres. All graphed data in the figure are mean ± SEM, n=75 cells. Statistical significance was 
determined using one-way ANOVA. *P≤ 0.05, **P≤ 0.001, ***P≤ 0.001, ****P< 0.001. All scale bars, 5m. 
 
To determine if PAR modulation of HIRA might affect ALT, we examined whether ectopic 
expression of wildtype or mutants of HIRA could rescue the phenotypes of HIRA knockdown 
(Figure 29A). We found that PAR-modulated WT and ASF1a I461D mutants, but not non-PAR-
modulated homotrimerization or ΔB-domain mutants, fully restored APBs and telomere clustering 
(Figure 29B). These observations indicated that the HIRA complex and PAR-regulation of the B-
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domain in HIRA are critical for its recruitment and residency at telomeric breaks that are repaired 
by HDR during G2-phase. Taken together, this analysis reveals that HIRA is directly recruited to 
telomeric chromatin by PAR-dependent mechanisms during G2-phase. PAR-modulated HIRA 
mediates deposition of histone H3.3 at telomeric DSBs undergoing HDR in order to compensate 
for the loss of ATRX-DAXX. 
 
Figure 29. PAR-modulation of HIRA is essential for its function in ALT. A) Western blot showing depletion of 
endogenous HIRA and complementation with the indicated HIRA constructs in U2OS cells. B) Left: Quantification 
of APBs (%) in U2OS cells and right: TRF1-FokI-induced clustering in U2OS cells. All graphed data in the figure 
are mean ± SEM. B) left: n=1200 cells and right: n=150 cells. Statistical significance was determined using one-way 
ANOVA. *P≤ 0.05, **P≤ 0.001, ***P≤ 0.001, ****P< 0.001. 
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 HIRA compensates for loss of ATRX/DAXX function in ALT cells  
Due to the absence of functional ATRX-DAXX complex in ALT cells, HIRA is likely to 
be solely responsible for histone H3.3 deposition at ALT telomeres. To assess whether it usurps 
ATRX’s role at telomeres, we reconstituted ATRX in U2OS cells using a previously characterized 
U2OS cell line, U2OSATRX, where ATRX expression can be induced with Doxycycline. Indeed, 
following induction of ATRX in these cells, transiently transfected YFP-HIRA was largely absent 
from WT TRF1-FokI DSBs after PARGi. Instead, a clear focal accumulation of ATRX was 
observed at telomeric DSBs (Figure 30A-B). This implied that HIRA fulfills an elevated role in 
ALT cancer cells and its prolonged depletion could be cytotoxic.  
 
Figure 30. HIRA localization to ALT telomeres relies on loss of ATRX. A) Representative IF images of YFP-
HIRA localization in U2OS cells expressing WT-ATRX following addition of Doxycycline (40ng/ml). B) 
Quantification of ATRX-TTAGGG and (YFP-HIRA)-TTAGGG foci in U2OSATRX cells ± (40g/l) for 5 days. All 
graphed data in the figure are mean ± SEM, n=150 cells. Statistical significance was determined using one-way 




Notably, we found that stable depletion of HIRA using independent lentiviral expressed 
short hairpin RNAs elicited a more potent cytotoxic effect in ALT+ U2OS, Saos2, LM216J cells 
than in TEL+ HOS, SJSA1, LM216T counterparts (Figure 31 and Figure 49). Thus, HIRA gains 
an elevated importance in ALT+ cancer cells – perhaps as an adaptation to the loss of functional 
ATRX and DAXX. This implicates HIRA as a target for a novel epigenetic synthetic lethal 
interaction with ATRX deficiency that could specifically target ALT+ cancers. 
 
Figure 31. Loss of HIRA induces greater cytotoxicity in ALT cancers. Representative images and quantification 
of proliferation assays by crystal violet staining with the indicated ALT+ and TEL+ cell lines stably expressing 
scrambled non-targeting (NT) and HIRA shRNAs (#1 and #2) for 5 days. All graphed data in the figure are mean ± 





Chromatin reorganization is necessary to coordinate the accessibility of damaged ALT 
telomeres for repair factors that mediate HDR processes. As described in chapter 2, one facet of 
disrupted PAR metabolism is the alteration of protein dynamics during complex assembly and 
compartmentalization of damaged telomeres. In addition, the perturbation of HDR observed upon 
PARG inhibition can also arise from aberrations in DNA synthesis and resulting ssDNA gaps. It 
has been established that PAR accumulates at replication intermediates to prevent untimely 
processing (179). This is also consistent with studies demonstrating a role for PARP1 and PARG 
in replication fork stabilization (197,198). However, ssDNA gaps can also accumulate due to 
defects in chromatin assembly and provoke replicative stress, which are recurrent factors in 
initiating and sustaining the mechanisms of the ALT pathway (300). When present, ATRX and 
DAXX form a multifunctional complex that not only functions as the default telomeric histone 
H3.3 chaperone complex, but also fulfills additional roles to alleviate replicative stress and DNA 
damage at telomeres (228). For instance, due to the intrinsic inefficiency of repair-coupled DNA 
synthesis during G2-phase, it was proposed that ATRX physically associates with PCNA and Pol 
to maximize the efficiency of DNA synthesis coupled histone H3.3 deposition by resolving 
replicative barriers like G4-structures (282). It thus seems logical that the restoration of chromatin 
at ALT telomeres takes on greater urgency due to the loss of functional ATRX and DAXX.  
Our data indicates that the HIRA complex plays a critical role at ALT telomeres since 
depletion of HIRA and the complex subunits abrogates HDR processes that mediate ALT. As seen 
in previous studies, depletion of HIRA severely decreases protein expression for CABIN1 and 
UBN1, which confirms that HIRA serves as the molecular scaffold for the stable assembly of the 
complex (284,285). Depletion of UBN1 and CABIN1 also results in decreased HIRA expression, 
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showing that each subunit contributes to the stability of the HIRA complex. Decreased levels of 
UBN1 leads to diminished incorporation of H3.3 onto chromatin. On the other hand, depletion of 
CABIN1 was shown to be dispensable for H3.3 deposition (88,284,287).  
We propose that HIRA recruitment represents a fail-safe to prevent inadequate 
chromatinization of ALT telomeres and that PARylation plays a major role in enabling this 
adaptation. This is in line with a role for HIRA to preserve chromatin integrity that would be 
modulated by PARylation. Previous studies have shown that HIRA associates transiently to UV-
C damaged chromatin prior to repair (226). As above, the greater detection of HIRA at telomeres 
upon PARG inhibition likely reflect its impaired dissociation from initial binding sites at telomeric 
DSBs. Due to the immobilization of HIRA, chromatin restoration could be uncoupled from G2-
BIR since chromatin imposed topological barriers can block replisome progression. 
Immobilization of HIRA could also impinge on chromatin expansion from the DSB site by altering 
localized histone modification patterns, histone H4 lysine 16 acetylation for example, that 
contribute to chromatin expansion at break sites (296).  
However, in G2 and TRF1-FokI cells, few HIRA foci still persist at ALT telomeres without 
PARG inhibition, suggesting that HIRA can be partially recruited by other PAR-independent 
mechanisms. In fact, Zhang et al. showed that RPA1 directly recruits HIRA to regulatory elements 
and regulates H3.3 deposition in the G1 phase of the cell cycle (301). RNA transcripts at promoters 
and enhancers may generate R-loop structures, which contain a DNA-RNA hybrid and displaced 
ssDNA, to which RPA can bind to. Similarly, ALT cancers contain telomeric repeat-containing 
RNA (TERRA), which are a class of long noncoding RNAs transcribed at telomeres. These can 
also form R-loops and render ALT telomeres recombinogenic. It is possible that HIRA can localize 
to RPA-bound R-loops to alleviate replication stress in ALT. However, this likely does not occur 
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in parallel with PARylation since our unpublished data and data from Illuzzi et al. show that PAR 
accumulation displaces RPA from telomeric DNA and chromatin, respectively (302). In addition, 
UBN1 harbors a lysine-rich middle domain that binds to DNA without sequence specificity (288). 
It also binds to free H3.3, but not nucleosomes or tetrasomes. It is speculated that UBN1 can target 
HIRA to chromatin or stretches of nucleosome-free DNA. UBN1-mediated targeting has been 
reported on HIRA’s role in a gap-filling mechanism. Further studies need to be completed to 
further elucidate the interplay between different factors that mediate HIRA localization to ALT 
telomeres. 
Blocking PARylation of HIRA interferes with its recruitment to ALT telomeres, with 
ensuing defects in HDR that largely phenocopied HIRA depletion. Thus, we sought to determine 
the region of HIRA that was PARylated in order to observe whether this could result in the 
uncoupling of chromatin restoration from DNA synthesis. The homotrimerization (W799A-
D800A) mutant does not form a HIRA complex and is not enriched at damaged sites upon UV 
irradiation (227). Similarly, the absence of complex formation could hinder its ability to become 
PARylated and localize to damaged lesions in ALT.  The ASF1a binding mutant (I461D) localizes 
to ALT telomeres and rescues the suppression of ALT that is seen with HIRA depletion. The I461D 
mutant is sufficient to abolish HIRA binding to ASF1a  (227). On the other hand, the B-domain 
mutant (Δ427-472), which contains the I461 residue, cannot be recruited to ALT telomeres and 
does not restore HIRA function. This suggests that PARylation of HIRA proceeds ASF1a binding 
and is key for HIRA enrichment at ALT telomeres.  
It seems significant that the PARylation of HIRA occurs within its B-domain. Its location 
within the disordered region of HIRA is consistent with the preferential targeting of PARylation 
to low complexity (LC) or disordered protein regions that are important conduits of adaptive 
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protein interactions (224). Though the precise functional contribution of the B-domain to HIRA 
function remains to be fully elucidated, this region makes contacts with ASF1a, suggestive of a 
pivotal role in histone H3.3 transfer and deposition (286). In addition to ASF1a, histone deposition 
at DSBs was shown to involve PARylation of constituents of the Nucleosome 
Remodeling/Deacetylase (NuRD) complex, some of which have previously been implicated in 
telomeric HDR (116,204). It would be of interest to determine whether PARylation of HIRA 
influences the recruitment of other PAR-regulated histone deposition factors. This could provide 
insights as to how the sequestration of HIRA to ALT telomeres and telomeric DSBs is distinct 
from mechanisms that recruit it to transcriptional units and sites of UV-C damage. 
Finally, it should be noted that even though HIRA efficiently reconstitutes chromatin with 
histone H3.3, it does not fulfill ATRXs other roles in mitigating replicative stress 
(228,279,282,303). Aberrant secondary structures (e.g. G4s, ssDNA loops) that would otherwise 
be dealt with could remain and impair chromatin assembly. Shelterin would also not bind such 
structures. In this way, HIRA’s inability to fully compensate for ATRX-DAXX would contribute 
to basal replicative stress and stochastic DNA damage that is observed in ALT cells lacking ATRX 
and DAXX. However, it also provides a rationale for the greater dependency on HIRA that was 
exhibited by the subset of ALT cells used in this study. Investigations into the outcomes of HIRA 
deficiency on ALT cancer cell viability and the mechanisms by which cells succumb to this 
vulnerability could be expanded in precise detail. If proven that HIRA expression and function at 
telomeres is a determinant of ALT cancer cell survival, inhibitors of HIRA expression or HIRA 
protein regulation could provide an attractive opportunity for anti-ALT therapy development. This 






GraphPad Prism was used to calculate statistical significance for one-way ANOVA or 
student t-test. Statistical tests, number of cells scored, and biological replicates are indicated in the 
figure legends. *P≤ 0.05, **P≤ 0.001, ***P≤ 0.001, ****P< 0.001. 
 Cell Culture 
U2OS, Saos2, Hela LT, HOS, SJSA1 cell lines were obtained from ATCC. VA13, 
LM216T/J and WT/DA TRF1-FokI U2OS cell lines were obtained from Roger Greenberg 
(University of Pennsylvania). U2OSATRX cell line was acquired from David Clynes (University of 
Oxford). Each cell line was cultured in DMEM +Glutamax (Life Technologies) supplemented with 
10% bovine growth serum or 10% fetal bovine serum. U2OSATRX cells were specifically grown in 
tetracycline-free FBS (Takara). Cells were cultured at 20% O2 and 7.5% CO2. U2OS, HeLa LT 
and 293FT cell lines were validated by STR profiling and confirmed mycoplasma free by ATCC 
cell line authentication services.  
 siRNA knockdown 
For siRNA knockdown the On-Target Plus (OTP) siRNA SMARTpools from Dharmacon 
(GE) were used. To deplete endogenous HIRA for rescue experiments siRNA targeting the 3’UTR 
of HIRA mRNA (see Supplementary Table S1) synthesized and purchased from Dharmacon (GE). 
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400,000 cells were seeded per well of a 6-well plate containing growth medium without antibiotics. 
4hrs later cells were transfected. siRNAs and Dharmafect were diluted in OptiMEM (Life 
Technologies). A working siRNA concentration of 20nM was used. We used 2.5 L Dharmafect 
transfection reagent per well. The transfection reagent mixture was added dropwise to one well in 
1.8 mL of media without antibiotics. The next day, cells were transferred to 10-cm plates with 
coverslips. Transfection medium was replaced with complete culture media. Cells were harvested 
at 72hrs post transfection. Inhibitors were added 24 hours prior to collection.   
 Lentiviral production and infection 
pLKO-based lentivirus was produced in 293FT cells by co-transfecting pLKO constructs 
containing either control or shRNAs against HIRA together with psPAX2 (#12260) and pMD2.G 
(#12259) packing plasmids (Addgene) to produce lentivirus. 48hrs after transfection, filtered 
supernatants were used to infect cell lines. Cells were selected with puromycin for 2 days and 
protein knockdown was analyzed by western blot. 
 APB Quantification 
After 72 hours of siRNA knockdown, coverslips from 10-cm plates were collected for APB 
analysis. Anti-PML antibody was used in conjunction with telomere-FISH to identify APBs. Cells 
were visualized by conventional florescence with 40X objective (1.4 oil) using a Nikon 90i 
microscope. Large image scans of 3x3 fields were taken. Colocalization of PML and telomeres 
were analyzed using a macro in the NIS Elements software (Nikon). APB+ cells were scored if 
there was at least one colocalization event per cell.  
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 TRF1-FokI Telomere Clustering 
After 48 hours of siRNA knockdown, mcherry-DD-ER-WT TRF1-FokI U2OS cells were 
induced by adding 40ng/mL Doxycycline. After additional 24 hours, 4-OHT (1M) and Shield1 
ligand (1M) were added to the media for 4 hours. Inhibitors were added at the start of induction. 
Cells were processed for immunofluorescence and telomere number and size were quantified using 
NIS-Elements software (Nikon). 
 BrdU Pulldown Dot Blot 
The BrdU pulldown was performed after 72 hours of siRNA knockdown of HIRA in WT 
TRF-FokI U2OS cells. 48 hours post siRNA transfection, 40ng/mL Doxycycline was added to the 
media. 24 hours later, 4-OH (1M) and Shield1 ligand (1M) were added for a total of 4 hrs. The 
last 2 hrs, cells were pulsed with 100μM BrdU (Sigma) before collection. Extracted genomic DNA 
was sheared by sonication into 100–300 bp fragments. Sheared gDNA was denatured for 10mins 
at 95°C and cooled in an ice-water bath. Denatured gDNA was incubated with 2μg anti-IgG 
(Sigma) or anti-BrdU antibody (BD) diluted in immunoprecipitation buffer (0.0625 % (v/v) Triton 
X-100 in PBS) rotating overnight at 4°C. The next day, samples were incubated with 30μl Protein 
A/G agarose beads (Santa Cruz) pre-bound to a bridging antibody (Active Motif) for 1h rotating 
at 4°C. Beads were then washed three times with immunoprecipitation buffer and once with TE 
buffer. Beads were then incubated twice in elution buffer (1% (w/v) SDS in TE) for 15mins at 
65°C. Pooled eluates were purified with ChIP DNA Clean & Concentrator kit (Zymo). Samples 
were diluted into 2×SSC buffer, treated at 95°C for 5mins, and dot-blotted onto an Amersham 
Hybond-N+ nylon membrane (GE). The membrane was then denatured in a 0.5N NaOH/1.5M 
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NaCl solution, neutralized, and ultraviolet crosslinked. The membrane was hybridized with 32P-
labelled (TTAGGG)4 oligonucleotides in Church Buffer overnight at 55°C. The next day, the 
membrane was washed four times in 2×SSC buffer and once in 2xSSC/0.5% SDS, exposed onto 
a storage phosphor screen (GE Healthcare), scanned and analyzed with ImageJ.  
 H3.3 and HIRA IF 
GFP-H3.3 and HIRA-YFP were transiently transfected into U2OS or WT TRF1-FokI 
U2OS cell lines. U2OS cells were arrested in G2 by adding 1  of RO-3306 at 24 hours post 
transfection. 40 ng/mL of Doxycycline was added to WT TRF1-FokI U2OS cells. Inhibitors were 
also added at this time point.  24 hours later, WT TRF1-FokI U2OS cells were induced with 4-
OHT and Shield Ligand. Cells were pre-extracted for 5 minutes at RT using pre-extraction buffer 
(0.06M EGTA, 0.5 PIPES, 0.5M MGSO4, 3M KCl, and 0.5% Triton-X). Cells were then fixed in 
4% PFA at 4oC. IF proceeded normally after this step.  
 In Vivo PARylation Assay 
GFP-immunoprecipitation was performed with GFP-TRAP®_A agarose beads 
(Chromotek). Briefly, 1 x 106 WT TRF1-FokI cells were seeded in a 10cm dish. ~24hrs later, cells 
were transfected with GFP-constructs using Lipofectamine 2000 (Invitrogen) as per 
manufacturer’s instructions and 40ng/mL Doxycycline was added to the media as before. Cells 
were later induced with 4-OHT (1M) and Shield1 ligand (1M) for 4hrs with the addition of 
PARGi (5M). Cells were harvested using ice-cold PBS, scraped from the dish and transferred to 
pre-cooled tubes. Cell pellets were resuspended in 200L ice-cold RIPA buffer (10mM Tris-HCl 
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(pH 7.5), 150mM NaCl, 0.5mM EDTA, 0.5% NP-40, 0.09% Na-Azide) with 1mM PMSF, 2.5mM 
MgCl2, 1mg/ml DNase (Pierce) and protease inhibitor cocktail (Sigma). To extract HIRA proteins, 
modified RIPA buffer (500mM NaCl) was used as before. Tubes were placed on ice for 30mins 
with extensive pipetting every 10mins. Tubes were centrifuged at 20,000x g for 10 min at 4ºC and 
lysates were transferred to pre-cooled tubes. 300L ice-cold dilution/wash buffer (10mM Tris-
HCl (pH 7.5), 150mM NaCl, 0.5mM EDTA, 0.018% Na-Azide) with 1mM PMSF, 2.5mM MgCl2, 
and protease inhibitor cocktail (Sigma) was added to tubes. 50L of lysate was resuspended in 
50L 4X LDS buffer to save as 10% input samples. GFP-TRAP®_MA magnetic beads were 
equilibrated in dilution/wash buffer. 25L of the bead slurry was added to each tube and rotated 
for 1hr at 4ºC. Beads were magnetically separated and washed twice with wash/dilution buffer. 
Beads were resuspended in 100L 4X LDS buffer and boiled for 10mins at 95ºC. Beads were 
magnetically separated and SDS-PAGE was performed with the supernatant. PARylated proteins 
were detected using specific anti-PAR (10H) antibody.  
 ATRX re-expression 
ATRX cDNA was cloned into the Tet-on 3G Inducible Expression System 
(Clontech) and transfected into using Xfect transfection reagent (Clontech), to generate the 
U2OSATRX stable cell line. This was acquired from David Clynes (University of Oxford). 
100 ng/mL of Doxycycline was added onto cells for 5 days. WB analysis was performed 
to ensure re-expression of ATRX in U2OS cell lines that were treated with Doxycycline. 
All experiments were performed after U2OSATRX   cells have been treated with Doxycycline 
for 5 days.  
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 Clonogenic Assay 
Clonogenic assays were started after cells were infected with lentivirus carrying control or 
shRNAs against HIRA. 2 days post infection, 2000 cells were seeded in 6 well plates in duplicate 
and cultured for 7 days with 1g/mL of puromycin selection. Plates were then fixed and stained 
in a 1% crystal violet solution. Plates were scanned and analyzed with ImageJ, which was used to 






5.0 Future Directions 
This thesis highlights the importance of controlled ALT activity to limit the toxicity of 
rampant DNA damage. Disrupted PAR metabolism tips the delicate balance between pro- and anti-
recombinogenic signals for productive ALT activity. Our data shows that PAR-regulated HIRA 
fulfills a protective function at ALT telomeres. HIRA exhibits elevated importance in ALT+ 
cancers to compensate for the loss of ATRX/DAXX. This body of work has given rise to several 
future directions that would provide greater insight into the molecular events that drive ALT 
telomere maintenance. Taken together, these proposed experiments provide a stepping stone to the 
development of anti-ALT therapeutic agents.  
5.1 Does Disrupted PAR Metabolism Have Direct Effects on ALT Telomere Maintenance? 
Perturbations in PAR metabolism alter ALT activity. While PARPi substantiates ALT 
phenotypes and HDR processes, PARGi holds the opposing effect and leads to substantial loss of 
telomere length. Additionally, ALT cancers exhibit modest sensitivity to prolonged exposure to 
PARGi.  Although it is undisputed that PARGi elicits a negative impact on ALT activity, it will 
be important to test if the effects are due to direct effects of PARGi on ALT-mediated mechanisms 
or indirect effects due to PARP1 and PAR accumulation at damaged sites. PARP1 overactivation 
leads to massive consumption of NAD+ and consequential depletion of cellular ATP pools (304). 
Prolonged PARP1 activation decreases the half-life of NAD+ in a dose-dependent manner. In fact, 
mammalian cells exposed to a high dosage of genotoxic stress display 20% reduction in NAD+ 
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within 5-15 minutes. This depletion of cellular NAD+ pools also affects other metabolic processes 
that rely on NAD+ as a cofactor to generate ATP, such as glycolysis and tricarboxylic acid cycle 
(TCA cycle) (305–307). Additionally, accumulation of PAR polymers is detrimental to cells and 
leads to a cellular process known as PARthanatos, which harnesses cytological and morphological 
features of apoptosis and necrosis (159,160). Cellular toxicity is dependent on the length and 
complexity of PAR polymers. Direct delivery of PAR polymers that consisted of greater than 60 
ADPr units are toxic to neurons and Hela cells (159,161). Toxicity is observed at 20 nM of PAR 
and cell death induced at 80 nM of PAR. 
NAD+ and ATP measurements can be performed to test the indirect effects of cellular 
energy consumption. There are several NAD/NADH and ATP/ADP quantification kits that are 
commercially available (308). The NAD/NADH kit is based on an enzymatic cycling reaction that 
reduces NAD+ to NADH. NADH then reacts with a colorimetric probe that can be measured at 
450 nm. The ATP/ADP assay works through the reaction of released cellular ATP with the 
substrate (D-luciferin) to produce light. ADP is also converted to ATP, which then reacts with D-
luciferin as in the first step. As a result, this measures the total ADP and ATP levels as well as 
ATP concentration in cells. We can measure NAD+ and ATP levels in TEL+ and ALT+ cells that 
are subjected to acute or prolonged exposure to PARGi, as reported in chapter 2.  
These experiments would likely show that NAD+ and ATP levels drop in both ALT+ and 
TEL+ cell lines because PARGi prevents PAR metabolism, which leads to excessive consumption 
of NAD+ as a substrate to generate PAR. This is probably more evident during extended PARGi 
treatment due to gradual depletion of a limited NAD+ pool. Thus, we can determine the appropriate 
dosage and timing of PARGi that elicits direct effects as oppose to toxicity from PAR 
accumulation. In particular, ALT+ cells may either exhibit greater energy depletion or higher 
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sensitivity due to the burden of telomeric damage. To further elaborate on this, we can rescue 
energy depletion by administering dihydronicotinamide riboside (NRH), which is a potent NAD+ 
concentration enhancer both in vitro and in vivo (309). NRH structurally resembles NAD+ 
precursors and can be converted by cellular ATP-dependent kinase activity. NRH-treated cells are 
resistant to cell death induced by hydrogen peroxide and methylmethane sulfonate. Likewise, the 
phenotypes observed with PARGi in ALT+ cells may be attenuated. However, if ALT+ cells are 
not fully restored upon addition of NRH, then this would imply a specific and direct mechanism 
of PARGi at ALT telomeres.  
5.2 How does PAR Modulation Contribute to HDR Pathway Choice?  
One of the outstanding questions in the field is what determines telomere synthesis via 
RAD51-dependent or RAD51-independent mechanisms at ALT telomeres. Several studies have 
identified the unique molecular machinery involved in each HDR pathway. First, telomeric DSBs 
undergo resection that is mediated by the MRN complex, BLM-EXO1-DNA2, or WRN-DNA2 
(54,244). Subsequently, ATR activation leads to RPA/RAD51/HOP2-MND1-mediated homology 
searches and inter-telomeric recombination that occur primarily in S-phase (60,96). There are two 
RAD51-independent pathways that have been reported: spontaneous mitotic DNA synthesis 
(MiDAS) and G2-BIR in G2/M (93,98). These processes are optimal during the narrow window 
of late G2 and mitosis when there is not sufficient time for RAD51-driven homology searches. 
MiDAS is RAD52-dependent and engages in MMBIR (less than 1-6 nucleotide required 
homology) for template switching (109–111). Min et al. proposed that ALT cells exhibit more 
telomeric replication defects that lead to engagement of MiDAS (93). However, MiDAS is 
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restricted to prometaphase and occurs at a low frequency, which likely means that it is not the 
primary mode of DNA synthesis in ALT cancers (94). On the other hand, G2-BIR can persist in 
mitosis (interphase, prometaphase, and metaphase) and does not rely on RAD52 and SLX4-
MUS81. Ultimately, these RAD51-independent pathways converge on a noncanonical replisome 
that comprises of PCNA-RFC-POLD3 for DNA synthesis (94,98).  
ALT telomeres engage in these distinct HDR pathways depending on the initial telomere 
lesion and cell cycle phase. However, the differential contribution of cellular factors and initial 
stimulus of each pathway in ALT still remains poorly understood. Chapter 2 demonstrated that 
PARGi disrupted both canonical and non-canonical HDR, resulting in negative consequences for 
ALT telomere maintenance. Chapter 3 revealed that the molecular machineries involved in these 
diverse repair pathways are regulated by PARylation. A reasonable explanation could be that 
PARylation perturbs cell-cycle distribution and increases the probability of specific HDR 
processes to occur during a particular cell cycle phase. PARGi-treated ALT cells display modest 
perturbations in cell cycle progression, with some cells accumulating in S-phase. (Hoang et al. 
unpublished data). In addition, a similar cell cycle is observed in shControl and shPARG Hela LT 
cells in unstressed conditions and after short HU treatment (302). PARG-deficient cells haven been 
shown to exhibit impaired S-phase progression upon prolong exposure of HU. This suggests that 
the basal level of replication stress in ALT cells mimics that of short HU exposure as ALT 
telomeres undergo recurrent cycles of stochastic DNA damage.  
Another avenue to explore is whether PARGi favors canonical or non-canonical HDR. A 
simple approach would be to parse our Af1521 mass spectrometry data, as discussed in chapter 3, 
to see whether PARylated factors at telomeric DSBs belong to either RAD51-dependent or -
independent pathways. We could perform the Af1521 pulldown in isogenic cell lines LM216J 
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(ALT+) and LM216T (TEL+) WT TRF1-FokI cell lines that are synchronized at specific cell cycle 
phases. This experiment is under the premise that these are competing HDR mechanisms and do 
not occur in parallel with each other. The expectation would be that the PARylome changes 
depending on cell-cycle progression since distinct HDR pathways are employed at either S and 
G2-phases or early and late mitosis. The resulting PARylomes of ALT+ and TEL+ cancers will 
likely be fundamentally different since ALT+ cells have characteristic features that prime them for 
increased recombination. This is supported by the distinct telomeric composition of unperturbed 
U2OS and Hela LT cells, in which 139 proteins were specific to ALT+ cancers (87). Additionally, 
we could expand our in vivo PARylation assay to include known factors of RAD51-dependent and 
-independent factors using the same conditions described above. Together, this would yield useful 
insights into the diverse contributions of PARylation at different time points in the regulation of 
ALT activity.  
Proteomics has its limitations though and cell-based studies need to be performed to 
validate the fine-tune control of HDR mechanisms by PARylation. In our proteomics strategy, it 
is likely that some key mediators will not be accounted for in the mass spectrometry data due to 
their low abundance, poor sequence coverage, or loss during the Af1521 pulldown. Alternatively, 
the mode of replication can be indicative of HDR pathway choice. RAD51-dependent mechanisms 
will undergo semi-conservative replication while RAD51-independent mechanisms engage in 
conservative replication that is mediated by break-induced replication processes. We can utilize a 
triple-FISH method to differentiate between telomeric semi-conservative and conservative 
replication (Figure 32). Previous studies have used Cyclin E overexpression to induce DNA 
replication stress at U2OS cells to trigger repair by BIR. Cyclin E-potentiated fork collapse leads 
to elevated conservative synthesis (97).  
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Thus, we would use U2OS WT TRF1-FokI that are treated with PARGi to see if this alters 
the preference in an HDR mechanism. Metaphase chromosomes that are treated with BrdU and 
BrdC for one cell-cycle will be subjected to three consecutive strand-specific FISH staining steps 
(97) (Figure 32). First, metaphases are stained using telomere strand-specific dual color FISH 
under denaturing conditions. This marks both telomeric strands for reference in subsequent 
staining steps. Second, after destaining, metaphases are labelled by non-denaturing, telomere 
strand-specific, dual color CO-FISH. Newly synthesized DNA strands are degraded and only 
parental strands that have been replicated in a semi-conservative manner can hybridize with the 
telomeric probes. Conservatively replicated telomeres would result in one sister chromatid with 
both nascent strands degraded while the other sister chromatid would comprise of parental strands 
that cannot hybridize with the probe. Both outcomes lead to no signal at chromosome ends. The 
final step is destaining, followed by telomere strand-specific, dual color FISH under denaturing 
conditions. At semi-conservatively replicated telomeres, the labelling pattern will remain the same. 
In contrast, conservatively replicated telomeres have two annealed parental strands that will 
hybridize with the telomeric probes. This third step further confirms that the absence of a signal in 
conservatively replicated telomeres during the second step was not due to technical errors. 
Additionally, triple-FISH can provide valuable information on partial semi-conservatively and 
conservatively replicated telomeres, which can occur at telomeric replication fork collapse that is 
repaired by BIR or if these HDR processes are occurring simultaneously in ALT. Overall, this 
would be highly informative as to whether PARGi is sufficient to shift the balance in HDR 





Figure 32. Triple-FISH schematic to quantify BIR. Semiconservative replication results in non-overlapping 
signals at both strands. B) Conservative replication leads to an overlapping yellow signal on one strand. C) Partial 
conservative and semi-conservative replication lead to staining patterns that incorporate A and B. Adapted from 
Roumelioti FM et al., EMBO Rep, 2016  (97) (https://www.embopress.org/doi/full/10.15252/embr.201643169). 
 
Our current Af1521 data in chapter 3 provides valuable insight into PAR-regulated early 
responders of ALT, which could be key to determining what is the initial stimulus of HDR pathway  
choice. Interestingly, we found ARP2/3, a component of the actin polymerization machinery, to 
be enriched at ALT telomeres. Schrank et al. showed that ARP2/3 binds to DSBs and mediates 
HDR instead of NHEJ. ARP2/3 enhances the movement of sites of DSBs resection. This actin-
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driven clustering also promotes processing and resolution of DSBs that are undergoing HDR. 
These two results show that there is a positive feedback loop between DSB mobility and end 
resection, resulting in propagation of repair factors at the site of damage (106). We show that 
ARP2/3 is directly PARylated. Additionally, we determined that inhibition of ARP2/3 using CK-
666 (ARP2/3i) hinders telomere clustering and telomeric mobility to levels seen with PARGi 
(Figure 47). This implicates ARP2/3 in orchestrating the early decision for long-range HDR in the 
hierarchy of signaling. The link between PARylation and the organization of the cytoskeleton in 
mammalian cells have been enigmatic. However, there are studies in other organisms that reveal 
the importance of ADP-ribosylation in modulating actin polymerization. For example, 
overexpression of PARP in the Drosophila developing eye causes disorganization of cytoskeletal 
filamentous actin (F-actin) and disrupts tissue polarity (310). The authors posited that excessive 
MAR or PAR interacts with actin and prevents F-actin formation. In addition, the bacterium 
Photorhabdus luminescens utilizes TccC3 and TccC5, adenosine diphosphate 
ADP(ribosyl)transferases, to ADP(ribosyl)ate actin to initiate actin polymerization (311). These 
studies suggest a possibly conserved mechanism of ADP(ribosyl)ation in modulating biological 
processes that rely on actin organization.  
Therefore, it is promising to understand the function of PAR-mediated ARP2/3 actin 
nucleation in the homology search mechanism at ALT telomeres. To determine whether 
PARylation disrupts ARP2/3 function, we could transfect nuclear-actin-chromobody-tag-GFP in 
U2OS eRFP-TRF1 cells and U2OS mCherry-WT TRF1-FokI cells treated with PARGi or 
ARP2/3i (106). We would measure the colocalization of actin structures resembling foci (actin-cb 
foci) with eRFP-TRF1 or mCherry-TRF1-FokI. WT TRF1-FokI cells will exhibit more and larger 
actin-cb foci at ALT telomeres since it is known that telomeric damage initiates long-range 
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homology search through the RAD51-dependent pathway (96). It has already been proven that 
adding ARP2/3i abolishes these actin-cb-foci, confirming that these structures are sites of ARP2/3-
dependent nucleation. It is likely that PARGi will elicit similar effects if it inhibits the downstream 
activity of ARP2/3. It would also be informative to arrest cells in G2/M phase, where long-range 
homology is dispensable for BIR-related processes. It is likely that ARP2/3i may not play a large 
role in G2/M.  The observed phenotype would be smaller actin-cb-foci or the absence of actin-cb-
foci. Moreover, Schrank B.R et al. only shows the enrichment of ARP2/3 at damaged chromatin, 
but does not look at whether ARP2/3 directly binds to DNA (106). It would be valuable to 
determine whether ARP2/3 binds to telomeric DNA and if that association is disrupted upon PAR 
accumulation. Biotinylated telomeric ssDNA oligos can be preincubated with purified ARP2/3. 
Then, increasing concentrations of PAR polymers can be added to assess displacement of ARP2/3 
from telomeric DNA. Additionally, we can identify potential PAR-binding or PARylatable regions 
in ARP2/3 and test mutants using the in vitro and in vivo PAR-binding and PARylation assays. 
Together, these experiments would directly implicate PARylation or PAR-binding of ARP2/3 as 
a driver of HDR in S-phase.  
Another interesting notion to follow is the role of PARylation in the repression of alt-
NHEJ, which also uses DSBs as substrates for repair. Normally, alt-NHEJ is a backup for defective 
HR and c-NHEJ (194) . PARP1 is a key component of alt-NHEJ and is in direct competition for 
binding of DSBs with Ku70/80, which is a determinant of c-NHEJ pathway selection (312). Alt-
NHEJ is also implicated in the repair of telomere-internal DSBs (195). In the context of ALT, 
PARP1 loading onto resected DNA would initiate alt-NHEJ. However, ALT cells favor other HDR 
mechanisms because alt-NHEJ is mutagenic and pushes genome instability beyond tolerable 
levels. It is possible that ALT cells activate alt-NHEJ to counteract abrogation of HDR processes 
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and c-NHEJ due to PARGi. Indeed, we found several alt-NHEJ factors, such as LIG3 and XRCC1, 
enriched at ALT telomeres upon PARGi.  
This raises the question of whether the PARylation of several alt-NHEJ factors contributes 
to the inhibitory effects of ALT. We can deplete alt-NHEJ factors in conjunction with HR factors 
in U2OS cells, followed by quantification of ALT phenotypes, such as APBs, T-SCEs, and c-
circles. Depletion of alt-NHEJ factors in ALT+ cells likely would not repress ALT because the 
preferred HDR mechanisms are still present. However, depletion of alt-NHEJ with HR factors, 
such as RAD51 or POLD3, might lead to greater ALT suppression compared to depletion of the 
HR factors by themselves. This would help determine if alt-NHEJ arises as the ultimate backup in 
ALT cells. To tackle the role of PARylation, we can observe the recruitment of endogenous and 
GFP-tagged alt-NHEJ factors, such as LIG3 and XRCC1, at ALT telomeres in U2OS WT TRF1-
FokI cells treated with PARGi. We expect alt-NHEJ factors to localize to ALT telomeres in the 
presence of PARGi since important HR factors, such as PCNA, POLD3, and RPA2 are displaced. 
In fact, loss of RPA has been shown to stabilize annealed intermediates that promote alt-NHEJ 
(271). These experiments would provide a convincing argument that the tight regulation of PAR 
metabolism is imperative in maintaining the competition for DSB repair at ALT telomeres (Figure 




Figure 33. PARGi uncouples HDR proccesses at ALT telomeres. PARGi leads to retention of PARylated and 
PAR-binding DDR factors, as well as negatively charged PAR polymers at telomeres. This abrogates the efficiency 
of ALT-mediated pathways and impairs ALT activity.   
5.3 What is the Prospect of PARG Inhibitor Use in the Clinic?  
There have not been many studies that have elucidated the efficacy of PARG inhibitors in 
the clinic. Loss of PARG is a major resistance mechanism to PARPi in HR-deficient cancers, such 
as ovarian and triple-negative breast cancers. Gogola et al. show that PARG inhibition rescues 
PARP1 signaling and reduces toxic accumulation of PARP1-DNA complexes (313). Although 
PARG inhibition deters PARPi treatment, it exposes therapeutic vulnerabilities that could be used 
to target resistant tumors. This is supported by a study that demonstrates radiosensitization of 
BRCA1/2-deficient cancers upon treatment with PARGi (314). Additionally, PARG inhibition in 
ovarian cancers renders them sensitive to persistent replication stress and replication catastrophe 
(315). PARGi is synthetic lethal with inactivation of several DNA replication factors, such as 
TIMELESS, HUS1, and RFC2. Pharmacological induction of replication stress through CHK1 
inhibition sensitizes cancer cells to PARGi. Notably, PARGi toxicity is enhanced by WEE1 kinase 
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inhibition and forces arrested cells into mitotic catastrophe. This sensitization to replication stress 
provides merit for potential combination therapies with PARGi.  
ALT is more reliant on replication stress for telomere maintenance, which creates the 
opportunity to exploit the vulnerabilities in disrupted DDR for therapy (Figure 34). In our survival 
assays, ALT cells appear to have a modest decrease in growth upon PARGi treatment. It is possible 
that PARGi leads to cell death in ALT+ cells because the replication stress levels surpass the 
normal levels required to maintain telomeric integrity. There have been several instances, where 
inhibition or depletion of HDR factors disrupts the ALT mechanism and provokes death of ALT 
cancer cells. Indeed, ALT cell lines were reported to exhibit acute sensitivity to inhibition of ATR 
kinase, an apical sensor of replicative stress and mediator of the repair response (316,317). 
Similarly, depletion of FANCM and TOP3A induces a potent acute apoptotic phenotype in ALT 
cancer cell lines (30). In addition, chemical stabilization of G4 quadruplexes that require 
dissolution by BLM could also be harnessed to elicit a cytotoxic response (318). Thus, targeting 
the FANCM-BTR complex represents a potentially viable option for therapy development. The 
key may lie in determining combinations that induce ALT-specific synthetic lethality through 
either restricting HDR pathway switches or inducing catastrophic recombination, as implied by 
the systemic death of cells lacking SLXIP and SLX4 (112). 
It is not unreasonable to assume, based on the striking correlation with ALT, that the 
absence of functional ATRX-DAXX complex affords the opportunity to determine synthetic lethal 
interactions that eliminate ALT cancer cells. Identifying and targeting factors that functionally 
compensate for ATRX loss in remediation of replicative stress might yield some benefits for 
exploitation of ALT-specific vulnerabilities. CRISPR-based or small compound library screens to 
identify synthetic lethal partners of ATRX deficiency are yet to be reported. Mitigating factors 
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might be the heterogeneity of available standard ALT cells lines in terms of tissue of origin, ploidy 
and somatic mutation burden. However, one interesting example of synthetic lethality with ATRX 
inactivation was reported in which the specific killing of ALT cancer cells was induced following 
infection with mutant Herpes Simplex Virus-1 (HSV-1) (319). This was directly attributed to 
repression and proteasomal degradation of PML protein isoforms upon loss of ATRX and 
demonstrated the potential utility of viral-based therapy to kill ATRX-deficient ALT cancer cells.  
Like ATRX inactivation, PML proteins hold unique importance in the biology of ALT 
cells. Shuttling of telomeres to PML bodies by SUMOylation driven liquid phase separation is a 
signature event in ALT (55,225). Conventionally, this is linked with productive DNA synthesis at 
telomeres. However, it was recently shown that the sequestration of telomeres within APBs could 
be a poison pill.  POT1 – an ssDNA binding constituent of Shelterin that is essential for 
chromosome end protection and telomere replication is targeted for Ubiquitin specific protease-7 
(USP7)-dependent proteolysis (320). Yet, this detrimental event that could unleash ATR-
dependent DNA damage signaling is prevented by a newly identified ALT specific factor, Testis-
Specific Y-encoded Like Protein (TSPYL5). TSPYL5 counteracts the destabilizing activity of 
USP7. In doing so, TSPYL5 fulfills a key role in sustaining ALT cell viability since its depletion 
elicits rampant apoptosis due to compromised telomere function. This remarkable finding shows 
that disrupting APBs, or more specifically, APB-resident factors that confer protection against 
PML-USP7-dependent proteolysis could be a silver bullet for ALT-based cancers.  
Interfering with the processing of DNA intermediates of telomere recombination has 
typically provoked acute cytotoxicity and apoptotic cell death. In those contexts, telomere 
shortening is often not observed. Rather, there seems to be a complete systems failure. This 
contrasts with chronic, progressive telomere shortening and DNA damage accumulation due to 
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disruption of key mediators of HDR like RAD52 that culminate in a senescence-like growth arrest 
(55,64). However, in one surprising case, the perturbation of telomere maintenance in ALT cells 
lacking RAD51AP1, a co-regulator of RAD51, provoked a cytoprotective autophagic phenotype 
(28). As with autophagy during crisis, telomere dysfunction and Cyclin GMP-AMP Synthase 
(cGAS)-dependent sensing of telomeric DNA fragments appears to mediate autophagy in ALT 
cells (321,322). However, in contrast to autophagy during cellular crisis, this autophagic pathway 
conferred cell survival (28). Only when autophagy was inactivated did the ALT cells succumb by 
apoptosis. The absence of Stimulator of Interferon Genes (STING) seems to be a prime culprit for 
this distinction since it is required for telomere dysfunction-induced autophagy during crisis and 
repressed in ALT cells (321). Other factors are likely to dictate outcomes such as the particular 
burden of telomere damage. For instance, autophagy in crisis responds to overwhelming and 
catastrophic telomere deprotection during mitosis. In contrast, the RAD51AP1 KO ALT cells 
displayed a relatively modest chronic telomere damage phenotype (28). If ALT cancer cells rely 
on autophagy for survival, this could represent a new vulnerability in ALT cells that presents an 
opportunity for therapeutic evaluation. These implicate novel and somewhat unexpected means by 
which ALT cancers could be targeted. 
This rationale aligns with the potential for exploiting elevated replication stress at ALT 
telomeres. We can interrogate the gene expression of proteins involved in resolution of replication 
stress to see if this drives vulnerability in ALT cancers (323). A comparison of the gene profile in 
ALT+ and TEL+ cancers would allow us to determine differential upregulation and 
downregulation of replication stress-related genes that are specifically involved in ALT+ cancers. 
We could also cross reference this to a previous BioID analysis that identified a unique network 
of 139 proteins that converge at ALT telomeres (87). We can then select genes that are upregulated 
 
 137 
specifically in ALT+ cancers and conduct synthetic lethal screens with PARGi in a wide array of 
ALT+ cells, using TEL+ cell lines as controls. ALT telomeres exist in an atypical chromatin and 
genomic configuration that act in concert to manage genomic instability. Thus, deregulation of 
factors involved in relieving replicative stress in conjunction with PARGi may tip this delicate 
balance towards cell death. This screen could be invaluable in identifying replication stress 
enrichment biomarkers that would be informative to develop effective combinatorial therapies that 





Figure 34. The fate of ALT-inhibited cancer cells. ALT cancers exist in an equilibrium between beneficial HDR 
and telomere dysfunction. A shift from this equilibrium poses a therapeutic vulnerability that can be exploited for 
selective killing of ALT cancers. Synthetic lethality with ATRX/DAXX is a promising target since ATRX/DAXX 
loss of function mutations are prevalent in ALT cancers. Similarly, ALT-associated PML bodies (APBs) is an 
attractive target for therapy since APBs are unique to ALT cancers and are implicated in telomere metabolism of 
ALT cells. Disruption of APBs with infection of Herpes Simplex Virus-1 (HSV-1) or depletion of TSPYL5 have 
been shown to elicit cytotoxicity. In addition, several lines of evidence report that inhibition of HDR factors perturbs 
ALT activity and provokes to cell death. Intriguingly, the absence of STING in ALT cancers enables activation of 
the pro-survival autophagic pathway. This reliance on autophagy may present a unique opportunity in ALT cancers 
to tip the balance in favor of apoptotic cell death. 
5.4 Is HIRA Directly PAR-modulated?  
In chapter 4, we demonstrate that HIRA is directly PARylated through our mass 
spectrometry analysis and in vivo PARylation assay. Jungmichel et al. have confirmed that these 
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methodologies yield covalent modification of target proteins through validation in both in vivo and 
in vitro PARylation approaches (223). However, protein activity and subcellular localization can 
be influenced by either direct covalent modifications by PARP1 or free PAR that can bind to 
proteins in a non-covalent manner (166). Thus, it would be instrumental to confirm that HIRA 
activity is modulated by direct PARylation of the protein. It would be useful to initially inspect the 
HIRA protein sequence for potential PAR-binding modules. These can include PAR-binding 
consensus motifs (PBMs), PAR-binding zinc finger motifs (PBZs), macrodomain folds, WWE 
domains, and RGG repeats (154). PBMs have been identified in over 800 proteins and comprise 
of approximately 20 amino acids with a cluster of hydrophobic amino acids spaced by basic 
residues. PBZs contain a consensus sequence of less than 30 amino acids. Only two proteins in the 
human proteome contain high-affinity PBZ motifs (Kd ~ 10
-3M). 11 human proteins have 
macrodomains, which are large regions containing 130-190 amino acids. The WWE domain is 
found in 12 human proteins and contains the conserved amino acids tryptophan (W) and glutamate 
(E). The RGG motif are regions that are rich in arginine (R) and glycine (G). Over 1000 diverse 
human proteins comprise of RGG motifs.  
We can analyze the amino acid sequence of HIRA through protein domain databases to 
predict potential PAR-binding modules. Several protein domain and alignment databases can be 
used, such as SMART (Simple Modular Architecture Research Tool), NCBI CDD (Conserved 
Domain Database), UniProt (Universal Protein Resource), MUSCLE (Multiple Sequence 
Alignment), and LALIGN (FASTA Package of Sequence Analysis Program). This reveals that 
HIRA does not contain the previously described PAR-binding modules. To further support this, 
HIRA is not found in a study that characterized the PAR-binding interactome through large-scale 
mass spectrometry-based proteome analysis (153). In fact, using Peptide 2.0, the HIRA amino acid 
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composition is found to be 41.6% hydrophobic, 13.37% basic, 10.52% acidic, and 34.41% neutral. 
As mentioned in chapter 4, HIRA’s hydrophobic cleft is important for its association with ASF1a. 
There are also clusters of salt bridges that form between the basic residues of HIRA and the acidic 
residues of ASF1a. Intriguingly, these basic residues lie within the B-domain of HIRA and are 
interspersed throughout small patches of hydrophobic residues. We can envision that this can act 
similar to PBMs and can potentially facilitate PAR binding to HIRA. However, these basic 
residues can also serve as sites for covalent conjugation of PAR onto HIRA. Taken together, 
further experimental studies need to be performed to eliminate the potential for indirect PAR 
accumulation to prevent HIRA localization and function.    
Interestingly, our results indicate that the mutant HIRA construct that lacked the B-domain 
cannot localize to ALT telomeres and be PAR-modulated. The 36 amino acids that span the B-
domain are within a highly disordered region of HIRA. Regions of structural low complexity are 
preferentially targeted for PAR-seeded liquid de-mixing (224). Additionally, the B-domain 
contains the critical I461 residue for ASF1a binding (286). The interface between HIRA’s B-
Domain and ASF1a is mediated through B-sheet, salt bridge and van der Waals interactions. 
Downstream of I461 are three arginine residues (458-460), which can be acceptors of PAR and 
are required for ASF1a binding. A potential explanation is that negatively charged PAR at these 
basic residues can disrupt the B-sheet and repel ASF1a through electrostatic forces. Thus, the B-
domain in HIRA could be PAR-regulated to prevent histone exchange from ASF1a. The next step 
to confirm the importance of these arginine residues would be to generate HIRA mutant constructs 
that contained individual point mutations of residues 458-460 or a HIRA mutant construct with all 
three residues mutated to alanine. These constructs would be tested in the same experiments as 
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reported in chapter 4. It is expected that the RRR mutant constructs would generate similar results 
to that of the B-domain if it is the region that directly engages with PAR.  
To further confirm that HIRA is covalently PARylated, we can perform an in vitro 
PARylation assay with purified, recombinant human HIRA, full length human His-PARP1, [32P]-
NAD+, and double-stranded DNA oligomer. HIRA can be separated using an SDS-gel and detected 
using autoradiography. The caveat of this assay is that HIRA is the same size as automodified 
PARP1, which would not allow for differentiation on the SDS-gel. To overcome this, we would 
need to optimize a method to remove PARP1 from the end reaction. Unfortunately, automodified 
PARP1 is abundant and likely to be challenging for a full cleanup of the reaction. We would need 
to purify His-PARP1 with a mutated BRCT domain to prevent automodification. Although it has 
been shown that the binding of PAR to the BRCT domain recruits other DDR factors to sites of 
damage, perhaps it would not be necessary for an in vitro PARylation assay where HIRA and 
PARP1 are in the same vicinity. Alternatively, we can attempt to IP HIRA after these reactions. In 
addition, HIRA may not be stable without the presence of the other complex subunits. Ray-Gallet 
et al. determined that the HIRA subunit forms a homotrimer and binds two CABIN1 subunits in 
vitro (227). It is possible that we need to complement the in vitro PARylation assay with 
recombinant CABIN1 and UBN1 to maintain the complex stability required for its PARylation. If 
these practical limitations are overcome, then this approach will confirm that PARP1 can 
covalently target HIRA for PARylation. 
 In addition, we can carry out an in vitro PAR binding assay where we immunoprecipitate 
YFP-HIRA or YFP-HIRA mutant constructs and then detect the binding or not of biotinylated 
PAR. YFP-PARP1 would be used as a positive control. YFP constructs will be separated on an 
SDS-PAGE denaturing gel and transferred to a nitrocellulose membrane. The membrane will be 
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incubated with biotinylated PAR polymers. The membrane can then be probed for streptavidin-
HRP and re-probed for YFP to detect the HIRA constructs as well as PARP1. If HIRA contains 
PAR-binding modules, then we should only detect PAR-binding in the YFP-HIRA and YFP-
I461D constructs. These constructs have been previously shown to localize to ALT telomeres, be 
PARylated in our in vivo PARylation assay, and are able to rescue the phenotypes seen with 
depletion of HIRA. Collectively, these anticipated results would provide compelling evidence for 
the direct role of PAR modulation on HIRA localization and activity. 
5.5 What is the Interplay between Factors that Mediate HIRA Recruitment to ALT 
Telomeres?  
HIRA localization to ALT telomeres is not completely dependent on PAR modulation, 
which suggests that there might be other unknown modes of recruitment. Ray-Gallet et al. 
confirmed that the HIRA complex showed direct binding to DNA without any sequence specificity 
(291). In addition, UBN1 and CABIN1 could bind directly to DNA, unlike ASF1a. They argued 
that the lack of sequence specificity for DNA binding targets HIRA to destabilized nucleosomal 
DNA regions, where it could alter nucleosome organization as part of a gap-filling mechanism. It 
has been determined that the lysine residues within the 176-295 region of UBN1 contribute to its 
ability to non-specifically bind DNA (288). Whereas the UBN1 middle domain interacts 
specifically with H3.3/H4 over H2A/H2B. However, it is not involved in nucleosome binding and 
cannot associate with H3.3/H4 after it has been deposited onto DNA. Interestingly, DNA 
fragments of over 24 bp can compete with H3.3/H4 for UBN1 binding. This infers that UBN1 
disassociates from DNA immediately after incorporation of H3.3/H4. We can acquire a mutant 
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construct of YFP-UBN1 that lacks the DNA-binding region to test whether UBN1 facilitates 
intermittent binding of the HIRA complex to ALT telomeres. If UBN1 can bind to ALT telomeres 
through its lysine-rich region, then we would expect the YFP-UBN1 DNA binding mutant to lack 
the ability to colocalize at ALT telomeres in the absence of PARGi. Furthermore, we can deplete 
these cells of UBN1, transiently transfect in YFP-UBN1 or the YFP-UBN1 DNA binding mutant, 
and then perform IF on endogenous HIRA localization at telomeres. The HIRA complex should 
still assemble with the YFP-UBN1 DNA binding mutant. However, due to lack of DNA binding, 
it should not localize to ALT telomeres for subsequent H3.3 deposition. It would also be interesting 
to test whether UBN1 DNA binding becomes dispensable with PARGi. If the same experiment is 
performed with PARGi, depletion of UBN1 should not affect endogenous HIRA localization to 
ALT telomeres. In addition, a rescue with YFP-UBN1 would not enhance HIRA recruitment to 
telomeres, unless PARylated UBN1 has additional roles. These set of experiments would elucidate 
whether UBN1 ensures that the HIRA complex is in close proximity to ALT telomeres. 
Another hypothesis is that HIRA can be partially recruited to ALT telomeres by interacting 
with RPA. Zhang et al. showed that HIRA may bind to RPA-coated R-loops that form at gene 
regulatory units in the G1 phase (301). RPA is also involved during ALT, where it may coat 
resected telomeric ends for the RAD51-dependent pathway or bind to the ssDNA loop of TERRA-
generated R-loops. Similar to the UBN1 experiments, we can knock down RPA and look at HIRA 
localization to ALT telomeres in the absence of PARGi. Likewise, if RPA is required, we would 
expect a decrease in HIRA localization to these telomeres. Our unpublished work shows that 
accumulation of PAR displaces RPA from telomeric oligos and abolishes RPA recruitment to 
U2OS TRF1-FokI telomeres. This is supported by data from Illuzzi et al. showing that excessive 
PAR prevents binding of RPA onto chromatin in HU-treated cells (302). This implicates an early 
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role of RPA in keeping the HIRA complex proximal to ALT telomeres. However, once the 
complex is recruited, RPA quickly disassociates to allow H3.3 deposition by HIRA. 
It would be valuable to expound on the intricacy of PAR modulation in regulating the 
outcome of HIRA complex assembly at ALT telomeres. A simple scenario would be that PAR 
modulation of HIRA recruits the entire complex to incorporate H3.3 at ALT telomeres undergoing 
HDR-mediated DNA synthesis. A more intricate model would suggest that UBN1 and CABIN1 
are not solely part of the complex for stability and H3.3 deposition. As suggested by our Af1521 
PAR proteomics, both subunits could be PARylated or bind to PAR to propagate a positive 
feedback loop that generates a permissive chromatin environment for recombination. Thus, to 
confirm their regulation by PAR, we can perform in vitro PARylation, in vitro PAR-binding, and 
in vivo PARylation assays. 
 If UBN1 and CABIN1 are indeed modulated by PAR, it begs the question of whether their 
PAR regulation is necessary for HIRA complex recruitment or function. An approach we can take 
is to generate non-PARylatable constructs of UBN1 and CABIN1 and test their capacity for PAR-
binding or PARylation. Initially, we would create truncated mutants to determine what region of 
the subunits are PAR-binding or PARylated. After we acquire our non-PAR-binding or non-
PARylatable UBN1 and CABIN1 constructs, we could test their ability for complex assembly, 
recruitment at ALT telomeres, and efficiency of H3.3 deposition in the context of UBN1, CABIN1, 
or HIRA depletion. The data regarding these mutant UBN1 and CABIN1 constructs would be 
compared to our data with the YFP-HIRA B-domain mutant, as well as repeated with the YFP-
HIRA RRR (458-460) mutant construct that was previously described in 5.4. In an ideal situation, 
we would find non-PAR-binding or non-PARylatable UBN1 and CABIN1 constructs, together 
with the previous YFP-HIRA RRR (458-460) mutants, that could still form a stable HIRA 
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complex, but has disrupted recruitment and/or activity at ALT telomeres. This would provide 
greater insight into whether PAR regulation signals the assembly of the complex or its recruitment 
to ALT telomeres.  
5.6 What is the Role of PAR-mediated HIRA Chromatin Assembly at ALT Telomeres? 
 Does PAR modulation of HIRA disrupt de novo H3.3 synthesis at ALT telomeres? 
Although the role of HIRA has been characterized in the context of transcription recovery 
and nucleosome gap-filling, its function and dependency on PAR at ALT telomeres has only been 
explored in this thesis dissertation (226,291). We demonstrated that HIRA and its PAR modulation 
is necessary to facilitate the HDR mechanisms that direct ALT telomere maintenance. The HIRA 
complex deposits the variant H3.3, which is constitutively expressed throughout the cell-cycle 
(277). Interestingly, Kraushaar et al. showed that there is differential H3.3 deposition kinetics in 
mouse embryonic fibroblasts (MEFs) (324). H3.3 incorporation is rapid and robust at promoters, 
enhancers, and gene bodies. The slowest incorporation of H3.3 occurs at heterochromatic regions, 
such as telomeres while no turnover is observed at pericentromeric regions. Slow H3.3 turnover at 
telomeres represents a continuous exchange of nucleosomes that is required for telomere 
maintenance.  This implies that there are distinct mechanisms of nucleosome assembly, stability, 
and eviction at different regions of the genome to mediate transcription and chromatin integrity 
(324). Indeed, the ATRX/DAXX complex deposits H3.3 at telomeres and pericentric 
heterochromatin while HIRA incorporates H3.3 at actively transcribed regions (275). 
ATRX/DAXX loss of function mutations are prevalent in ALT cancers (325,326). This means that 
 
 146 
H3.3 deposition in ALT is solely dependent on the HIRA complex, as we show for the first time 
in this thesis. Thus, it is possible that HIRA’s function in H3.3 incorporation can extend beyond 
its known role to support telomere maintenance in ALT. Based on this speculation, the next 
question to ask is whether PAR modulation of HIRA alters H3.3 deposition at ALT telomeres and 
whether this uncouples ALT HDR-coupled nucleosome assembly.   
Histone management shapes the chromatin landscape and orchestrates the fate of DNA 
repair. It has been shown that parental H3.3 recycling is independent of new H3.3 deposition at 
UVC-damaged sites (327). Adam et al. demonstrated that parental H3.3 redistribution precedes 
incorporation of newly synthesized H3.3. While parental H3.3 rapidly distributes within minutes 
of UVC irradiation, new H3.3 accumulation is detected starting at 30 minutes after damage. HIRA 
does not function to facilitate parental H3.3 dynamics in response to UV irradiation. Rather, HIRA 
mediates H3.3 de novo deposition throughout the cell cycle, but is excluded from replication sites 
in S-phase. However, H3.3 can be incorporated at replication sites when H3.1 incorporation is 
impaired due to CAF1 depletion, which only interacts with the replisome to deposit H3.1/H4 onto 
newly synthesized DNA in S-phase (291,328). This highlights the notion that HIRA can be a 
compensatory mechanism to manage chromatin assembly defects. Notably, Orsi et al. showed that 
HU treatment and ASF1a depletion impairs the recycling of parental H3.1 and H3.3 histones and 
their nuclear distribution (329). ASF1 depletion leads to recycling of parental H3.3 at sites distant 
from their initial location during mid/late S-phase. They hypothesized that parental histones that 
are not properly secured during replication fork progression are recognized as new histones and 
deposited to distant regions by HIRA or ATRX/DAXX. It has also been shown that the added 
stress caused by ASF1 depletion could compound on the replicative challenges at telomeres to 
trigger the ALT pathway (243). Taken together, these studies emphasize the importance of histone 
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management at homeostatic levels. Thus, a parsimonious model to explain the relevance of HIRA 
at ALT telomeres is that HIRA-mediated H3.3 deposition is coupled to DNA synthesis in ALT 
during G2-BIR, where CAF1 does not deposit H3.1/H4 and ATRX/DAXX is not available to 
incorporate H3.3/H4. HIRA simply acts as a safeguard mechanism to ensure that replication stress 
levels at ALT telomeres does not surpass a threshold that would be detrimental to survival.   
An important future direction to pursue is characterization of HIRA-mediated newly 
synthesized H3.3 during HDR-mediated DNA synthesis at ALT telomeres. We can visualize 
newly synthesized H3.3 and parental H3.3 at replication sites in U2OS cells that stably express the 
SNAP-tag labelling system with depletion of HIRA (329) (Figure 35). The SNAP-tag technology 
allows the distinction between old and newly deposited histones. The SNAP-tag is an engineered 
version of the DNA repair protein O6-alkylguanine-DNA alkyl transferase. It covalently and 
irreversibly binds to O6-benzylguanine (BG) that is coupled to the fluorophore 
tetramethylrhodamine (TMR). The SNAP-tag also reacts with the optically inert group 
bromothenylpteridine (BTP), which is referred to as the “Block”. Our methodology would involve 
the “quench-chase-pulse” labelling of G2 arrested H3.3-SNAP U2OS cells that are depleted of 
HIRA or expressing the various HIRA mutants.  During the “Quench” step, all pre-existing 
histones are bound to the “Block”. The “Chase” step enables new H3.3 to be deposited at telomeric 
DNA. During this step, we would also add EdU to mark sites of replication. The “Pulse” phase 
includes the addition of TMR to label all SNAP-H3.3. Using IF, we can stain for TRF2 and 
quantify the colocalization between SNAP-H3.3, EdU, and TRF2. This would represent 
incorporation of newly synthesized H3.3 at replicating telomeres in G2-phase, allowing us to 




Figure 35. H3.3 SNAP-TAG system to observe histone dynamics. H3.3 is fused to SNAP-TAG, which reacts 
covalently with benzylguanine derivatives that are labelled with fluorescent TMR.  B) Schematic for labelling new 
histones. The Quench step involves the addition of the “Block”, an optically inert molecule, that binds to old H3.3. 
At the Chase phase, newly synthesized H3.3-SNAP is not bound by the Block. During the Pulse step, addition of 
TMR leads to a covalent, non-reversible interaction with H3.3-SNAP. Newly synthesized H3.3 bound to fluorescent 
TMR can be visualized after Triton-X extraction to remove soluble histone pools. Adapted from Torne J. et al., 
Histone Variants, 2018 (329) (https://link.springer.com/protocol/10.1007%2F978-1-4939-8663-7_11). 
 
Based on the proposed model, we would expect that depletion of HIRA will impede H3.3 
incorporation at telomeres during G2-BIR because there is no other histone chaperone to 
compensate for its activity. This is supported by Ray-Gallet et al. who showed that H3.3 can 
substitute for impairment in H3.1 deposition at replication sites, but H3.1 cannot replace the loss 
of H3.3 incorporation outside of S-phase (291). To confirm this in our system, we could also 
perform the same experimental scheme, but with depletion of CAF1, to which we should not see 
an effect on newly synthesized H3.3 at ALT telomeres. It would also be informative to generate 
WT TRF1-FokI cells with the SNAP-H3.3 tag, especially since we observe decreased nascent 
telomere synthesis with the absence of HIRA in WT TRF1-FokI cells. Taken together, it is 
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tempting to envisage a model where replication stress can subject ALT telomeres to HDR-coupled 
DNA synthesis that would require HIRA-mediated H3.3 deposition to maintain chromatin 
integrity at the moving D-loop.  
PAR modulation poses an additional layer to control HIRA recruitment and activity at ALT 
telomeres that are primed for HDR-mediated DNA synthesis. To tease out the role of PAR 
regulation in HIRA-dependent H3.3 incorporation in ALT, we can deplete endogenous HIRA in 
the U2OS SNAP-tag cells and reintroduce WT-HIRA, as well as the varying HIRA mutant 
constructs mentioned previously (homotrimerization, I461D ASF1 binding, ΔB-domain, and 
RRR). If HIRA’s PAR modulation is essential for its sequestration at ALT telomeres, then we 
would not expect the defective PAR-modulated HIRA mutants to rescue H3.3 incorporation at 
ALT telomeres. Both the ΔB-domain and RRR mutants contain the regions necessary for 
interaction with ASF1a. A viable model would be that PAR regulation precedes ASF1a binding 
by recruiting HIRA to ALT telomeres. Since PAR turnover is rapid, removal of PAR likely allows 
for ASF1a binding to HIRA. Retention of PAR at HIRA within the B-domain would actually block 
the HIRA-ASF1a contact and subsequent deposition of H3.3 at ALT telomeres. Thus, we should 
see impaired H3.3 incorporation if we simply treat the U2OS SNAP-tag cells with PARGi. This 
means that PAR regulation of HIRA can provide immediate and localized restoration of chromatin 
at HDR intermediates in ALT.  
 How does HIRA-mediated H3.3 deposition couple with HDR mechanisms in ALT? 
It is possible that PAR modulation facilitates ASF1a’s regulation of H3.3 biogenesis and 
usage during HDR in ALT. Perhaps ALT cells employ a similar mechanism observed during the 
tight coordination of histone buffering during S-phase. Groth et al. proposed that inhibition of 
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DNA replication triggers the shuttling of ASF1a from a histone-free form to an active 
multichaperone complex in order to counteract low histone biogenesis (330). These S-phase 
histones become readily available to enable CAF1-mediated histone loading for recovery and 
repair. We can speculate the importance of a parallel mechanism in G2-BIR to relieve the 
replicative burden that naturally occurs at ALT telomeres. In ALT, ASF1a shuttling of H3.3 for 
the HIRA complex during G2 could play an important role because of the lack of redundancy in 
histone chaperones during this phase. CAF1 only acts in S-phase and H3.1 cannot replace H3.3 
incorporation throughout the cell-cycle. ATRX/DAXX is not present in most ALT cancers to 
compensate for loss of H3.3 incorporation. To address this idea, we can follow the pool of soluble 
H3.3 throughout the cell-cycle in ALT cells. This will be done using stable expression of C-
terminal FLAG-and HA-epitope tagged H3.1 and H3.3 by retroviral transduction (273). Cells will 
be collected in S-phase or G2-phase after a double thymidine block. In control samples, we should 
see the increased pool of soluble H3.1 in S-phase, but not H3.3 since H3.3 supports chromatin 
assembly uncoupled from DNA replication. The opposite results should be seen in G2-phase, 
which would promote G2-BIR in ALT cells. Immunoprecipitation of these extracts should show 
higher proportion of endogenous ASF1a and HIRA bound to H3.3 if HIRA and ASF1 are required 
for H3.3 coupled G2-BIR.   
The presence of mutant H3.3 has been shown to alter epigenetic marks near genes involved 
in cancer processes and brain function (331). Frey et al. observed that a mutation of H3.3K27, a 
residue whose trimethylation is associated with polycomb target gene silencing, also exhibits 
similar sensitivity to the knockout of H3.3 (332,333). The histone H3.3K27 mutation has been 
reported in 60% of pediatric brain cancers (121). To add on, H3.3 G34R/V mutations also 
contribute to gliomagenesis and is hypothesized to activate the oncogene MYCN in pediatric 
 
 151 
gliomas (334). This is of particular importance because ALT has a high prevalence in pediatric 
high-grade gliomas, with 44% of pediatric glioblastoma (GBM) demonstrating ALT activity (335). 
In fact, it was recently shown that the presence of H3.3-ATRX/DAXX- P53 mutations is a strong 
driver of ALT (336,337). The prevalence of H3.3 mutations in the pediatric cancer setting clearly 
raises the importance of chaperones, histone-modifying enzymes and factors that feed into H3.3 
function.  Given the importance of H3.3 mutations in ALT, it would be worthwhile to test if this 
correlates to elevated levels of HIRA protein expression or transcription of mRNA in ALT+ and 
TEL+ cancers. A cycloheximide (CHX) chase experiment, through pulse labelling of newly 
synthesized proteins with 35S-methionine and cysteine, would further address HIRA protein 
stability (28). This will shed light on the tight regulation of HIRA, either through post-
transcriptional or post-translational mechanisms, that is necessary to mediate H3.3 incorporation 
in ALT.  
ALT cancer cells must maintain a balance between pro- and anti-recombinogenic signals. 
A shift from this equilibrium poses rampant replicative stress that leads to unproductive ALT 
activity. It is plausible to assume a mode of G2-BIR coupled nucleosome assembly to protect the 
integrity of advancing forks. Several studies have reported the impact of histone dynamics on 
replication fork progression and stability (338–342). Nucleosomes are a physical barrier for the 
replication machinery. During S-phase, histones are evicted ahead of the fork while de novo 
histones are synthesized behind the fork (343). CAF1 is the most well-characterized replication-
coupled chromatin assembly factor (299). CAF1 associates with the replication fork through its 
interaction with PCNA and collaborates with ASF1, which has the capacity to bind to RFC as seen 
in budding yeast (344,345). The obligate coupling of chromatin remodeling and DNA synthesis is 
underscored by the fact that depletion of CAF1 or ASF1 evokes stalled replication forks and 
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inhibits S-phase progression (299,346,347). Intriguingly, MCM2, a component of the replicative 
helicase, can bind to either a H3-H4 tetramer or dimer (348,349). The latter involves initial capture 
of parental H3-H4 by MCM2 at the proximity of the fork, which is disrupted by ASF1 to mediate 
redeposition of H3-H4 dimers and free the MCM complex so it can progress with the fork (350).  
In budding yeast, BIR has been documented to require all essential DNA replication factors, 
including the MCM complex (351).  
It would be incredibly valuable to assess whether the HIRA complex is part of the G2-BIR 
replisome to facilitate ALT telomere maintenance. In situ analysis of protein interactions at DNA 
replication forks (SIRF) can be employed to quantify protein associations with nascent DNA at 
active and stalled replication forks (Figure 36). SIRF is a robust and sensitive combination of the 
isolation of proteins on nascent DNA (iPOND) and proximity ligation (PLA) assay (352,353). In 
WT TRF1-FokI U2OS cells that are arrested in G2, newly synthesized DNA is labeled with EdU 
and then biotinylated by click chemistry. Primary antibodies are added against biotin and HIRA 
or ASF1a. Cells are then incubated with secondary antibodies conjugated with oligonucleotides 
that serve as proximity probes. Secondary antibodies that are within 40 nm in proximity will allow 
for the oligomers to anneal and form a nicked circular DNA molecule, which become a template 
for rolling circle amplification. A telomere sequence-specific fluorescence DNA probe is annealed 
to these amplified DNA circles and the signal intensity is then quantified. This is a powerful tool 





Figure 36. Schematic of SIRF method. A) Cells are pulsed with EdU. B) EdU is biotinylated by click chemistry. 
C) Primary antibody against protein of interest and biotin are added to slides. Slides are then incubated with 
secondary PLA antibodies containing DNA-oligomers. D) Upon association, DNA oligomers ligate and enable 
rolling circle amplifcation. E) Fluoresent DNA probe anneals to the sequence. Adapted from Roy S et al., JCB, 2018 
(https://rupress.org/jcb/article-lookup/doi/10.1083/jcb.201709121). 
 
DNA synthesis and histone deposition also partner during DNA repair and oncogenesis. 
CAF1 is known to promote Recombination-Dependent-Replication (RDR) in fission yeast. It was 
observed that RDR-coupled histone deposition stabilizes D-loop intermediates and counteracts the 
activity of Rqh1, the fission yeast orthologue of human RecQ1. Thus, histone deposition ensures 
continuous chromatin assembly upon damaged lesions induced by Hydroxyurea and Camptothecin 
(354). In chicken DT40 cells, loss of H3.3 leads to defective fork progression on UV-damaged 
DNA (333). Intriguingly, replication stress has been shown to perturb H3.3 epigenetic stability by 
interfering with pre-deposition marking and histone recycling. Jasencakova et al. observed that 
replication stress traps new and old H3.3 at ASF1, both of which can be incorporated at 
unscheduled sites upon fork restart (355). In particular, there was mainly the accumulation of 
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H3K9me1 at ASF1 complexes. H3K9me1 can be a precursor of H3K9me3, which poses a hazard 
for unscheduled silencing and challenges the integrity of the epigenome (355–357). ALT cancers 
likely use the previously mentioned mechanisms to manage recurrent cycles of replication stress 
to generate DSBs for HDR mechanisms. Loss of the HIRA complex simply unleashes unwarranted 
telomeric defects that are not resolved by DNA repair and eventually become hazardous to cells. 
As a consequence, either absence of HIRA or loss of its activity will lead to replication defects, 
such as telomere fragility, inefficient replication, or delay into mitosis. These examples illustrate 
how distinct chromatin reorganization could mediate the intricate balance between genome 
instability and survival.  
 Why is H3.3 incorporation necessary at ALT telomeres? 
If the above speculations are true, then it raises the question of why the histone variant 
H3.3 is particularly important in ALT. There are seven human H3 variants in the H3 family: two 
canonical H3.1 and H3.2, replication-independent H3.3, centromere protein A (CENP-A), testis-
specific histone H3t and the primate specific H3.X and H3.Y (358). Although H3.3 only differs 
from its canonical counterparts by 4-5 amino acids, this confers distinct epigenetic patterns and 
chromatin regulation that lead to diverse biological outcomes (359). Canonical H3.1 and H3.2 do 
not contain introns, are organized in multi-clusters, and the mRNA is not polyadenylated. On the 
other hand, H3.3 is redundantly encoded from two intron-containing H3F3A and H3F3B genes 
(359,360). Nucleosomes that contain H3.3 are intrinsically unstable and are even less stable with 
the combination of H3.3 and H2A.Z, a noncanonical H2A histone (361). These unstable histone 
variants could possibly be more easily displaced by transcription factors at active gene bodies. 
They can also serve as temporary placeholders to prevent the binding of stable, canonical histones 
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or leave the region vacant for non-specific association of chromatin-binding factors.  This implies 
a dynamic cycling of histone occupancy at different regions in the genome (362). Therefore, 
narrow windows exist where chromatin is bound or free during these exchanges.  
The high level of amino acid homology between H3 variants means that the same PTMs 
can decorate shared residues. However, each histone variant carries a characteristic histone 
signature and occupies different regions of the genome, which confers distinct function (324). H3.3 
is enriched with post-translational modifications (PTMs) associated with active chromatin (362–
364). Tvardovskiy et al. employed a quantitative middle-down proteomics approach to determine 
the dynamic changes in the H3.3 PTM landscape across the lifespan of mice from 3-24 months 
(365). They report that H3.3 accumulates in somatic issues with increasing age. Unexpectedly, 
they found that individual and combinatorial H3 methyl PTMs exhibit stable enrichment on H3.3. 
These PTM signatures may allow cells to rapidly turn on or off specific genes in response to 
specific stimuli. Despite H3.3 being correlated with gene activation, a study showed its 
underappreciated role in the establishment of the bivalent chromatin landscape at developmental 
genes that exhibit low expression in embryonic stem cells (ESCs) (289). Thus, HIRA-dependent 
H3.3 deposition is essential to maintain accurate gene expression upon differentiation. This is an 
important feature because some cancers, including gliomas, are speculated to arise from regression 
to a less differentiated state or initial failure to establish differentiation (366–368). Thus, the unique 
properties of H3.3 might be beneficial to accommodate the dynamic chromatin landscape of ALT.  
Given the importance of H3.3 and its PTMs, we need to conduct experiments to validate 
that the specific loss of H3.3 perturbs telomeric chromatin in a manner that impairs HDR at ALT. 
Depletion of H3.3 should mimic the phenotypes seen with loss of HIRA, if HIRA-mediated H3.3 
incorporation is indeed important for ALT activity. Furthermore, depletion of HIRA or H3.3 
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possibly leads to a more permanent, open chromatin environment that is permissive to cleavage 
by the SLX-MUS endonuclease to generate more DSBs. We can use the micrococcal nuclease 
(MNase) digestion to determine chromatin accessibility in response to absence of HIRA or H3.3 
(369). Cell lysates are incubated in MNase, which cleaves at nucleosome linker regions. The DNA 
can be fractionated by agarose gel electrophoresis and subjected to southern blotting with a 
radioactive telomeric probe. The blot will reveal a ladder of bands that correspond to the size of 
the nucleosome core and linker (~200 base pairs). Greater distance between the bands represents 
nucleosome-free regions. With loss of H3.3 or HIRA, we expect de-condensation of the chromatin, 
which will be represented by the increased distance in the ladder of bands in the MNase digestion. 
We reason that tight regulation of H3.3 incorporation is necessary to maintain the proper 
chromatin dynamics that facilitates ALT. H3.3 PTMs at ALT telomeres could serve as an 
additional layer for fine-tune control. Similar to the approach taken by Tvardovskiy et al., we could 
utilize a MS-based middle-down proteomics approach to measure H3.3 proteoforms in ALT+ and 
TEL+ isogenic cell lines, ALT+ cancers in each cell cycle, and WT TRF1-FokI U2OS cells (365). 
We expect the H3.3 PTM profiles to be distinct between ALT+ and TEL+ cancers as well as 
throughout the cell cycle. WT TRF1-FokI U2OS cells will likely have a similar pattern to that of 
U2OS cells arrested in G2-phase, which supports the notion that TRF1-FokI telomeric DSBs 
induces DNA synthesis in G2/M. It would be reaffirming to observe specific PTMs at H3.3K27 
and H3.3 G34R/V across all ALT+ cancers, especially since these H3.3 mutants are common in 
pediatric brain tumors. This strategy has the potential to uncover novel H3.3 PTMs that could be 
driver mutations or biomarkers of ALT.  
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 Is there a crosstalk between PAR and H3.3 post-translational modifications? 
The crosstalk between these epigenetic marks at H3.3 and PARylation merits further 
exploration because it potentially orchestrates localized action at ALT telomeres. As discussed in 
prior chapters, PARylation has broad effects on chromatin configuration to enable the plasticity 
for DNA repair. PARylation has been shown to restrain the enzymatic activity of SIRT1, a NAD+-
dependent deacetylase (370). Thus, PARylation cooperates with histone acetylation to maintain 
accessible chromatin and transcription. While acetylation is attributed to active transcription at any 
modified residue, the outcome of methylation varies depending on the degree of methylation 
(mono-, di-, or tri-) and the modified lysine residue. PARylation of EZH2 histone 
methyltransferase, a member of the polycomb repressive complex 2 (PRC2) leads to decreased 
levels of H3K27me3. It was also reported that PARP1 can PARylate H3 and disrupt the affinity 
of EZH2 to its substrate (371). These factors work in concert to enhance chromatin decondensation 
and prevent EZH2 from repressing genes involved in DNA repair. Interestingly, chromatin 
remodeler CHD2 is recruited to DSBs in a PARP1-dependent manner to incorporate H3.3 at these 
sites and promote repair by cNHEJ (204). NHEJ and HR compete for DSBs as a substrate so it 
would be interesting to uncover whether PTMs at H3.3 could alter pathway choice outside of S-
phase (372). This is certainly relevant in the context of G2-BIR processes that occur in ALT 
cancers. It is plausible that the interplay between PAR and PTMs at H3.3 create a unique barcode 
in ALT that shunts NHEJ repair to productive HDR mechanisms.   
This opens a vast area of exploration into how PAR and different PTMs modulate the 
optimal balance of genome stability at ALT telomeres. If the previously described MS-approach 
to analyze H3.3 PTMs works, then we can add PARGi to the same conditions to determine if 
retention of PAR alters the profile of H3.3 PTMs. This is informative because it further elucidates 
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the exact outcomes of PARylation on ALT chromatin. We can envision a possibility where 
PARylation will abolish H3.3 PTMs that promote chromatin decondensation or DNA repair 
factors at ALT telomeres. In an ideal situation, it would be useful to see if PARylation directly 
disrupts the enzymes that catalyze H3.3 PTMs, such as Histone acetyltransferases (HATs) and 
DNA methyltransferases (DMNTs). However, these enzymes have broad, genome-wide roles so 
it would be challenging to tease out whether the observed effects are due to PARGi.  
 Does HIRA contribute to TERRA function at ALT telomeres? 
Another avenue to pursue is whether the RPA-HIRA-H3.3 axis that regulates transcription 
could have a non-canonical role at RNA-DNA hybrids in ALT. RNA-DNA hybrid structures (R-
loops) are frequently detected at gene regulatory elements (373). These structures comprise of a 
displaced ssDNA filament that is likely coated by RPA. R-loops are required for H3.3 deposition 
at promoters and enhancers since overexpression of RNase1 H1, which cleaves the RNA region, 
lowers the levels of H3.3 incorporation. This RPA and R-loop association promotes the 
recruitment of HIRA to these regions to regulate the directionality of transcription (301) (Figure 
37). There is mounting evidence that confirms the upregulation of recombinogenic long noncoding 
telomeric RNA TERRA at ALT telomeres, which forms RNA-DNA hybrids with the telomeric C-
rich strand (105,240,374,375). We can envision the resemblance of this structure to R-loops 




Figure 37. RPA-HIRA-H3.3 complex at R-loops. RPA co-localizes with HIRA and H3.3 at R-loops within gene 
regulatory elements. This regulates transcriptional directionality at promoters. Adapted from Zhang et al., Mol Cell, 
2017 (301) (https://www.sciencedirect.com/science/article/pii/S1097276516307754?via%3Dihub). 
 
An attractive possibility would be that HIRA functions to relieve telomere instability 
related to TERRA-telomeric hybrids. Long stretches of ssDNA in telomeric R-loops are prone to 
breakage, which can be DSB substrates for HR and subsequently promote ALT activity. Nguyen 
DT et al. proposed that ATRX normally plays a role in processing R-loops or preventing their 
formation at G-rich regions (303). It is speculated that ATRX could recruit other enzymes that 
degrade R-loops to sustain genome stability. In ALT cells that lack functional ATRX/DAXX, 
HIRA is likely present at telomeric R-loops to re-establish a normal chromatin structure during 
telomere synthesis. However, it remains unknown whether HIRA’s recruitment to telomeric R-
loops is sufficient to signal other factors to resolve these structural impediments. This could 
include RNaseH1, which has been shown to inhibit hybrid formation and the recombinogenic 
 
 160 
potential of ALT telomeres (105). Thus, HIRA can either fully or partially restrain unwarranted 
R-loop formation to maintain HR without compromising telomere integrity too severely.  
TERRA is also implicated in telomeric heterochromatin assembly through H3 
trimethylation marks, which was previously attributed to downregulation by PARylation. It was 
reported that TERRA directly associates with the PRC2 complex components EZH2 and SUZ12, 
which establishes H3K9me3, H4K20me3, H327me3, and HP1 at telomeres (376). A genome-wide 
analysis revealed that the targeting and function of PRC2 is dependent on ATRX at Xist RNA and 
polycomb targets (377). ALT cancers that lack ATRX must then rely on elevated TERRA levels 
to compensate for PRC2 recruitment. It was also reported that SET Domain Bifurcated 1 
(SETDB1) histone methyltransferase governs H3K9me3 deposition, a signature mark for 
heterochromatin, at ALT telomeres (378). Thus, ALT cells exhibit atypical heterochromatinization 
that can drive TERRA transcription at telomeres and other ALT features. This heterochromatin 
mark is necessary for ATRX localization to telomeres and suppression of ALT activity. Taken 
together, there appears to be a complex epigenetic landscape that is conducive for HIRA activity 
during TERRA transcription.  
Based on these speculations, we could envision that loss of HIRA permits excessive levels 
of TERRA-telomeric loops that would unleash telomere instability and lead to unproductive ALT. 
Initially, we can perform a TERRA RNA-pulldown in ALT+ cancer cells to determine whether 
HIRA interacts with TERRA. Biotinylated RNA oligonucleotides containing UUAGGG repeats 
are incubated with nuclear abstracts from ALT+ cells (240). Streptavidin pulldown of TERRA can 
be performed and HIRA interaction can be detected using gel electrophoresis. We then need to 
investigate whether HIRA can promote telomere RNA-DNA hybrids. RT-PCR and Northern 
blotting can quantify the amount of detectable TERRA transcript in HIRA KD cells (240,379). 
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Both techniques use primers that amplify the subtelomeric portions of TERRA, which originate 
from chromosomes 1 and 21, or chromosomes 2, 10, and 13. RNA-FISH would show TERRA 
localization to APBs in ALT cells (105). We would measure the formation between TERRA and 
the telomeric C-strand through co-immunocytochemistry with antibodies to TRF1 and purified 
S9.6 monoclonal antibodies, which specifically detects RNA-DNA hybrids in a sequence-
dependent manner. If HIRA antagonizes TERRA formation in ALT cells, then we would expect 
its loss to contribute to downstream telomeric replication defects that eventually become 
unmanageable for ALT telomere maintenance.   
 What is the role of HIRA in ALT cell survival by autophagy? 
HIRA’s implicated role in innate immune defense could aid the autophagic pathway that 
confers ALT cell survival. In Hela cells, HIRA-mediated H3.3 incorporation at the host’s 
chromatin facilitates transcription of Herpes simplex virus type 1 (HSV-1) upon the early lytic 
stage of infection (380). It appears that HSV-1 manipulates the distinct features of H3.3 to increase 
viral transcription. H3.3 at actively transcribed genes can allow them to be accessible and primed 
for transcription. H3.3 is enriched at active chromatin marks, which could accommodate the rapid 
recruitment of cellular and viral transcription factors. In contrast to these findings, Rai TS et al. 
reported that HIRA recognizes naked viral DNA and suppresses viral gene expression, virus 
replication and lytic infection in an array of primary cell lines (298). In primary cells, HIRA 
responds to anti-viral interferons (IFNs) and localizes to PML nuclear bodies (PML-NBs), which 
are thought to be sites of anti-viral activity. Ultimately, this induces heterochromatinization and 
silencing of foreign viral DNA (298,381). This is an important anti-viral response because many 
viruses have evolved antagonizing strategies, such as expression of ICP0 (RING-finger ubiquitin 
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ligase with SUMO-Targeting Ubiquitin Ligase (STUbL) properties), to disrupt HIRA targeting to 
infecting viral genomes and PML-NBs (382,383). They reconciled these observed differences by 
suggesting that the anti-viral function of HIRA may be cell-type dependent since some cancer cell 
have evolved distinct mechanisms to counteract this response. To confirm this hypothesis, they 
showed that Hela cells and other transformed human cell lines do not display HIRA localization 
to PML-NBs upon IFN treatment.  
Although there have been several studies that implicate HIRA in anti-viral intrinsic 
immunity, there has been no evidence that link this to ALT oncogenesis. Given the propensity for 
HIRA to deposit H3.3 at naked DNA through its gap-filling function, it is possible that HIRA 
could recognize extrachromosomal telomere repeat DNA within APBs or freely in the nucleus. In 
human fibroblasts with a STING-cGAS axis, ECTRs that are detected in the cytoplasm activate 
IFN and cytokine signaling, resulting in proliferation defects (321). ATRX/DAXX have been 
shown to restrict viral infection through epigenetic silencing or entrapment mechanisms (381,384). 
Simultaneous re-expression of STING and ATRX in ALT cancers restores the STING-mediated 
cytosolic DNA-sensing pathway (321). Taking these findings into consideration, HIRA could be 
an additional safeguard mechanism to sequester and resolve high levels of ECTRs in ALT cells.  
Nassour et al. showed that activation of autophagy is an integral tumor suppression 
mechanism (322). Telomere dysfunction in epithelial and fibroblast cells during crisis generates 
cytosolic telomeric DNA fragments that activate the cGAS-STING pathway.  It was also reported 
that inhibition of ALT telomere maintenance in ALT cancers lead to the release of cytosolic 
telomeric fragments that are recognized by cGAS and removed through AMPK-ULK1 (AMP-
Activated Protein Kinas-Unc-51 Like Autophagy Activating Kinase)- and ATG7 (Autophagy 
Related 7)-mediated autophagosome biogenesis (28,321). ALT cancers do not exhibit an 
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alternative autophagy pathway that involves the cGAS-STING axis because STING expression is 
barely detectable in these cancers (28). Studies have shown that cells with impaired autophagy 
exhibit reduction in DNA damage repair capacity, such as HR and NHEJ (385). The synthetic 
lethal relationship between autophagy and HDR holds promise to exploit the vulnerabilities of 
ALT cancers. Indeed, Barroso-Gonzalez et al. showed that RAD51AP1 knockout ALT cells were 
more sensitive to autophagic inhibition (28). We can envisage a scenario where HIRA’s regulatory 
role in innate immunity could converge with this pathway to remove cytosolic telomeric DNA and 
manage genome stability in ALT cancers. 
To shed light on this, we can examine HIRA’s role in autophagy as a chronic survival 
mechanism to offset telomere instability in ALT. First of all, we should confirm whether HIRA 
depletion leads to increased frequency of micronuclei, which are fragments of damaged DNA 
expelled into the cytoplasm, or elevated c-circle levels (72,386). We would expect that HIRA 
depletion can potentiate the presence of these extrachromosomal DNA species. However, HIRA 
KD cells likely fail to mitigate these detrimental events and telomere dysfunction ensues, leading 
to apoptotic death instead of pro-survival autophagy. We would expect that HIRA KD cells would 
be committed to apoptosis, which can be quantified through the cleavage of Caspase-3 or detection 
of Annexin V by flow cytometry (387).  
Thus, absence of HIRA may impair ALT cell viability by autophagy survival mechanisms 
and activate apoptotic cell death to eliminate cells with aberrant DNA species. We can measure 
the levels of autophagic markers in siRNA knockdown of HIRA in ALT+ cells through western 
blotting. Light chain 3 protein A (LC3A) and its lipidated B-form (LC3B) are required for 
autophagosome biogenesis. An increase in lysosomal-associated membrane protein 1(LAMP1) 
and degradation of the autophagy receptor protein p62 (SQSTM1) correlates with autophagic 
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maturation and autophagic flux (388). To monitor autophagic flux, we can employ a tandem 
mCherry-GFP-tagged LC3B pH-based autophagy reporter strategy, which labels autophagosomes 
in yellow (mCherry and GFP) and acidic autolysosomes in red (mCherry) (389). When the double 
positive mCherry and GFP LC3 become acidified in mature autolysosomes, this quenches the GFP 
signal and leaves an mCherry positive autolysosome. We can also observe whether HIRA also 
contributes to the AMPK-ULK1 autophagy pathway (390). This will involve measuring 
phosphorylation of AMPK, ULK1, and Beclin1. We would expect a decrease in all these 
autophagic markers if HIRA does govern nuclear events leading to autophagy-mediated survival 
in ALT+ cancers. 
5.7 How does ATRX Deficiency Contribute to Dependency on HIRA in ALT Cancers? 
Drug-driven synthetic lethality is a promising strategy to take advantage of the distinct 
survival mechanisms employed by ALT. Synthetic lethality occurs when the combinatorial loss of 
two genes results in cell death, but the deficiency in one alone does not. A recent study conducted 
a genome-wide CRISPR-Cas9 screen to select for sensitivities in ATRX-generated knockout 
hepatocellular carcinoma cell lines, which are wild-type for the gene (391). Under stringent 
analysis, they identified 58 genes to be potential synthetic partners for ATRX. These genes were 
involved in mRNA processing, mitosis, chromatin organization, and cell cycle regulation. They 
pursued the G2/M checkpoint regulator Wee1 since it is the only target with a small molecule 
inhibitor designed and tested in clinical trials (392,393). ATRX KO cells are selectively killed by 
the Wee1 inhibitor due to DSBs generated by replication fork collapse and S-phase arrest. Wee1 
inhibition also impairs growth of ATRX-deficient cell lines from glioma patients. Aside from 
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Wee1, they also found two components of the HIRA complex: ASF1a and CABIN1, which they 
speculated to compensate for H3.3 deposition pathways in certain contexts (391). However, they 
did not provide further detail about the mechanism or importance in ATRX KO cell lines or 
ATRX-deficient ALT cancers.  
This finding corroborates the entire premise of chapter 4 in this thesis dissertation. We have 
essentially shown the first epigenetic synthetic lethality that is exclusive to ALT cancers. To 
current knowledge, the HIRA complex is the only histone chaperone that could function in place 
of ATRX throughout the cell cycle. H3K9me3 acts as a docking site for ATRX at telomeres to 
maintain heterochromatic assembly (394). ATRX can also be recruited by G4 DNA at telomeres 
and it can resolve these structures (283,395). It is speculated that ATRX recruitment loads H3.3 at 
nucleosomal free telomeric regions that arise during stalled replication or disrupted transcription. 
In agreement with this, the Drosophila ATRX homolog, Xnp, guides H3.3 loading to nucleosome-
depleted chromatin gaps at active transcription sites (396).  
HIRA and ATRX appear to share similar stimuli, epigenetic marks, and role in mitigating 
DNA damage. As discussed in previous chapters, the H3K9me3 mark is associated with ASF1 and 
TERRA, and HIRA carries a nucleosome-gap filling function (291,376). The ATRX-DAXX-H3.3 
complex has been shown to promote HR at genomic DSBs (282). ATRX provides topological 
stability to the moving D-loop through the coordination of histone disassembly ahead and 
reassembly behind it. It seems counterintuitive that HR is upregulated at telomeres in ALT+ 
cancers with an ATRX deficiency. This alludes to a fundamental difference between non-telomeric 
and telomeric DSBs, in which telomeric DSBs engage in a distinct HIRA-mediated HDR pathway 
choice that is more prone to replication stress. However, HIRA is not completely redundant for 
ATRX since it has not been shown to resolve G4 structures. This is an important feature because 
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it allows HIRA to moderate replication stress, but still provides the chromatin environment that is 
conducive to ALT telomere maintenance. 
Another key question relates to whether HIRA’s elevated role in ALT is solely dependent 
upon the lack of ATRX/DAXX in ALT+ cancers.  Our cell survival assays demonstrate that ALT+ 
cells are more sensitive to loss of HIRA in comparison to TEL+ cancers, which have 
ATRX/DAXXX activity. So far, we have not validated that the phenotypes seen are due to direct 
loss of HIRA. Conventional CRISPR-Cas9 knockout of HIRA is virtually impossible to conduct 
since ALT+ U2OS cells are completely inviable after prolonged loss of HIRA (unpublished data). 
To circumvent this issue, we can employ the CRISPR-FLIP strategy to create bi-allelic conditional 
knockouts of HIRA in ALT+ cells (397) (Figure 38). This involves fusing an invertible intronic 
cassette (FLIP) to Cas9-assisted gene editing. The non-mutagenic orientation of the FLIP cassette 
enables the selection of the correct nuclease-assisted targeting into the exon of one allele and the 
simultaneous accumulation of cells that inactivate the second allele by nuclease-mediated NHEJ. 
With the addition of Cre recombinase, the FLIP cassette becomes inverted and triggers a cryptic 
splice acceptor and polyadenylation signal (pA), which is mutagenic because it terminates 
transcription and results in the complete loss of gene function. This approach will allow us 
temporarily deplete HIRA and then rescue the phenotype with re-expression of HIRA upon release 




Figure 38. CRISPR-FLIP strategy for bi-allelic conditional gene modification. Schematic for the CRISPR-FLIP 
approach. B) Design of the FLIP cassette. SD: Splice donor, SA1 and SA2: Splice acceptor, purple triangles: LoxP1 
sites, pink triangles: Lox5171 sites, blue circles: BP1 and BP2, branching point, and pA: polyadenylation signal. 
Adapted from Andersson-Rolf A et al., Nat Methods, 2017 (397) (https://www.nature.com/articles/nmeth.4156). 
 
Studies have already documented that the depletion of ATRX is not sufficient to induce 
ALT, which implies that several factors work in conjunction to create the pro-ALT environment 
(42). Additionally, our clonogenic assays fail to address whether loss of ATRX directly attributes 
to the sensitivity of ALT+ cancers to HIRA depletion. We could still attempt to simultaneously 
deplete TEL+ cells of ATRX and HIRA using shRNA knockdown. If this combinatorial depletion 
impedes cell survival in TEL+ cells, then it would further affirm the importance of H3.3 deposition 
via ATRX or HIRA in cancer cells. This would support the effectiveness of targeting the synthetic 
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lethality of ATRX and HIRA in ALT+ cancers that already have a deficiency in ATRX. As we’ve 
shown in chapter 4, reconstitution of ATRX in U2OS cells prevents HIRA localization to ALT 
telomeres. This suggests that ATRX seems to be the preferred histone chaperone at telomeres and 
directly competes with HIRA in ALT. To explore the functional consequence of this, we could 
determine whether re-expression of ATRX in HIRA-depleted U2OS cells would rescue 
proliferation. Additionally, we can examine whether depletion of HIRA inhibits growth in patient-
derived primary cell lines from ALT+ tumors, such as gliomas and osteosarcomas. This would 
raise the significance of our findings because it validates that this reliance on HIRA can be 
exploited to treat aggressive ALT+ tumors. Collectively, these studies will confirm the unique role 





Figure 39. Proposed model of PAR-modulated HIRA at ALT telomeres. Tel+ cancers rely on ATRX/DAXX to 
resolve G4 structures during replication. ATRX/DAXX also sequesters the MRN complex and inhibits HDR at 
replication forks, allowing for normal replication to ensue. ALT+ cancers, which lack functional ATRX/DAXX, 
have an elevated reliance on the HIRA complex for H3.3 deposition during HDR-coupled replication. The HIRA 
complex is regulated by PAR to ensure localization to damaged telomeric lesions. However, persistence of PAR 
interferes with chromatin expansion associated with HR and G2-BIR, leading to ALT inhibition. 
5.8 Can HIRA be Therapeutically Targeted to Specifically Kill ALT Cancer Cells?  
We still need to decipher the HIRA protein interactions at ALT telomeres in order to fully 
understand the outcomes of HIRA inhibition. There are no current studies that have characterized 
the HIRA interactome or even explored the role of HIRA in ALT. ATRX-deficiency in ALT 
cancers may have driven an adaptation for HIRA-mediated H3.3 incorporation, which should 
extensively reshape the telomeric landscape in ALT. Using proximity-dependent biotinylation 
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(BioID), we can fuse HIRA to promiscuous BirA and trace transient and temporal proteins that are 
proximal to HIRA in ALT+ U2OS cells (398). This will be compared to a pre-existing dataset that 
characterized the ALT+ U2OS telomere-associated and proximal proteins (87). By looking at the 
overlap between the two datasets, we can identify ALT+ telomeric proteins that interact with 
HIRA. This will lead to greater insight into a complex HIRA-telomere network, where we can 
begin to dissect for the development of more selective and impactful therapies against ALT, as 
previously discussed. 
Therapeutic strategies that target HIRA will tip the delicate balance between replication 
stress and ALT cancer survival. There are no known drugs that are designed against HIRA, 
especially since there are not many studies that directly implicate HIRA in cancer progression. A 
recent study connected the dynamics of histone variants to tumor progression and metastasis 
formation (399). Gomes et al. reported that suppression of CAF1 is required for metastatic 
colonization in breast cancers. Low levels of H3.1/H3.2 essentially leaves the space for 
nucleosome gap-filling by HIRA-dependent H3.3 deposition at the promoter of EMT (epithelial 
to mesenchymal transition) and pro-metastasis transcription factors. This is the first study to 
directly implicate HIRA with acquisition of aggressive traits in tumorigenesis. This is relevant to 
the field of ALT because ALT+ cancers are known to be highly aggressive and lead to poor patient 
outcomes (31,400). Cumulatively, these findings and our results support the notion for 
development of a small-molecule inhibitor of HIRA to target ALT tumors. This will make a huge 
impact since it has the potential to impair the initiation and progression of ALT cancers through 
deregulation of ALT telomere maintenance and restraint of metastasis.  
Specific small-molecule inhibitors can be designed against HIRA to target its complex 
assembly or protein-protein interactions. Based on our findings and structural studies, the B-
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domain is an appealing region to perturb because it would disrupt ASF1a binding and subsequent 
H3.3 deposition at ALT telomeres. As discussed in chapter 4, the B-domain is key to the HIRA-
ASF1a interface, where it forms a β-hairpin that associates with the β-sandwich structure of the 
ASF1a N-terminal core domain through β-sheet, salt bridge and van der Waals interactions (Figure 
40A-B) (286). The minimum HIRA fragment that binds to ASF1a spans residues 421–729. The 
binding site forms a shallow hydrophobic pocket that is lined by the residues Val60, Val62, Val65, 
Pro66, Phe72, and Phe74 from the β5–β6 region and residue Phe28 and Leu38 from the β3 and β4 
strands of ASF1 to residues Ile461, Pro463 and Leu464 of the HIRA B-domain (Figure 40A). A 
cluster of salt bridges is seen between the acidic residues Asp37, Glu39, and Asp58 and of ASF1a 




Figure 40. HIRA and ASF1a interface. A) HIRA is represented as a green ribbon. ASF1a is shown as a gold 
ribbon with a semi-transparent surface representation. Residues involved with hydrophobic interactions, hydrogen 
bonds, and salt bridge formation, are represented as sticks with CPK coloring. Hydrogen bonds: dashed lines, 
yellow: intra-molecular, and red: inter-molecular. B) Surface electrostatic representation of ASF1a and HIRA 
association. Left: HIRA surface shown in an open-book format. Critical residues that mediate salt-bridge formation 
is revealed on the surface. Right: HIRA fragment shown as sticks with CPK coloring within the complex. Adapted 
from Tang Y. et al., Nat Struct Mol Biol, 2006 (286) (https://www.nature.com/articles/nsmb1147). 
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Most of these residues are conserved in both ASF1 and HIRA, which emphasizes the 
importance of this interaction. Thus, we could envision peptide-like inhibitors with primary 
epitopes that could mimic short linear peptides, such as ASF1’s acidic residues or secondary 
structural epitopes that could disrupt the β-sheet interface. To date, the B-domain has not been 
widely reported outside of the HIRA family, with the exception of some shared homology with 
the p60 subunit of CAF1 (286,401). Although the HIRA B-domain and the B-domain-like motifs 
of CAF1 p60 bind to ASF1a in similar manner, a striking difference is CAF1’s lack of conservation 
of the three arginine residues 458-460 in HIRA. This brings forth the possibility for targeting this 
region to selectively uncouple HIRA-ASF1a activity.  
Another attractive option is to disrupt HIRA homotrimerization, which is a prerequisite for 
CABIN1 binding and efficient H3.3 deposition at UV-enriched sites (227). The crystal structure 
of the HIRA C-domain reveals that the β-strand region is essential for homotrimerization and β-
loop region mediates direct interaction with CABIN1 (Figure 41A-D). The residues Tryp799 
and/or Asp800, which are located within the β2 strand, are critical for HIRA homooligomerization 
(Figure 41B). Asp800 does not associate with an adjacent HIRA subunit, but Trp799 forms a 
hydrophobic patch with Ile771 and Val806, which then interacts with Leu 851 and Thr853 of an 
adjacent HIRA subunit (Figure 41C). Mutations of Asp800 and Trp799 are sufficient to abolish 
HIRA complex assembly and function. We can imagine a small molecule inhibitor that could 
wedge within this hydrophobic pocket and block the association between adjacent HIRA subunits. 




Figure 41. HIRA crystal structure reveals homotrimerization. Structure of homotrimeric HIRA (644-1017). 
Subunits A, B, and C are represented in light green, emerald green, and blue, respectively. Loop regions (860-907) 
shown in red. B) Structure of the HIRA monomer. The β1 and β2 motifs are represented as pink and yellow, 
respectively. The α-helical domain and the loop region are represented as white and red, respectively. The black 
triangles indicate critical residues of HIRA for homotrimerization. C) Trp799 is located at the interface between 
HIRA subunits A and B (yellow and emerald green). D) HIRA homotrimerization is required for CABIN1 binding 
to HIRA. The CABIN-binding loop is shown in red, highlighting residues Phe870 and Arg871. The α-helical 




5.9 Concluding Remarks 
This thesis establishes a fundamental role of PARylation in the tight regulation of early 
factors that mediate ALT telomere maintenance. We have identified the first epigenetic synthetic 
lethality between ATRX and HIRA in ALT+ cancers. We envision a model where PAR-
modulation of HIRA relieves chronic replication stress at ALT telomeres. The absence of HIRA 
leads to irreversibly stalled forks at telomeric DNA, which collapse into DSBs that remain 
unresolved. The saturation of DNA damage overwhelms the repair machinery and uncouples 
productive ALT activity. There are still plenty of questions regarding the mechanistic details that 
govern the initiation and progression of ALT. It is our hope that the findings and models in this 
dissertation shed light into one critical aspect of the ALT pathway that could be targeted to treat 
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Figure 42. PARP and PARG depletion induces opposing effects on frequency of APBs. Representative 




Figure 43. PARGi decreases telomere length in VA13 cells. PFGE of DMSO, PARPi (100nM) or PARGi (1M) 




Figure 44. PARGi diminishes telomere clustering in ALT+ VA13 cells and not TEL+ Hela LT cells. Left: 
Representative IF images of VA13 and Hela LT cells transfected with WT TRF1-FokI.  Right: TRF1-FokI foci size 
observed in each condition, including DA TRF1-FokI cells (images not shown).  All graphed data in the figure are 
mean ± SEM, n=150 cells. Statistical significance was determined using one-way ANOVA. *P≤ 0.05, **P≤ 0.001, 
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Figure 45. PAR-dependent recruitment of factors to ALT telomeric DSBs. A) Spectral counts for the indicated 
proteins that were identified by Af1521-PAR proteomics. B) Western blot analysis illustrating the expression of 




Figure 46. PAR-regulated factors localize to ALT telomeres. Representative IF images showing the localization 
of the indicated GFP fusion proteins in WT TRF1-FokI U2OS cells following treatment with DMSO, PARPi (5M) 




Figure 47. Inhibition of ARP2/3 impairs HDR in ALT. Quantification of TRF1-FokI telomeric foci A) number 
and B) size in WT cells treated with ARP2/3 inhibitor (ARP2/3) and ARP2/3 inactive inhibitor (ARP2/3ix). C) 
Tracked telomere (eGFP-TRF1) movement in U2OS cells treated with ARP2/3i. Graph displays the cumulative 
Mean Squared Displacement (MSD) of telomeres imaged and analyzed, n=100 telomeres. Inhibitors used at 1M. 
All graphed data in the figure are mean ± SEM. A) and B) n=150 cells and C) n=10 cells. Statistical significance 
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Figure 48. Selectivity of HIRA localization for UV-C damage. Representative IF images of YFP-HIRA 
localization in U2OS cells after exposure to 150 J/m2 ultra-violet C (UV-C) and 10Gy ionizing irradiation (IR). B) 
Quantification of YFP-HIRA foci in U2OS cells treated as indicated above. All graphed data in the figure are mean 
± SEM, n=50 cells. Statistical significance was determined using one-way ANOVA. *P≤ 0.05, **P≤ 0.001, ***P≤ 





Figure 49. WB of HIRA KD using shRNA. Western blot validation of HIRA knockdown using two independent 




D.1 Af1521 PAR proteomics 







CHD1L 20.57 23.6 
CABIN1 13.36 20.2 
HIRA 8.69 12 
CHD7 8.64 93.8 
UBN1 8.52 15 
XRCC1 7.58 24.2 
PCNA 7.39 6.2 
HUWE1 7.26 16.4 
MLL2 7.24 21.8 
UBN2 6.44 10 
VCP 5.8 6.8 
WDR1 5.68 11.4 
AKAP2 4.74 7.4 




Table 1 continued. 
KIAA1671 4.05 11.2 
SPECC1 4.03 6.6 
SPTAN1 4.02 273 
CASC3 3.93 6.4 
UNC45A 3.92 12.2 
TGM2 3.86 4.4 
CORO1C 3.77 114.8 
SALL1 3.75 4.4 
TFAM 3.67 5 
UACA 3.65 31.4 
CFL2 3.59 6.2 
PPP1CB 3.57 10.4 
SPTBN1 3.56 298.4 
SYNPO 3.4 28.4 
AMOTL1 3.35 3.4 
NFATC1 3.32 4 
LIG3 3.27 59.8 
MYLK 3.13 4 
BAZ2B 3.08 14 
NEXN 3.04 30.4 
ARPC2 3.04 9.6 
ZNF185 3.04 5 
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Table 1 continued. 
CASZ1 3.04 2.6 
GNB2 3.02 8.4 
SATB2 2.98 5 
NFAT5 2.93 6.2 
TWF1 2.92 8.8 
CORO1B 2.91 3 
LIMA1 2.85 92.6 
FN1 2.79 48 
YES1 2.78 7.6 
ITPR3 2.73 3.6 
HNRNPA2B1 2.71 74.8 
ZFHX4 2.71 38 
PARP2 2.71 13.6 
PARP1 2.68 288.2 
TNKS 2.63 2 
CBFB 2.6 3.2 
MYO18A 2.59 87.6 
RAD50 2.58 2.6 
LMO7 2.57 142 
GLDC 2.57 1.4 
TMOD3 2.56 9.6 
LZTS2 2.56 2.8 
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Table 1 continued. 
CTTN 2.55 16.8 
UTRN 2.55 3.2 
TRPS1 2.52 11 
SSH1 2.52 3.6 
GAPDHS 2.51 3.8 
POTE2B 2.48 3.4 
HNRNPH3 2.47 3.6 
H2BFS 2.46 2 
HNRNPA1 2.44 45.6 
DBN1 2.41 82.8 
PABPC4 2.4 7.8 
MGA 2.39 6.6 
COL1A1 2.37 2.2 
HNRNPD 2.36 10 
YLPM1 2.34 40.2 
ACTR3 2.33 12.6 
DAPK3 2.28 2.8 
CALD1 2.26 5.4 
SPRR3 2.24 1.8 
AMOTL2 2.2 1.6 
PPP1R12A 2.19 98.2 
LRRC59 2.18 2.6 
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Table 1 continued.  
PAWR 2.17 2.4 
CHAF1A 2.16 4.6 
CAV1 2.15 10.8 
ILF2 2.15 2.8 
ACTR2 2.14 9.2 
RPL9 2.13 12.2 
KPNA2 2.13 6 
DST 2.11 322.2 
CD59 2.11 9.4 
ARPC3 2.11 7.8 





E.1 Plasmids, siRNAs, shRNAs, and Antibodies 
Table 2. Plasmids 
Name Source 
GFP-PARG-FL Dr. Dea Slade (Max Perutz Lab, Vienna) 
GFP-PARG-Q76A-
K409A 
Dr. Dea Slade (Max Perutz Lab, Vienna) 
GFP-SAFB1 Dr. Steffi Oesterreich (University of Pittsburgh) 
GFP-RBMX Dr. Kyle Miller (University of Texas at Austin) 
GFP-hnRNPUL1 Dr. Sophie Polo (Université Paris Diderot) 
GFP-FUS1 Dr. Matthias Altmeyer (University of Zurich) 
GFP-EWS1 Dr. Matthias Altmeyer (University of Zurich) 
GFP-TAF15 Dr. Matthias Altmeyer (University of Zurich) 
GFP-VCP/p97 Dr. Nico Dantuma (Addgene, #23971) 
GFP-ARP3 Dr. Matthew Welch (Addgene, #8462) 
YFP-HIRA Dr. Geneviève Almouzni (Institut Curie) 
YFP-HIRA-799-
800 
Dr. Geneviève Almouzni (Institut Curie) 
YFP-HIRA-I461D Dr. Geneviève Almouzni (Institut Curie) 
YFP-HIRA-∆B This study 
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Table 2 continued. 
GFP-Histone H3.3 Dr. Geneviève Almouzni (Institut Curie) 
 
Table 3. siRNAs 
Name Description/Cat# 
HIRA 5’-GAUGACGACAGUGUUAUCCUU-3’ 
HIRA 3’UTR 5’-UUUACAUAGGUCUUAGGUCUU-3’ 
CABIN1 Dharmacon SMARTpool, #J-012454-09 
UBN1 Dharmacon SMARTpool, #J-014195-05 
SAFB1 5’-UCAAUUUCGUCAGGAUUACUU-3’ 
RBMX Dharmacon SMARTpool, #J-011691-09 
hnRNPUL1 Dharmacon SMARTpool, #J-004132005 
FUS Dharmacon SMARTpool, #J-009497-07 
VCP/p97 Dharmacon SMARTpool, #J-008727-09 
ARP2 Dharmacon SMARTpool, #L-012076-02 









Target Sequence: CGTGGATAACACTGTCGTCAT 
HIRA #2 
Sigma/TRCN0000020517 
Target Sequence: GCTTGGTCAAAGGGTTGACAT 
PARG Dr. Robert W. Sobol (University of South Alabama) 
PARP1 Dr. Robert W. Sobol (University of South Alabama) 
 
Table 5. IF antibodies 
Target Source/Cat# Dilution 
PCNA Cell Signaling, #2586 1:2500 
Poly (ADP-ribose) Millipore, #MABC547, clone [10H] 1:400 
POLD3 Abnova, #H00010714-M01 1:500 
PML Santa Cruz, #sc-377390 1:200 





Table 6. WB antibodies 
Target Source/Cat# Dilution 
PCNA Cell Signaling, #2586 1:2000 
RPA2 Abcam, #ab2175 1:1000 
Poly (ADP-ribose) Millipore, #MABC547 1:400 
PARP1 Active Motif, #39559 1:5000 
PARG Cell Signaling, #66564 1:1000 
ALC1 (CHD1L) Bethyl, #A303-342A 1:2000 
TRF1 Dr. Jan Karlseder (Salk Institute, CA) 1:1000 
TRF2 Novus, #NB110-57130 1:1000 
POLD3 Abnova, #H00010714-M01 1:1000 
RECQ1 Bethyl, #A300-447A 1:1000 
NFB/p65 Santa-Cruz c-20 1:250 
Histone H2AX S139 Millipore, #05-635 1:1000 
CHK2 T68 Cell Signaling, #2197 1:1000 
SAFB1 Bethyl, #A300-812A 1:1000 
FUS Bethyl, #A300-292A 1:200 
hnRNPUL1 Bethyl, #A300-862A 1:1000 
HIRA Active Motif, #39557 1:200 
CABIN1 Abcam, #ab3349 1:1000 





F.1 List of Abbreviations 
ADPr: ADP-ribose 
ALC1: Amplified in Liver Cancer 1  
alt-NHEJ: Alternative Non-Homologous End-Joining 
APBs: ALT-associated PML bodies 
ARP 2/3: Actin-Related Proteins 2 and 3  
ASF1a: Anti-Silencing Function 1A Histone Chaperone  
ATM: Ataxia-Telangiectasia-Mutated  
ATR: Ataxia-Rad3-related 
ATRX: Alpha-thalassemia/Mental Retardation Syndrome, X-linked 
BARD1: BRCA1-Associated RING Domain Protein 1  
BIR: Break-Induced Replication  
BLM: Bloom Helicase 
BRCA1: Breast Cancer Gene 1 
BRCA2: Breast Cancer Gene 2 
BTR Complex: BLM-TOP3A-RMI1-2  complex  
CABIN1: Calcineurin Binding Protein 1 
CAF1: Chromatin Assembly Factor  
cGAS: Cyclin GMP-AMP Synthase  
CHD2: Chromatin Remodeler Chromodomain Helicase DNA-binding Protein 2 
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c-NHEJ: Classical Non-Homologous End-Joining 
CO-FISH: Chromosome-orientation Fluorescent in situ Hybridization 
DAXX: Death Domain Associated Protein 
DNMT: DNA methyltransferase 1 
DSB: Double-stranded Break 
ECTR: Extrachromosomal Telomeric Repeat 
EWS: Ewing Sarcoma 
EZH2: Enhancer of Zeste 2 
FANCM: Fanconi Anemia Complementation Goup M 
FUS: Fused in Liposarcoma 
G2-BIR: G2-Break Induced Repair  
gH2AX: Gamma-H2A Histone Family Member X 
HDR: Homology-Directed Repair 
HIRA: Histone Regulator A 
hnRNPUL1: heterogenous nuclear ribonucleoprotein U-like 1 
HOP2: Homologous Pairing Protein 2 
HSV-1: Herpes simplex virus type 1 
IDH1: Isocitrate Dehydrogenase 
IF-FISH: Immunofluorescence-Fluorescence in situ Hybridization 
IFN: Interferon 
MARylation: Mono(ADP-ribosyl)ation  
MiDAS: Spontaneous Mitotic DNA synthesis 
MND1: Meiotic Nuclear Division Protein 1 
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Mre11: Meiotic Recombination 11 Homolog 1 
NBS1: Nijmegen Breakage Syndrome Protein 1 
NER: Nucleotide Excision Repair 
NuRD Complex: Nucleosome Modeling and Histone Deacetylation  
PanNET: Pancreatic Neuroendocrine Tumor 
PARG: Poly(ADP-ribose) Glycohydrolase 
PARP1: Poly(ADP-ribose) Polymerase 1 
PARylation: Poly(ADP-ribosyl)ation  
PBM: PAR-Binding Motif  
PBZ: PAR-Binding Zinc Finger  
PCNA: Proliferating Cellular Nuclear Antigen 
POT1: Protection of Telomere 1 
Rad50: ATP-binding Cassette-ATPase 
RAP1: Repressor/Activator Protein 1 
RBMX: RNA-Binding Motif Protein X-Linked 
RFC: Replication Factor C 
RPA: Replication Protein A 
RRM: RNA Recognition Motif  
SAFB1: Scaffold Attachment Factor B1  
SETD2: SET domain containing 2  
SIM: SUMO-interacting motif 
SMARCAL1: SWI/SNF-related, Matrix-associated, Actin-dependent Regulator of Chromatin, 
Subfamily A-like 1 
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SMC4/6: Structural Maintenance of Chromosomes Protein 5/6 
SMX Complex: SLX1-SLX4, MUS81-EME1, and XPF-ERCC1 
SSA: Single-strand Annealing  
SSB: Single-stranded Break 
STING: Stimulator of Interferon Genes  
SUMO: Small Ubiquitin-like Modifiers (SUMO) 
TAF15: TATA-box Binding Protein Associated Factor 15 
TIN2: TRF1-and TRF2-Interacting Nuclear Protein 2 
TNKS: Tankyrase 
TPP1: Adrenocortical Dysplasia Homolog (ACD) 
TRF1: Telomere Repeat Binding Factor 1 
TRF2: Telomere Repeat Binding Factor 2 
T-SCE: Telomere Sister Chromatid Exchange 
UBN1: Ubinuclein 1  
VCP/p97: Vasolin-Containing Protein  
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